<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Taibah Univ Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Taibah Univ Med Sci</journal-id><journal-id journal-id-type="pmc-domain-id">3709</journal-id><journal-id journal-id-type="pmc-domain">jtumed</journal-id><journal-title-group><journal-title>Journal of Taibah University Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">1658-3612</issn><publisher><publisher-name>Taibah University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9758618</article-id><article-id pub-id-type="pmcid-ver">PMC9758618.2</article-id><article-id pub-id-type="pmcaid">9758618</article-id><article-id pub-id-type="pmcaiid">9905666</article-id><article-id pub-id-type="pmid">36570799</article-id><article-id pub-id-type="doi">10.1016/j.jtumed.2022.11.007</article-id><article-id pub-id-type="pii">S1658-3612(22)00222-0</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Al-Hatamleh</surname><given-names initials="MAI">Mohammad A.I.</given-names></name><degrees>MSc</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Abusalah</surname><given-names initials="MA">Mai A.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Hatmal</surname><given-names initials="MM">Ma'mon M.</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Alshaer</surname><given-names initials="W">Walhan</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Ahmad</surname><given-names initials="S">Suhana</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Mohd-Zahid</surname><given-names initials="MH">Manali H.</given-names></name><degrees>MSc</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Rahman</surname><given-names initials="ENSEA">Engku Nur Syafirah E.A.</given-names></name><degrees>MSc</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Yean</surname><given-names initials="CY">Chan Y.</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Alias</surname><given-names initials="IZ">Iskandar Z.</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Uskokovi&#263;</surname><given-names initials="V">Vuk</given-names></name><degrees>PhD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Mohamud</surname><given-names initials="R">Rohimah</given-names></name><degrees>PhD</degrees><email>rohimahm@usm.my</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia</aff><aff id="aff2"><label>b</label>Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Zarqa University, Zarqa, Jordan</aff><aff id="aff3"><label>c</label>Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan</aff><aff id="aff4"><label>d</label>Cell Therapy Center (CTC), The University of Jordan, Amman, Jordan</aff><aff id="aff5"><label>e</label>Department of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia</aff><aff id="aff6"><label>f</label>Department of Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia</aff><aff id="aff7"><label>g</label>TardigradeNano LLC, Irvine, CA, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding address: Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, USM Health Campus, Kubang Kerian, Kota Bharu, Kelantan, 16150, Malaysia. <email>rohimahm@usm.my</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0015">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>6</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2022</year></pub-date><volume>18</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">428487</issue-id><fpage>600</fpage><lpage>638</lpage><history><date date-type="received"><day>20</day><month>8</month><year>2022</year></date><date date-type="rev-recd"><day>29</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>19</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-08 13:25:10.147"><day>08</day><month>02</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">9758618</article-id><article-id pub-id-type="doi">10.1016/j.jtumed.2022.11.007</article-id><article-version>1</article-version><pub-date><day>17</day><month>12</month><year>2022</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">9905666</article-id><article-id pub-id-type="doi">10.1016/j.jtumed.2022.11.007</article-id><article-version>2</article-version><pub-date><day>17</day><month>12</month><year>2022</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; 2022 [The Author/The Authors]</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0015"><p>Unlike pandemics in the past, the outbreak of coronavirus disease 2019 (COVID-19), which rapidly spread worldwide, was met with a different approach to control and measures implemented across affected countries. The lack of understanding of the fundamental nature of the outbreak continues to make COVID-19 challenging to manage for both healthcare practitioners and the scientific community. Challenges to vaccine development and evaluation, current therapeutic options, convalescent plasma therapy, herd immunity, and the emergence of reinfection and new variants remain the major obstacles to combating COVID-19. This review discusses these challenges in the management of COVID-19 at length and highlights the mechanisms needed to provide better understanding of this pandemic.</p></abstract><trans-abstract xml:lang="ar"><title>&#1575;&#1604;&#1605;&#1604;&#1582;&#1589;</title><p>&#1593;&#1604;&#1609; &#1593;&#1603;&#1587; &#1575;&#1604;&#1571;&#1608;&#1576;&#1574;&#1577; &#1601;&#1610; &#1575;&#1604;&#1605;&#1575;&#1590;&#1610;&#1548; &#1588;&#1607;&#1583; &#1578;&#1601;&#1588;&#1610; &#1605;&#1585;&#1590; &#1603;&#1608;&#1601;&#1610;&#1583;-19 &#1575;&#1604;&#1584;&#1610; &#1610;&#1606;&#1578;&#1602;&#1604; &#1576;&#1587;&#1585;&#1593;&#1577; &#1601;&#1610; &#1580;&#1605;&#1610;&#1593; &#1571;&#1606;&#1581;&#1575;&#1569; &#1575;&#1604;&#1593;&#1575;&#1604;&#1605; &#1606;&#1607;&#1580;&#1575; &#1605;&#1582;&#1578;&#1604;&#1601;&#1575; &#1578;&#1605;&#1575;&#1605;&#1575; &#1604;&#1604;&#1590;&#1608;&#1575;&#1576;&#1591; &#1608;&#1575;&#1604;&#1578;&#1583;&#1575;&#1576;&#1610;&#1585; &#1575;&#1604;&#1578;&#1610; &#1578;&#1605; &#1578;&#1606;&#1601;&#1610;&#1584;&#1607;&#1575; &#1601;&#1610; &#1580;&#1605;&#1610;&#1593; &#1575;&#1604;&#1576;&#1604;&#1583;&#1575;&#1606; &#1575;&#1604;&#1605;&#1578;&#1590;&#1585;&#1585;&#1577;. &#1604;&#1575; &#1610;&#1586;&#1575;&#1604; &#1593;&#1583;&#1605; &#1601;&#1607;&#1605; &#1575;&#1604;&#1591;&#1576;&#1610;&#1593;&#1577; &#1575;&#1604;&#1571;&#1587;&#1575;&#1587;&#1610;&#1577; &#1604;&#1578;&#1601;&#1588;&#1610; &#1575;&#1604;&#1605;&#1585;&#1590; &#1610;&#1580;&#1593;&#1604; &#1605;&#1606; &#1603;&#1608;&#1601;&#1610;&#1583;-19 &#1578;&#1581;&#1583;&#1610;&#1575; &#1604;&#1603;&#1604; &#1605;&#1606; &#1605;&#1605;&#1575;&#1585;&#1587;&#1610; &#1575;&#1604;&#1585;&#1593;&#1575;&#1610;&#1577; &#1575;&#1604;&#1589;&#1581;&#1610;&#1577; &#1608;&#1575;&#1604;&#1605;&#1580;&#1578;&#1605;&#1593; &#1575;&#1604;&#1593;&#1604;&#1605;&#1610;. &#1604;&#1575; &#1578;&#1586;&#1575;&#1604; &#1575;&#1604;&#1578;&#1581;&#1583;&#1610;&#1575;&#1578; &#1575;&#1604;&#1578;&#1610; &#1578;&#1608;&#1575;&#1580;&#1607; &#1578;&#1591;&#1608;&#1610;&#1585; &#1575;&#1604;&#1604;&#1602;&#1575;&#1581; &#1608;&#1578;&#1602;&#1610;&#1610;&#1605;&#1607;&#1548; &#1608;&#1575;&#1604;&#1582;&#1610;&#1575;&#1585;&#1575;&#1578; &#1575;&#1604;&#1593;&#1604;&#1575;&#1580;&#1610;&#1577; &#1575;&#1604;&#1581;&#1589;&#1585;&#1610;&#1577;&#1548; &#1608;&#1593;&#1604;&#1575;&#1580; &#1575;&#1604;&#1576;&#1604;&#1575;&#1586;&#1605;&#1575; &#1601;&#1610; &#1601;&#1578;&#1585;&#1577; &#1575;&#1604;&#1606;&#1602;&#1575;&#1607;&#1577;&#1548; &#1608;&#1605;&#1606;&#1575;&#1593;&#1577; &#1575;&#1604;&#1602;&#1591;&#1610;&#1593;&#1548; &#1601;&#1590;&#1604;&#1575; &#1593;&#1606; &#1592;&#1607;&#1608;&#1585; &#1575;&#1604;&#1593;&#1583;&#1608;&#1609; &#1605;&#1585;&#1577; &#1571;&#1582;&#1585;&#1609; &#1608;&#1575;&#1604;&#1605;&#1578;&#1594;&#1610;&#1585;&#1575;&#1578; &#1575;&#1604;&#1580;&#1583;&#1610;&#1583;&#1577;&#1548; &#1607;&#1610; &#1575;&#1604;&#1593;&#1602;&#1576;&#1575;&#1578; &#1575;&#1604;&#1585;&#1574;&#1610;&#1587;&#1610;&#1577; &#1571;&#1605;&#1575;&#1605; &#1605;&#1603;&#1575;&#1601;&#1581;&#1577; &#1603;&#1608;&#1601;&#1610;&#1583;-19. &#1578;&#1606;&#1575;&#1602;&#1588; &#1607;&#1584;&#1607; &#1575;&#1604;&#1605;&#1585;&#1575;&#1580;&#1593;&#1577; &#1607;&#1584;&#1607; &#1575;&#1604;&#1578;&#1581;&#1583;&#1610;&#1575;&#1578; &#1601;&#1610; &#1573;&#1583;&#1575;&#1585;&#1577; &#1603;&#1608;&#1601;&#1610;&#1583;-19 &#1576;&#1588;&#1603;&#1604; &#1605;&#1601;&#1589;&#1604; &#1608;&#1578;&#1587;&#1604;&#1591; &#1575;&#1604;&#1590;&#1608;&#1569; &#1593;&#1604;&#1609; &#1575;&#1604;&#1570;&#1604;&#1610;&#1575;&#1578; &#1575;&#1604;&#1604;&#1575;&#1586;&#1605;&#1577; &#1604;&#1605;&#1587;&#1575;&#1593;&#1583;&#1578;&#1606;&#1575; &#1593;&#1604;&#1609; &#1601;&#1607;&#1605; &#1607;&#1584;&#1575; &#1575;&#1604;&#1608;&#1576;&#1575;&#1569; &#1576;&#1588;&#1603;&#1604; &#1571;&#1601;&#1590;&#1604;.</p></trans-abstract><kwd-group xml:lang="ar" id="kwrds0010"><title>&#1575;&#1604;&#1603;&#1604;&#1605;&#1575;&#1578; &#1575;&#1604;&#1605;&#1601;&#1578;&#1575;&#1581;&#1610;&#1577;</title><kwd>&#1587;&#1575;&#1585;&#1587;</kwd><kwd>&#1603;&#1608;&#1601;&#1610;&#1583;-19</kwd><kwd>&#1601;&#1610;&#1585;&#1608;&#1587; &#1603;&#1608;&#1585;&#1608;&#1606;&#1575;</kwd><kwd>&#1593;&#1608;&#1583;&#1577; &#1575;&#1604;&#1593;&#1583;&#1608;&#1609;</kwd><kwd>&#1593;&#1604;&#1575;&#1580; &#1575;&#1604;&#1576;&#1604;&#1575;&#1586;&#1605;&#1575;</kwd><kwd>&#1605;&#1606;&#1575;&#1593;&#1577; &#1575;&#1604;&#1602;&#1591;&#1610;&#1593;</kwd></kwd-group><kwd-group id="kwrds0015"><title>Keywords</title><kwd>2019-nCoV</kwd><kwd>Convalescent plasma therapy</kwd><kwd>Coronavirus</kwd><kwd>Herd immunity</kwd><kwd>Reinfection</kwd><kwd>SARS-CoV-2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Since it was first reported in Wuhan, China, in December 2019, communicable coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to impose health and socioeconomic threats globally. SARS-CoV-2 belongs to the coronavirus family but is different from previous human coronaviruses (e.g., SARS-CoV and Middle East respiratory syndrome CoV [MERS-CoV]) in that it results in disease progression that is difficult to predict and is varied.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> SARS-CoV-2 has a receptor domain with high affinity toward angiotensin-converting enzyme 2 (ACE-2), which is abundant in many organs (<xref rid="fig1" ref-type="fig">Figure&#160;1</xref>), thus explaining the varying symptoms and severity of COVID-19.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><fig id="fig1" position="float" orientation="portrait"><label>Figure&#160;1</label><caption><p>Structure, cell entry and replication mechanisms of SARS-CoV-2. The SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2). The transmembrane protease serine 2 (TMPRSS2) protease enzyme cleaves the S protein, thus allowing viral entry into the host cell cytosol after fusion of the viral and cellular membranes (1). SARS-CoV-2 genomic RNA is translated into non-structural proteins (NSPs) from two open reading frames (ORF1a and ORF1b) (2). Some of the NSPs have RNA-dependent RNA polymerase (RdRp) activity (nsp12) (3). Negative-sense RNA intermediates are generated to serve as the templates for the synthesis of positive-sense genomic RNA (gRNA) (4) and sub-genomic RNAs (sgRNAs) (5). The gRNA is packaged by the structural proteins to assemble progeny virions. Shorter sgRNAs encode conserved structural proteins (S, E, M and N) and several accessory proteins. SARS-CoV-2 is known to have at least six accessory proteins (3a, 6, 7a, 7b, 8 and 10), and non-canonical sgRNAs are also shown in the subfigure (6). The AAGAA-type modification clusters in gRNA and sgRNAs are shown with yellow star annotations. Thereafter, budding and exocytosis of the virus occurs (7 and 8) (Adapted from Hatmal et&#160;al., 2020<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>).</p></caption><alt-text id="alttext0010">Figure&#160;1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0015">The medical community initially expected that reaching the vaccination stage would not be feasible for a very long time. Consequently, research studies and clinical trials were initiated to assess the potential effects of several existing drugs against COVID-19.<xref rid="bib12" ref-type="bibr"><sup>4</sup></xref> Furthermore, owing to its extensive history of efficacy against human respiratory viral infections, convalescent plasma (CP) therapy was used to treat COVID-19.<xref rid="bib13" ref-type="bibr"><sup>5</sup></xref> This treatment option was used primarily for severely ill patients hospitalized with COVID-19, and has been shown to be effective for reducing the mortality risk of COVID-19. However, given the unprecedented speed of community transmission, the CP therapy did not assisted in achieving herd immunity to COVID-19, which requires a sufficient number of people in a population to have developed protective antibodies against SARS-CoV-2 through either vaccination or natural infection. Hence, the world awaited COVID-19 vaccines that offered hope to defeat the COVID-19 pandemic.</p><p id="p0020">Currently, six vaccines (Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, Johnson &amp; Johnson, Sputnik V, Sinopharm and Sinovac) are authorized and available for immunization against COVID-19. However, no evidence indicates that recovered people with existing SARS-CoV-2 antibodies are protected against a second infection of COVID-19,<xref rid="bib14" ref-type="bibr"><sup>6</sup></xref> and a growing number of studies report COVID-19 reinfections.<xref rid="bib15" ref-type="bibr">7</xref>, <xref rid="bib16" ref-type="bibr">8</xref>, <xref rid="bib17" ref-type="bibr">9</xref> This comprehensive review provides a broad overview of the challenges associated with COVID-19 vaccines and treatment options, including the potential of CP therapy, herd immunity, and the probability of reinfection.</p></sec><sec id="sec2"><title>SARS-CoV-2 variants</title><p id="p0025">Since the early stages of the COVID-19 pandemic, multiple strains of SARS-CoV-2 have emerged and spread worldwide. In open-source platforms such as Pango,<xref rid="bib18" ref-type="bibr"><sup>10</sup></xref> Nexstrain (3103 genome sequences),<xref rid="bib19" ref-type="bibr"><sup>11</sup></xref> GISAID (10,298,748 genome sequences)<xref rid="bib20" ref-type="bibr"><sup>12</sup></xref> and NCBI Virus (4,616,599 nucleotide sequences),<xref rid="bib21" ref-type="bibr"><sup>13</sup></xref> more than 5 million genome sequences have been provided. According to their phylogenetic analyses, clades have been determined according to a collection of common mutations<xref rid="bib22" ref-type="bibr"><sup>14</sup></xref> and the ancestral clade known as clade O.<xref rid="bib23" ref-type="bibr"><sup>15</sup></xref> Other clades such as L, S and A2a, as well as clade G, have become more prevalent after 2020.<xref rid="bib24" ref-type="bibr">16</xref>, <xref rid="bib25" ref-type="bibr">17</xref>, <xref rid="bib26" ref-type="bibr">18</xref></p><p id="p0030">According to the WHO,<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref> the European Centre for Disease Prevention and Control (ECDC)<xref rid="bib28" ref-type="bibr"><sup>20</sup></xref> and Centers for Disease Control and Prevention (CDC),<xref rid="bib29" ref-type="bibr"><sup>21</sup></xref> a classification system has been developed to differentiate variants of concern (VOCs), variants of interest (VOIs), variants under monitoring (VUM), variants being monitored (VBM), formerly monitored variants (FMV) and variants of high consequence (VOHC).<xref rid="bib30" ref-type="bibr"><sup>22</sup></xref> After the emergence of variants that posed a greater risk to global public health in late 2020, characterization of specific VOCs, VUMs, VOIs and VOHCs became necessary to prioritize research and global monitoring, and to influence the continuing response to the COVID-19 pandemic.<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref></p><p id="p0035">COVID-19 variants that meet specific criteria, such as high transmission or adverse alterations in COVID-19 distribution; changes in clinical illness presentation or elevated clinical virulence; diminished effectiveness of social interventions and public health measures; or diminished effectiveness of diagnostics, treatments and vaccinations are defined as VOCs.<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>23</sup></xref> VOCs are mutant strains that are relatively more transmissible, elude antibody neutralization, induce more severe disease progression, confound identification and increase the incidence of mortality.<xref rid="bib30" ref-type="bibr"><sup>22</sup></xref> Particular VOCs may have selective benefits, on the basis of the existence of the same mutations repeatedly emerging in many virus strains in different geographic locations (i.e., convergent evolution).<xref rid="bib19" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>25</sup></xref> Most VOCs studied since the SARS-CoV-2 pandemic have had relatively higher transmissibility and virulence; these were the Alpha, Delta, Gamma and Beta variants. Although Gamma, Alpha, and Beta are no longer designated as VOCs, studying the causes that led to their emergence in populations is crucial.<xref rid="bib30" ref-type="bibr"><sup>22</sup></xref> According to the SARS-CoV-2 Interagency Group of the United States government, the Omicron variant is considered a VOC.<xref rid="bib29" ref-type="bibr"><sup>21</sup></xref> VOCs include Delta (1.617.2) and Omicron (B.1.1.529, BA.1, BA.2, BA.3, BA.4, BA.5, XE [a recombinant of Omicron BA.1 and BA.2] and descendent lineages).<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>21</sup></xref></p><p id="p0040">In contrast, VOIs are characterized as genetically mutated variants with predicted or known effects on viral characteristics, such as disease severity, transmissibility, immunological breakout, and therapeutic or diagnostic escape.<xref rid="bib31" ref-type="bibr"><sup>23</sup></xref> In addition, these variants are characterized by the presence of specific genetic markers that may be associated with high transmissibility or virulence, the ability to escape detection, a decrease in neutralizing antibodies (NAbs) acquired via natural infection or vaccination, or a decrease in the effectiveness of vaccination or therapeutics.<xref rid="bib31" ref-type="bibr"><sup>23</sup></xref> Furthermore, these variants have been identified as causing substantial and unique COVID-19 outbreak clusters or community transmission in various countries, with corresponding increases in the prevalence rates or other clear epidemiological effects, thus indicating a rising risk to global public health.<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref> VOIs include Omicron (BA.2.75) and Omicron (BA.2&#160;+ L452X (x)).<xref rid="bib28" ref-type="bibr"><sup>20</sup></xref></p><p id="p0045">VUMs are viral variants that bear genetic modifications suspected to affect the characteristics of the virus and that show indications of future risk to human health.<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref> Moreover, these variants are associated with more severe disease or greater transmission, but are either no longer detectable or are circulating at extremely low levels. However, the evidence of epidemiological or phenotypic influence is now uncertain, thus necessitating increased monitoring and reassessment in the absence of additional evidence. A VOI or VOC may be relegated to this category if its national and regional percentages have decreased significantly and consistently over time, or if other evidence suggests that a variant does not constitute a major risk to public health.<xref rid="bib29" ref-type="bibr"><sup>21</sup></xref> This category includes former VOIs/VOCs that will continue to be tracked for an extended length of time and will retain the WHO label assigned to them until further notice. Some evidence suggests that they may have characteristics identical to those of VOCs; however, the evidence is either insufficient or has not yet been evaluated by the ECDC. According to the ECDC, VUMs include Omicron (BA.3).<xref rid="bib28" ref-type="bibr"><sup>20</sup></xref> The WHO has established a new category in its variant tracking system, designated &#8220;Omicron subvariants under monitoring,&#8221; to indicate to public health authorities worldwide which VOC lineages may warrant prioritization and monitoring, in light of the broad transmission of the Omicron VOC worldwide and the expected increase in its viral diversity. Omicron subvariants under monitoring include BA.4 and BA.5, as well as lineages that share the same cluster of mutations in the spike, namely BA.2.12.1, BA.2.9., BA.2.11, BA.2.13 and BA.2.75, and the following variations seen outside the spike: BA.4: ORF7b:L11F, N:P151S; BA.5: M:D3N; ORF1a:del141/143 and ORF6:D61L.<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref></p><p id="p0050">Since September 2021, the ECDC has categorized some variants as de-escalated variants,<xref rid="bib28" ref-type="bibr"><sup>20</sup></xref> although these variants had been classified as VUMs by the CDC and as VOIs and/or VOCs by the WHO.<xref rid="bib27" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>21</sup></xref> These variants meet at least one of the following criteria: (1) the variant has spread for a long period of time without causing any overall epidemiological effects; (2) the variant is no longer circulating; and (3) scientific research has demonstrated that the variant does not contain any concerning features. Recently, on the basis of ECDC advice, the de-escalated variants have come to include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Epsilon (B.1.427 and B.1.429), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), B.1.640, Lambda (C.37) and Mu (B.1.621).<xref rid="bib28" ref-type="bibr"><sup>20</sup></xref></p><p id="p0055">In this section, we discuss the main COVID-19 variants along with their severity, transmissibility and immunity characteristics (<xref rid="tbl1" ref-type="table">Table&#160;1</xref>). Although some SARS-CoV-2 variants (e.g., B.1.1.7, P.1 and 501Y. V2) have been identified to be more transmissible variants and are already spreading rapidly worldwide,<xref rid="bib34" ref-type="bibr">26</xref>, <xref rid="bib35" ref-type="bibr">27</xref>, <xref rid="bib36" ref-type="bibr">28</xref> Delta and Omicron currently have the highest transmissibility and virulence.<xref rid="bib30" ref-type="bibr"><sup>22</sup></xref> Although Delta has dispersed worldwide, Omicron is growing at a faster rate than Delta, and it bears an increased risk of transmission, particularly among contacts outside the household.<xref rid="bib37" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>30</sup></xref> Consequently, although early indications have suggested that individuals may be less likely to require hospitalization, a much greater number of people are anticipated to become infected. Regular contact tracing analyses have revealed that transmission rates among people infected with BA.2 are expected to be higher (13.4%) than those among household contacts of other people infected with Omicron (10.3%).<xref rid="bib38" ref-type="bibr"><sup>30</sup></xref> The higher transmissibility of these variants has been associated with the mutations that they carry, including mutations that alter their S proteins (particularly the receptor-binding domain), the main target of COVID-19 vaccines and therapeutics.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> These mutations may decrease the binding affinity of anti-SARS-CoV-2 antibodies.<xref rid="bib39" ref-type="bibr"><sup>31</sup></xref> Therefore, the growing number of more transmissible SARS-CoV-2 variants may cause more reinfections. In addition, existing vaccines may require future updates to improve their efficacy, particularly if vaccine-resistant SARS-CoV-2 variants emerge.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;1</label><caption><p>Main COVID-19 variants and their severity, transmissibility and immunity characteristics.</p></caption><alt-text id="alttext0040">Table&#160;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">WHO label</th><th colspan="1" rowspan="1">Lineage (Pango)</th><th colspan="1" rowspan="1">GISAID clade</th><th colspan="1" rowspan="1">Other names</th><th colspan="1" rowspan="1">Most common countries (earliest date)</th><th colspan="1" rowspan="1">Status from September 2021</th><th colspan="1" rowspan="1">Effect on severity</th><th colspan="1" rowspan="1">Effect on transmissibility</th><th colspan="1" rowspan="1">Effect on immunity</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Delta</td><td colspan="1" rowspan="1">B.1.617.2 (Indian variant)</td><td colspan="1" rowspan="1">G/478K.V1</td><td colspan="1" rowspan="1">VUI-21APR-02</td><td colspan="1" rowspan="1">USA 21.0%, India 18.0%, UK 13.0%, Turkey 11.0%, Germany 5.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOC<break/>CDC: VBM<break/>ECDC: de- escalated</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1"><xref rid="bib245" ref-type="bibr">32</xref>, <xref rid="bib246" ref-type="bibr">33</xref>, <xref rid="bib247" ref-type="bibr">34</xref>, <xref rid="bib248" ref-type="bibr">35</xref>, <xref rid="bib249" ref-type="bibr">36</xref></td></tr><tr><td colspan="1" rowspan="1">Alpha</td><td colspan="1" rowspan="1">B.1.1.7 (British variant)</td><td colspan="1" rowspan="1">GRY</td><td colspan="1" rowspan="1">VOC 202012/01, 20I/501Y.V1</td><td colspan="1" rowspan="1">UK 24.0%, USA 20.0%, Germany 9.0%, Sweden 6.0%, Denmark 6.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOC<break/>CDC: VBM<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Identical to previous variants in that it was unlikely to have an effect</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1"><xref rid="bib250" ref-type="bibr">37</xref>, <xref rid="bib251" ref-type="bibr">38</xref>, <xref rid="bib252" ref-type="bibr">39</xref>, <xref rid="bib253" ref-type="bibr">40</xref></td></tr><tr><td colspan="1" rowspan="1">Beta</td><td colspan="1" rowspan="1">B.1.351 (South African variant)</td><td colspan="1" rowspan="1">GH/501Y.V2</td><td colspan="1" rowspan="1">20H/501Y.V2</td><td colspan="1" rowspan="1">South Africa 19.0%, Philippines 9.0%, USA 9.0%, Sweden 8.0%, Germany 7.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOC<break/>CDC: VBM ECDC: de-escalated</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1"><xref rid="bib239" ref-type="bibr"><sup>41</sup></xref>,<xref rid="bib253" ref-type="bibr">40</xref>, <xref rid="bib254" ref-type="bibr">42</xref>, <xref rid="bib255" ref-type="bibr">43</xref>, <xref rid="bib256" ref-type="bibr">44</xref>, <xref rid="bib257" ref-type="bibr">45</xref></td></tr><tr><td colspan="1" rowspan="1">Gamma</td><td colspan="1" rowspan="1">P.1 (Brazilian variant)</td><td colspan="1" rowspan="1">GR/501Y.V3</td><td colspan="1" rowspan="1">20J/501Y.V3</td><td colspan="1" rowspan="1">Brazil 56.0%, USA 29.0%, Chile 3.0%, Argentina 2.0%, Spain 1.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOC CDC: VBM ECDC: de-escalated</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1"><xref rid="bib253" ref-type="bibr"><sup>40</sup></xref>,<xref rid="bib258" ref-type="bibr">46</xref>, <xref rid="bib259" ref-type="bibr">47</xref>, <xref rid="bib260" ref-type="bibr">48</xref></td></tr><tr><td colspan="1" rowspan="1">Epsilon</td><td colspan="1" rowspan="1">B.1.427 and B.1.429 (Californian variant)</td><td colspan="1" rowspan="1">GH/452R.V1</td><td colspan="1" rowspan="1">CAL.20C/L452R</td><td colspan="1" rowspan="1">B.1.427: USA 98.0%, Mexico 1.0%, Aruba 0.0%, Argentina 0.0%, Canada 0.0%<break/>B.1.429: USA 97.0%, Canada 2.0%, Mexico 1.0%, South Korea 0.0%, Chile 0.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: VBM<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">Unclear</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib261" ref-type="bibr">49</xref>, <xref rid="bib262" ref-type="bibr">50</xref>, <xref rid="bib263" ref-type="bibr">51</xref></td></tr><tr><td colspan="1" rowspan="1">Eta</td><td colspan="1" rowspan="1">B.1.525</td><td colspan="1" rowspan="1">G/484K.V3</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Canada 19.0%, USA 15.0%, Germany 9.0%, France 8.0%, Denmark 7.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: VBM<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib264" ref-type="bibr">52</xref>, <xref rid="bib265" ref-type="bibr">53</xref>, <xref rid="bib266" ref-type="bibr">54</xref></td></tr><tr><td colspan="1" rowspan="1">Theta</td><td colspan="1" rowspan="1">P.3</td><td colspan="1" rowspan="1">GR/1092K.V1</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Philippines 83.0%, USA 3.0%, Germany 2.0%, Malaysia 2.0%, UK 2.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: N/A<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib251" ref-type="bibr"><sup>38</sup></xref>,<xref rid="bib265" ref-type="bibr"><sup>53</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Kappa</td><td colspan="1" rowspan="1">B.1.617.1</td><td colspan="1" rowspan="1">G/452R.V3</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">India 72.0%, UK 6.0%, Canada 6.0%, USA 5.0%, Ireland 3.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: VBM<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib267" ref-type="bibr">55</xref>, <xref rid="bib268" ref-type="bibr">56</xref>, <xref rid="bib269" ref-type="bibr">57</xref>, <xref rid="bib270" ref-type="bibr">58</xref></td></tr><tr><td colspan="1" rowspan="1">Zeta</td><td colspan="1" rowspan="1">P.2</td><td colspan="1" rowspan="1">GR/484K.V2</td><td colspan="1" rowspan="1">VUI-202101/01, B.1.1.28.2</td><td colspan="1" rowspan="1">Brazil 57.0%, USA 24.0%, Canada 4.0%, Argentina 2.0%, Paraguay 2.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: VBM<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib265" ref-type="bibr"><sup>53</sup></xref>,<xref rid="bib271" ref-type="bibr"><sup>59</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Lambda</td><td colspan="1" rowspan="1">C.37</td><td colspan="1" rowspan="1">GR/452Q.V1</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Peru 44.0%, Chile 19.0%, Argentina 13.0%, USA 12.0%, Ecuador 3.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: N/A<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib272" ref-type="bibr">60</xref>, <xref rid="bib273" ref-type="bibr">61</xref>, <xref rid="bib274" ref-type="bibr">62</xref></td></tr><tr><td colspan="1" rowspan="1">Mu</td><td colspan="1" rowspan="1">B.1.621</td><td colspan="1" rowspan="1">GH</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">USA 40.0%, Colombia 27.0%, Chile 8.0%, Spain 4.0%, Panama 4.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: VBM<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib251" ref-type="bibr"><sup>38</sup></xref>,<xref rid="bib265" ref-type="bibr"><sup>53</sup></xref>,<xref rid="bib275" ref-type="bibr"><sup>63</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Iota</td><td colspan="1" rowspan="1">B.1.526</td><td colspan="1" rowspan="1">GH/253G.V1</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">USA 97.0%, Ecuador 1.0%, Canada 1.0%, Puerto Rico 1.0%, Spain 0.0%</td><td colspan="1" rowspan="1">WHO: previously circulating VOI CDC: VBM<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib265" ref-type="bibr"><sup>53</sup></xref>,<xref rid="bib276" ref-type="bibr"><sup>64</sup></xref></td></tr><tr><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">XD (France variant)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">France 68.0%, Denmark 28.0%, Netherlands 4.0%</td><td colspan="1" rowspan="1">WHO: FMV<break/>CDC: N/A<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib277" ref-type="bibr"><sup>65</sup></xref></td></tr><tr><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">XE (British variant)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">UK 99.0%, USA 1.0%, Ireland 0.0%, Denmark 0.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: N/A<break/>ECDC: N/A</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib278" ref-type="bibr"><sup>66</sup></xref></td></tr><tr><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">XF (British variant)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">UK 100.0%</td><td colspan="1" rowspan="1">WHO: N/A CDC: N/A<break/>ECDC: de-escalated</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib279" ref-type="bibr"><sup>67</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Omicron</td><td colspan="1" rowspan="1">BA.1 (B.1.1.529)</td><td colspan="1" rowspan="1">GR/484A</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">USA 38.0%, UK 29.0%, Canada 5.0%, Germany 4.0%, Norway 3.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: VOC<break/>ECDC: VOC</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Decreased</td><td colspan="1" rowspan="1"><xref rid="bib280" ref-type="bibr">68</xref>, <xref rid="bib281" ref-type="bibr">69</xref>, <xref rid="bib282" ref-type="bibr">70</xref>, <xref rid="bib283" ref-type="bibr">71</xref>, <xref rid="bib284" ref-type="bibr">72</xref>, <xref rid="bib285" ref-type="bibr">73</xref>, <xref rid="bib286" ref-type="bibr">74</xref>, <xref rid="bib287" ref-type="bibr">75</xref></td></tr><tr><td colspan="1" rowspan="1">Omicron</td><td colspan="1" rowspan="1">BA.2 (B.1.1.529)</td><td colspan="1" rowspan="1">GR/484A</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">UK 67.0%, Germany 8.0%, USA 4.0%, Denmark 3.0%, France 3.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: VOC<break/>ECDC: VOC</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">Decreased</td><td colspan="1" rowspan="1"><xref rid="bib281" ref-type="bibr"><sup>69</sup></xref>,<xref rid="bib288" ref-type="bibr">76</xref>, <xref rid="bib289" ref-type="bibr">77</xref>, <xref rid="bib290" ref-type="bibr">78</xref>, <xref rid="bib291" ref-type="bibr">79</xref>, <xref rid="bib292" ref-type="bibr">80</xref></td></tr><tr><td colspan="1" rowspan="1">Omicron</td><td colspan="1" rowspan="1">BA.3(B.1.1.529)</td><td colspan="1" rowspan="1">GR/484A</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">UK 35.0%, Poland 24.0%, Germany 17.0%, South Africa 5.0%, USA 4.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: VOC<break/>ECDC: VUM</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib293" ref-type="bibr"><sup>81</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Omicron</td><td colspan="1" rowspan="1">BA.4 (B.1.1.529)</td><td colspan="1" rowspan="1">GR/484A</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">UK 28.0%, USA 27.0%, South Africa 8.0%, Israel 5.0%, Denmark 5.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: VOC<break/>ECDC: VOC</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib294" ref-type="bibr"><sup>82</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Omicron</td><td colspan="1" rowspan="1">BA.5 (B.1.1.529)</td><td colspan="1" rowspan="1">GR/484A</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">USA 24.0%, UK 19.0%, Denmark 9.0%, France 5.0%, South Africa 5.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: VOC<break/>ECDC: VOC</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib28" ref-type="bibr"><sup>20</sup></xref>,<xref rid="bib295" ref-type="bibr"><sup>83</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Omicron</td><td colspan="1" rowspan="1">BA.2&#160;+&#160;L452X</td><td colspan="1" rowspan="1">GR/484A</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">UK 32.0%, Germany 13.0%, Denmark 13.0%, USA 11.0%, France 5.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: VOC<break/>ECDC: VOI</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">Increased</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib288" ref-type="bibr"><sup>76</sup></xref>,<xref rid="bib296" ref-type="bibr"><sup>84</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Omicron</td><td colspan="1" rowspan="1">BA.2.75</td><td colspan="1" rowspan="1">GR/484A</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">India 76.0%, UK 8.0%, USA 4.0%, New Zealand 3.0%, Canada 2.0%</td><td colspan="1" rowspan="1">WHO: VOC CDC: VOC<break/>ECDC: VOI</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1">No evidence</td><td colspan="1" rowspan="1"><xref rid="bib296" ref-type="bibr"><sup>84</sup></xref>,<xref rid="bib297" ref-type="bibr"><sup>85</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>VOC, variants of concern; VOI, variants of interest; VUM, variants under monitoring; VBM, variant being monitored; FMV, formerly monitored variants; N/A, not applicable.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3"><title>Vaccine development against COVID-19</title><p id="p0060">Vaccines are artificial or natural biological preparations used to stimulate the immune response for antibody production against a particular disease. A vaccine typically consists of a pathogenic agent (either the microorganism itself, or its specific antigen epitope, surface protein, toxin or a synthetic substitute) treated to act as an antigen without causing disease in a host.<xref rid="bib40" ref-type="bibr"><sup>86</sup></xref> A vaccine works by &#8220;educating&#8221; the immune system to recognize and fight against microbial pathogens, i.e., either viruses or bacteria. Thus, a particular molecule (e.g., antigen epitope, surface protein or toxin) from the pathogen must be presented to the host to induce an immune response.<xref rid="bib41" ref-type="bibr"><sup>87</sup></xref> The production of antibodies from the given antigen provides immunity, which helps the immune system become stronger when it encounters a real infection.</p><p id="p0065">Vaccines aid in developing immunity against particular pathogens by imitating an infection caused by the given pathogen. Although this type of imitated infection almost never causes illness, it stimulates the immune system to generate T cell populations and antibodies.<xref rid="bib42" ref-type="bibr"><sup>88</sup></xref> As the body builds immunity, minor symptoms, such as fever, may develop and are considered normal. After the period of the imitated infection passes, the body is left with a population of memory T cells and B cells, which provide resistance against the particular disease in the future.<xref rid="bib41" ref-type="bibr"><sup>87</sup></xref> Although the steps in the traditional method for developing new vaccines tend to be sequential and well established (<xref rid="fig2" ref-type="fig">Figure&#160;2</xref>), some overlap exists between the stages. Because each phase is costly, particularly later phases, and every phase enhances understanding of whether the next step might be successful, the objective of this sequential strategy is partly to lessen the financial risk involved. The process can be halted at any point for a variety of reasons, including the detection of adverse events, such as major adverse effects, or if the data indicate that the vaccine is likely to be ineffective.<xref rid="bib43" ref-type="bibr"><sup>89</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>90</sup></xref> Combining phases of vaccine development can accelerate the process in situations such as the upheaval created by the COVID-19 pandemic and the urgent need for a vaccine that is both effective and widely available worldwide.<xref rid="bib45" ref-type="bibr"><sup>91</sup></xref> As of October 27, 2022, on the basis of the recent COVID-19 landscape report by the WHO, a total of 172 and 199 vaccine candidates are currently in clinical development and pre-clinical development worldwide, respectively.<xref rid="bib46" ref-type="bibr"><sup>92</sup></xref> As shown in the same report, these vaccine candidates have been developed by using different platforms including, but not limited to, protein subunits (32.2%), RNA (23.4%), non-replicating viral vectors (13.5%), inactivated viruses (12.9%), DNA (9.4%), virus-like particles (3.5%) and replicating viral vectors (2.3%).<xref rid="bib46" ref-type="bibr"><sup>92</sup></xref>
<xref rid="fig3" ref-type="fig">Figure&#160;3</xref> summarizes the immunological defense mechanisms involved in developing immunity to SARS-CoV-2 in either infected or vaccinated individuals.<xref rid="bib47" ref-type="bibr">93</xref>, <xref rid="bib48" ref-type="bibr">94</xref>, <xref rid="bib49" ref-type="bibr">95</xref>, <xref rid="bib50" ref-type="bibr">96</xref>, <xref rid="bib51" ref-type="bibr">97</xref>, <xref rid="bib52" ref-type="bibr">98</xref>, <xref rid="bib53" ref-type="bibr">99</xref><fig id="fig2" position="float" orientation="portrait"><label>Figure&#160;2</label><caption><p>Conventional vaccine development process. The conventional process for developing vaccines includes several phases, beginning with research and development; then pre-clinical studies; then phase I trials in a relatively small number of control volunteers; and finally more extensive phase II and phase III trials. After that, the Food and Drug Administration or the European Medicines Agency evaluates the findings of the clinical trials to determine whether the vaccine is sufficiently effective and safe to be authorized and is also affordable. The final phase is manufacturing and post-marketing surveillance, which is completed after the vaccine has been made available for use by the general public and after it has been monitored for its overall effectiveness among the population. Any negative adverse effects that may arise from the vaccination programs are also documented in the vaccine reports in this phase.</p></caption><alt-text id="alttext0015">Figure&#160;2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig><fig id="fig3" position="float" orientation="portrait"><label>Figure&#160;3</label><caption><p>Schematic representation of the mechanisms of development of immunity to SARS-CoV-2 in three situations. 1) Infection in a healthy individual (low viral load). 2) Reinfection with SARS-CoV-2 when previously infected people did not have an adequate neutralizing IgG response, which formed only after their secondary infection. Usually, the innate immune response regulates the immediate host response to SARS-CoV-2 infection, which is then accompanied by an early antibody response. Development of high titers of IgM, IgA, and IgG virus-specific antibodies peaks 3&#8211;4 weeks after symptom onset, then decreases. In some cases, IgM and IgA levels exceed baseline levels 2 months after onset, whereas IgG levels remain elevated for as many as 3 months in most patients. Intriguingly, the frequency and durability of the COVID-19 antibody response tend to be correlated with the severity of the disease. In patients who experienced asymptomatic infection or mild illness, short-lived immunity has been noted, thus indicating that a low neutralizing antibody response has been established, with the virus effectively cleared by the innate and early antibody response. In asymptomatic/mild cases of COVID-19, the viral-clearing antibody response wanes very quickly (&lt;90 days). Therefore, these people may be vulnerable to reinfection. High titers of NAbs have been found in the more extreme cases of COVID-19, and notably, no cases of reinfection of immunocompetent individuals have been identified. 3) Potential effects of different types of vaccines (DNA-based, RNA-based and non-replicating viral vector) after administration to the host. A vaccine works by imitating an infection caused by a particular pathogen for which the vaccine is developed. After the vaccine is injected into the host, the antigen inside the vaccine component is captured by antigen-presenting cells (APC), such as dendritic cells (DC), by phagocytosis. Subsequently, the DCs travel to a secondary lymphoid organ, such as lymph nodes, where immature T and B cells are situated. The antigen processed by the DCs is bound to the major histocompatibility complex (MHC) class II receptor on the DC surface. The antigen is then presented to immature T helper cells through binding the MHC class II to the T cell receptor (1st signal). Later, these T lymphocytes proliferate and mature. T helper cells activate B cells, which then proliferate into antibody-secreting plasma cells (2nd signal). These memory T and B cells are formed after the imitation infection by the vaccine ends.</p></caption><alt-text id="alttext0020">Figure&#160;3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><sec id="sec3.1"><title>COVID-19 vaccine challenges</title><p id="p0070">Infectious diseases can have enormous effects and devastating consequences on population health and country economies. Because prevention is always a better option than treatment, vaccines provide the best solution to combat infectious disease. Beyond providing long-term protection against infections, the ideal types of vaccines should be safe, easy to administer, simple and inexpensive to manufacture.<xref rid="bib54" ref-type="bibr"><sup>100</sup></xref> Careful evaluations at each step are required to develop novel vaccines while ensuring effectiveness and safety. Hence, the pipeline for traditional vaccine development usually requires more than 10 years before reaching the general public.<xref rid="bib55" ref-type="bibr"><sup>101</sup></xref> However, the highly infectious SARS-CoV-2 and the ensuing morbidity and mortality required urgent development of vaccines despite the challenges in vaccine development. The development of COVID-19 vaccines faces several policy challenges, as shown in <xref rid="fig4" ref-type="fig">Figure&#160;4</xref>. Therefore, the Government Accountability Office in the USA has highlighted nine policy options that might help overcome challenges to vaccine development technologies and methods, as well as economic challenges (<xref rid="fig4" ref-type="fig">Figure&#160;4</xref>).<fig id="fig4" position="float" orientation="portrait"><label>Figure&#160;4</label><caption><p>Challenges and policy options to address the challenges in the development of COVID-19 vaccines. The three primary &#8220;D&#8221; dimensions of obtaining broad global COVID-19 immunity by vaccinations are development, dissemination and deployment, which ensure continuing development of effective and safe vaccines, providing and distributing the vaccine globally, and deploying the vaccine across countries. To achieve these goals, 11 challenges must be addressed: maintaining robust and reasonable R&amp;D incentives; conducting cohesive clinical trials; authorizing effective and safe vaccines; surveilling effectiveness after and during vaccination; ensuring equitable availability of the vaccine worldwide; producing adequate amounts and sustaining supply chain ability; safely transferring and supplying vaccines; deploying vaccines equitably; supporting vaccine use; addressing ethical concerns re: vaccine passports and other obligations; and adapting systems for clinical and health research. From the beginning of vaccine R&amp;D until the adaption of the clinical system, financial and ethical decisions must be made.<xref rid="bib326" ref-type="bibr"><sup>102</sup></xref> Because vaccine development methods and techniques face numerous challenges, the Government Accountability Office has outlined several policy options for overcoming these obstacles. Policymakers, including those in the US Congress, state and local governments, federal agencies, academic and research organizations, and private industry, could take one of several new actions as a result of these policy options.<xref rid="bib43" ref-type="bibr"><sup>89</sup></xref></p></caption><alt-text id="alttext0025">Figure&#160;4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><sec id="sec3.1.1"><title>Immune responses</title><p id="p0075">Antigen selection for vaccine development requires a critical evaluation of whether to use whole-cell antigens (killed or weakened) or fragments of their viral materials (subunits). For the COVID-19 vaccine, vaccinologists are currently focusing on the S protein, which is believed to facilitate cell membrane fusion and viral entry.<xref rid="bib56" ref-type="bibr"><sup>103</sup></xref> Of note, vaccination should trigger a proper robust immune response to ensure long-term protection while posing no harm to people. However, the emergence of several new strains and mutant variants has resulted in infections in fully vaccinated people and even reinfections among people who have recovered from COVID-19. Thus, to select the antigen with the optimal immune response, many studies are needed to fully understand how the immune system responds to SARS-CoV-2 <sup>55</sup>. However, developing novel SARS-CoV-2 vaccines may be challenging because of the many unknowns regarding this virus. Therefore, further investigation is warranted.</p></sec><sec id="sec3.1.2"><title>Vaccine adjuvant and delivery system</title><p id="p0080">In the early years of vaccine development, Louis Pasteur introduced inactivated pathogens (attenuated viruses) to stimulate the immune system.<xref rid="bib57" ref-type="bibr"><sup>104</sup></xref> Since then, mainstream global vaccine development has evolved into a more minimalist design approach, wherein only one subunit of the peptide-based composition of the antigenic material is used in the formulation instead of the whole virus. Despite the higher safety and usually lower production cost for this type of vaccines, adjuvants are required because they are less immunogenic than inactivated whole-cell vaccines.<xref rid="bib57" ref-type="bibr"><sup>104</sup></xref><sup>,</sup><xref rid="bib58" ref-type="bibr"><sup>105</sup></xref> Adjuvants are often designed to function as both immunostimulators and delivery systems to enhance vaccine immunogenicity. To date, aluminum salts, which are very inexpensive to produce, have been the most commonly used vaccine adjuvant. They have been approved by the Food and Drug Administration since the 1930s because of their safety and long-term protection.<xref rid="bib59" ref-type="bibr"><sup>106</sup></xref><sup>,</sup><xref rid="bib60" ref-type="bibr"><sup>107</sup></xref> Despite showing an excellent safety profile and the longest history of use, aluminum adjuvant-containing vaccines also have some limitations. For example, aluminum-containing salts have been reported to induce strong humoral responses but not cellular responses.<xref rid="bib58" ref-type="bibr"><sup>105</sup></xref> An ideal immunization for adaptive immunity must provide long-term protection that involves both humoral and cellular immunity for a rapid response and immunological memory to fight future infections by pathogenic agents.<xref rid="bib41" ref-type="bibr"><sup>87</sup></xref> In addition, cellular immune responses have been suggested to be valuable for respiratory tract infections such as SARS-CoV-2, owing to the late onset of the production of antibodies after infection.<xref rid="bib61" ref-type="bibr"><sup>108</sup></xref> In adaptive immunity, the CD8<sup>+</sup> T cell subset is involved primarily in the cellular response, whereas CD4<sup>+</sup> T cells are responsible for long-term protection against subsequent infection.<xref rid="bib61" ref-type="bibr"><sup>108</sup></xref> Hence, the limited number of clinically approved adjuvants has restricted the choices for novel vaccines under development and prolonged the vaccine pipeline. The development of COVID-19 vaccines should, of course, meticulously consider every feature, including the type of adjuvants, to ensure optimal immunostimulation and antigen delivery. These considerations are complicated by the incomplete understanding of the exact mechanism of action of SARS-CoV-2, given its relatively recent emergence.</p></sec><sec id="sec3.1.3"><title>Financial commitment</title><p id="p0085">The development of new vaccines such as those for COVID-19 is costly, particularly during this pandemic. As described, the typical timeline for previous vaccine development processes was 10 years or more. However, during the emerging pandemic disease, shortening of the timeline for the vaccine development was necessary. For instance, the mRNA-1273 vaccine candidate from Moderna entered a phase 1 clinical trial on March 16, 2020, less than 10 weeks after China had released the genetic sequence of SARS-CoV-2 <sup>55</sup>. However, accelerating the process, such as by conducting research phases in parallel with other phases, poses a substantial financial risk, particularly in view of the many unknowns surrounding COVID-19. Nevertheless, the cost for the R&amp;D of a new vaccine has not been disclosed by the pharmaceutical company, which has lacked transparency regarding the actual costs. However, on the basis of common costs for new drug discovery, the range for the true cost has been estimated to have been approximately $2.6 billion.<xref rid="bib62" ref-type="bibr"><sup>109</sup></xref> Beyond the financial cost of R&amp;D, advanced technologies, which are often available to only high-income nations, are required for the development of COVID-19 vaccines. Consequently, the development of novel COVID-19 vaccines is very challenging, particularly in low-and middle-income countries (LMICs), owing to the enormous financial commitments required for R&amp;D.</p><p id="p0090">Because of global inequality in terms of vaccine development and production capacity, programs must be developed to enable the distribution of vaccines on the basis of population needs rather than wealth or social status.<xref rid="bib63" ref-type="bibr"><sup>110</sup></xref> Previously, operation Warp Speed, a US program, aimed to develop vaccines faster than ever before, to make them accessible for emergency use by the end of 2020 and to produce billions of doses by the end of the 2021.<xref rid="bib45" ref-type="bibr"><sup>91</sup></xref> However, vaccine manufacturing and procurement cost billions of dollars in high-income nations, thus resulting in an uneven distribution of vaccines to LICs.<xref rid="bib64" ref-type="bibr"><sup>111</sup></xref> Despite the recommendations made at the Global Vaccination Summit in favor of equal vaccine allocation, concerns remain that some governments might want to secure their citizens' vaccine supplies before sharing vaccines globally.<xref rid="bib65" ref-type="bibr"><sup>112</sup></xref> Several countries, such as the United States and Europe, have indicated that vaccines will initially be delivered to their own citizens because of the high demand for vaccines. However, questions have been raised regarding the ethics of distributing resources unequally. Nonetheless, positive steps have been made, including by the COVAX initiative and AstraZeneca's announcement of a partnership with an Indian institute to provide appropriate doses to LMICs.<xref rid="bib66" ref-type="bibr"><sup>113</sup></xref></p><p id="p0095">The unequal distribution of vaccine supplies worldwide has substantially affected progress in vaccination in LICs. According to a United Nations report released on March 28, 2022, vaccination distribution has increased worldwide but still shows inequality. Only 1% of the 10 billion doses distributed worldwide went to LICs, thus leaving about 2.8 billion individuals waiting for their first dose.<xref rid="bib67" ref-type="bibr"><sup>114</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>115</sup></xref> To date, slightly more than 3% of people have been vaccinated with at least one dose in LICs, as compared with 60% in high-income countries. As of the middle of 2022, the United Nations health agency sought vaccination for 70% of the world's population,<xref rid="bib67" ref-type="bibr"><sup>114</sup></xref> a goal scarcely attainable. Approximately 39 high-income nations have already met the 70% target as of January 2022, whereas the Republic of Congo, Ethiopia, South Sudan and Nigeria still seek to acquire sufficient vaccines to vaccinate 10% of their populations. A total of US$19,87 billion in gross domestic product has been lost as a result of these four countries failing to meet the 40% target for vaccination by the year 2021.<xref rid="bib69" ref-type="bibr"><sup>116</sup></xref></p><p id="p0100">The COVAX initiative stands out as an international project designed to acquire and distribute vaccines in an equitable manner. However, it has not been able to procure sufficient doses to achieve its modest objective for 2021 of covering 20% of the LICS population.<xref rid="bib64" ref-type="bibr"><sup>111</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>117</sup></xref> For example, Pfizer agreed to sell only 40 million doses to COVAX, and slightly more than 1 million doses had been delivered by mid-May 2021.<xref rid="bib70" ref-type="bibr"><sup>117</sup></xref> By the end of May 2021, 34 countries worldwide had contributed doses, and many more had committed to the goals of COVAX.<xref rid="bib71" ref-type="bibr"><sup>118</sup></xref> However, LMICs make up 6.5 billion of the world population, and high-income countries have purchased only 5.9 billion doses.<xref rid="bib72" ref-type="bibr"><sup>119</sup></xref> As of January 12, 2022, 84 vaccines were in late developmental phases (phase II or III), and another 33 were in post-registration. Of the 28 vaccine manufacturers, Pfizer/BioNTech has made a public commitment to provide the most doses, exceeding 5.1 billion, followed by AstraZeneca, with approximately 3.6 billion doses.<xref rid="bib73" ref-type="bibr"><sup>120</sup></xref> High-income countries have reserved most doses from Pfizer/BioNTech (83%) and Moderna (73%), but no bilateral agreements with low-income countries have been revealed. In contrast, AstraZeneca/Oxford, Johnson &amp; Johnson and Novavax have had a larger distribution in LMICs. Vaccines produced in middle-income countries (India, Cuba, China and Russia) are restricted primarily to the country where the vaccine was developed or other middle-income countries. Meanwhile, LICs have conserved relatively smaller quantities of each of these vaccine candidates bilaterally.<xref rid="bib73" ref-type="bibr"><sup>120</sup></xref> Therefore, AstraZeneca and the Serum Institute of India have collaborated to develop and supply vaccines to LMICs, in an attempt to partially avert this situation. Several organizations, such the WHO-led COVAX, African Vaccine Acquisition Task Team of African Union Africa in Africa,<xref rid="bib74" ref-type="bibr"><sup>121</sup></xref> Serum Institute of India, Bharat Biotech, Premas Bio-tech and Zydus Cadila in India,<xref rid="bib75" ref-type="bibr"><sup>122</sup></xref> have been established to work on vaccine development and procurement.<xref rid="bib64" ref-type="bibr"><sup>111</sup></xref> In addition, donations could have assisted in vaccination of health professionals and vulnerable communities worldwide if they had been made more quickly and achieved more widespread distribution.<xref rid="bib71" ref-type="bibr"><sup>118</sup></xref></p><p id="p0105">This disparity between developed and the developing countries in terms of the prospects of achieving a timely solution for the COVID-19 pandemic echoes the commonly observed inverse relationship between income and tendency to contract the disease,<xref rid="bib76" ref-type="bibr"><sup>123</sup></xref> given the pervasive outbreaks among low-income communities primarily working in manufacturing and the safety of online jobs available for the higher-income populace.<xref rid="bib77" ref-type="bibr"><sup>124</sup></xref> Therefore, COVID-19 discourse is expected to increasingly pose important questions that address the principles of socioeconomic disparities related not only to the healthcare industry but also to broader aspects of our lives; it is also likely to provide a platform for recognizing, addressing and ameliorating the aforementioned disparities.</p></sec><sec id="sec3.1.4"><title>Vaccine hesitancy and adverse effects</title><p id="p0110">The WHO defined vaccine hesitancy as a reluctance to be vaccinated despite the availability of vaccines.<xref rid="bib78" ref-type="bibr"><sup>125</sup></xref> In 2019, the WHO designated hesitancy to be vaccinated as one of the ten threats affecting global health.<xref rid="bib79" ref-type="bibr"><sup>126</sup></xref> Because the success of vaccination programs depends largely on the public's willingness to accept the vaccine, many studies have reported vaccine acceptance and hesitancy rates in various countries.<xref rid="bib80" ref-type="bibr"><sup>127</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>128</sup></xref> Furthermore, several research groups have aimed to assess the determinants of, and factors driving, vaccine hesitancy and acceptance.<xref rid="bib82" ref-type="bibr"><sup>129</sup></xref><sup>,</sup><xref rid="bib83" ref-type="bibr"><sup>130</sup></xref> Notably, many COVID-19 vaccine-associated studies have focused on healthcare workers (HCWs) in the early stages of the pandemic, because many countries prioritized vaccination of HCWs at the frontline of the pandemic response, who helped safeguard the lives of vulnerable populations.<xref rid="bib84" ref-type="bibr"><sup>131</sup></xref></p><p id="p0115">Although vaccine hesitancy and acceptance rates vary among populations,<xref rid="bib85" ref-type="bibr"><sup>132</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>133</sup></xref> several studies from different countries have shown that vaccine hesitancy is associated with a central concern regarding the lack of trust in COVID-19 vaccine safety and efficacy, particularly given that the COVID-19 vaccines were developed at an unprecedentedly rapid pace.<xref rid="bib85" ref-type="bibr"><sup>132</sup></xref><sup>,</sup><xref rid="bib87" ref-type="bibr"><sup>134</sup></xref><sup>,</sup><xref rid="bib88" ref-type="bibr"><sup>135</sup></xref> In addition, some psychosocial predictors, prior experience and preconceptions about vaccines, social media influence and trust in governments have been reported to be co-modulators of vaccine hesitancy/acceptance across different populations.<xref rid="bib89" ref-type="bibr">136</xref>, <xref rid="bib90" ref-type="bibr">137</xref>, <xref rid="bib91" ref-type="bibr">138</xref>, <xref rid="bib92" ref-type="bibr">139</xref> Moreover, since early 2021, multiple SARS-CoV-2 variants have emerged with reports of waning vaccine-induced immunity in various countries worldwide, thus leading to a surge in the demand for booster doses of COVID-19 vaccines. Studies have shown that booster immunization acceptance is attributable to the belief that boosters are necessary and efficient,<xref rid="bib93" ref-type="bibr"><sup>140</sup></xref> as well as to altruistic reasons, such as family, patient and community health protection.<xref rid="bib94" ref-type="bibr">141</xref>, <xref rid="bib95" ref-type="bibr">142</xref>, <xref rid="bib96" ref-type="bibr">143</xref></p><p id="p0120">In contrast, many post-authorization observational studies have been performed to assess the safety and effectiveness of COVID-19 vaccines. Independent studies not supported by vaccine development corporations have helped enhance public confidence in the safety of COVID-19 vaccines, thereby increasing vaccination rates in targeted populations.<xref rid="bib97" ref-type="bibr"><sup>144</sup></xref> Generally, although post-vaccination adverse effects have been reported by most participants, studies have shown that serious safety issues of COVID-19 vaccines are extremely rare, and long-term adverse effects are unlikely.<xref rid="bib98" ref-type="bibr">145</xref>, <xref rid="bib99" ref-type="bibr">146</xref>, <xref rid="bib100" ref-type="bibr">147</xref> The most commonly reported post-vaccination adverse effects are fatigue, chills, dizziness, fever, headache, joint pain and myalgia.<xref rid="bib101" ref-type="bibr">148</xref>, <xref rid="bib102" ref-type="bibr">149</xref>, <xref rid="bib103" ref-type="bibr">150</xref>, <xref rid="bib104" ref-type="bibr">151</xref> In addition, post-vaccination adverse effects are mostly resolved within 3 days without medical intervention.<xref rid="bib86" ref-type="bibr"><sup>133</sup></xref><sup>,</sup><xref rid="bib105" ref-type="bibr"><sup>152</sup></xref> However, the overall prevalence and severity of post-vaccination adverse effects may vary depending on the type of the vaccine.<xref rid="bib86" ref-type="bibr"><sup>133</sup></xref><sup>,</sup><xref rid="bib97" ref-type="bibr"><sup>144</sup></xref><sup>,</sup><xref rid="bib106" ref-type="bibr"><sup>153</sup></xref><sup>,</sup><xref rid="bib107" ref-type="bibr"><sup>154</sup></xref></p></sec></sec></sec><sec id="sec4"><title>COVID-19 therapeutics</title><p id="p0125">The Milken Institute's COVID-19 treatment and vaccine tracker<xref rid="bib108" ref-type="bibr"><sup>155</sup></xref> lists a total of 309 potential treatments from different categories, including repurposed drugs and drugs assessed in different stages of development against COVID-19, 195 of which have reached the clinical stage. In addition, five treatments (remdesivir, REGN-COV2, bamlanivimab, olumiant and chloroquine/hydroxychloroquine) have received emergency authorization. The chloroquine/hydroxychloroquine authorization was revoked thereafter, and 31 treatments have reached phase III trials.</p><p id="p0130">This repurposing of available drugs has involved several types of antimalarial drugs (e.g., chloroquine), antimalarial and antibiotic combinations (e.g., hydroxychloroquine and azithromycin), antiviral drugs (e.g., nafamostat, camostat, bromhexine, favipiravir, remdesivir and lopinavir) and antihelminthic/antiparasitic agents (e.g., nitazoxanide and ivermectin), which have shown potential antiviral effects against SARS-CoV-2.<xref rid="bib109" ref-type="bibr">156</xref>, <xref rid="bib110" ref-type="bibr">157</xref>, <xref rid="bib111" ref-type="bibr">158</xref> Although prior studies did not identify specific antiviral drugs against SARS-CoV or MERS-CoV, reports have recently suggested that several available drugs may act as antiviral agents against SARS-CoV-2, particularly hydroxychloroquine, chloroquine and nafamostat.<xref rid="bib112" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib113" ref-type="bibr"><sup>160</sup></xref> However, the clinical effectiveness of these drugs has not yet been fully evaluated, and several clinical trials remain underway.<xref rid="bib113" ref-type="bibr"><sup>160</sup></xref></p><p id="p0135">Furthermore, other types of repurposed drugs are expected to have regulatory effects on the immunity of patients with COVID-19, particularly those with severe disease. Anticoagulant treatments (e.g., heparin and nafamostat), for example, inhibit the cytokine storm and increase the percentage of lymphocytes.<xref rid="bib112" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib114" ref-type="bibr"><sup>161</sup></xref><sup>,</sup><xref rid="bib115" ref-type="bibr"><sup>162</sup></xref> Some immune-based therapies (e.g., tocilizumab and interferon alpha-2B) are also expected to have similar effects but continue to await experimental evaluation.<xref rid="bib109" ref-type="bibr"><sup>156</sup></xref> Other types of drugs have been repurposed and are currently being studied, such as antihypertensive drugs and non-steroidal anti-inflammatory drugs; however, no scientific evidence demonstrating the effectiveness of any drug or therapeutic compound against COVID-19 has been reported to date.</p><p id="p0140">Another proposed therapeutic strategy for COVID-19 is using potent NAbs against SARS-CoV-2. Several studies have shown promising results supporting this strategy.<xref rid="bib116" ref-type="bibr">163</xref>, <xref rid="bib117" ref-type="bibr">164</xref>, <xref rid="bib118" ref-type="bibr">165</xref> One study has reported that two human monoclonal antibodies isolated from a convalescent patient with COVID-19 demonstrated potent SARS-CoV-2-specific neutralization activity <italic toggle="yes">in&#160;vitro</italic>. One of these antibodies showed inhibitory therapeutic and prophylactic activity against SARS-CoV-2 in rhesus monkeys.<xref rid="bib116" ref-type="bibr"><sup>163</sup></xref> Structural studies of this antibody have indicated its ability to recognize an epitope that overlaps with ACE2-binding sites in the RBD of SARS-CoV-2 S protein.<xref rid="bib116" ref-type="bibr"><sup>163</sup></xref> However, NAbs are not produced exclusively against the RBD of S protein regions. Another study has shown that 19 of 61 monoclonal antibodies isolated from five patients with COVID-19 potently neutralized authentic SARS-CoV-2 <italic toggle="yes">in&#160;vitro</italic>. Epitope mapping has indicated that half of these antibodies were directed against the RBD of S protein, whereas other antibodies were directed against the N-terminal domain of S protein<xref rid="bib117" ref-type="bibr"><sup>164</sup></xref>; therefore, both the RBD and N-terminal domain are immunogenic regions of S protein. However, further research remains needed before this therapeutic strategy can enter the clinical stage.</p><p id="p0145">Combined and supplementary therapies have been suggested as potential therapeutic approaches. For example, an <italic toggle="yes">in&#160;vitro</italic> study has shown that using a combination of zinc ionophore (pyrithione) with Zn<sup>2+</sup> potently inhibits SARS-CoV RNA replication in cultured Vero cells as well as SARS-CoV RNA-dependent RNA polymerase (RdRp) elongation.<xref rid="bib119" ref-type="bibr"><sup>166</sup></xref> On the basis of the high sequence similarity between SARS-CoV and SARS-CoV-2 (79% at the genome level and 98% at the RdRp level), researchers have hypothesized that the antiviral effects of zinc or the aforementioned combination might be similarly effective against SARS-CoV-2.<xref rid="bib120" ref-type="bibr"><sup>167</sup></xref> An interesting approach has suggested that combining zinc with chloroquine or hydroxychloroquine&#8212;which inhibit SARS-CoV-2 replication after an increase in the pH of the intracellular vesicles and also inhibit the intracellular virus particle delivery&#8212;might provide a promising treatment for COVID-19.<xref rid="bib121" ref-type="bibr"><sup>168</sup></xref> Chloroquine or hydroxychloroquine may specifically target extracellular zinc and activate its entrance into the intracellular lysosomes, where it interferes with SARS-CoV-2 RNA replication and RdRp elongation activity, thereby enhancing the efficacy of these repurposed drugs. Furthermore, zinc, vitamin D, vitamin C and N-acetylcysteine have been suggested to have a potential role in the prevention and treatment of COVID-19. However, clinical evidence supporting the use of those supplements for these purposes is insufficient.<xref rid="bib122" ref-type="bibr"><sup>169</sup></xref><sup>,</sup><xref rid="bib123" ref-type="bibr"><sup>170</sup></xref> Taking over-the-counter doses of these supplements in the absence of a confirmed nutritional deficiency might pose risks to the treatment outcomes.<xref rid="bib122" ref-type="bibr"><sup>169</sup></xref> Thus, further research is required before doses above those recommended for these supplements could be approved.</p><p id="p0150">Overall, massive efforts have been made worldwide toward the development of COVID-19 therapeutics, and many clinical trials have aimed at evaluating the effectiveness of repurposed drugs. Given that their chances of reaching very advanced phases are moderate to high, we summarize the potential challenges of repurposed drugs<xref rid="bib124" ref-type="bibr"><sup>171</sup></xref> in <xref rid="fig5" ref-type="fig">Figure&#160;5</xref>.<fig id="fig5" position="float" orientation="portrait"><label>Figure&#160;5</label><caption><p>Challenges regarding repurposed drugs against COVID-19.</p></caption><alt-text id="alttext0030">Figure&#160;5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec5"><title>Convalescent plasma therapy for COVID-19</title><p id="p0155">According to the WHO, most studies have shown that people who have recovered from COVID-19 have antibodies against the virus; however, some of those people have very low levels of NAbs in their blood.<xref rid="bib14" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib125" ref-type="bibr"><sup>172</sup></xref> CP is a convalescent blood product obtained from patients who have recovered from a viral infection and have developed humoral immunity against a particular pathogen.<xref rid="bib126" ref-type="bibr"><sup>173</sup></xref> The isolated plasma from the whole blood of recovered patient donors has a high concentration of NAbs against the virus. Hence, the administration of CP to patients with severe SARS-CoV-2 infection might possibly decrease viral replication and disease severity via specific antigen&#8211;antibody binding.</p><p id="p0160">In general, CP is a passive antibody therapy that depends on the transfer of pathogen-specific antibodies from a recovered patient to aid in the prevention or treatment of disease.<xref rid="bib13" ref-type="bibr"><sup>5</sup></xref> Antibody treatment can also be used to treat individuals already exhibiting symptoms with varying severity. In contrast, passive antibody therapy is most successful when applied prophylactically, or when used immediately after the onset of signs and symptoms.<xref rid="bib127" ref-type="bibr"><sup>174</sup></xref> Passive antibody administration through transfusion of CP may be the only short-term method available for providing direct immunity to susceptible patients in a timely manner. Numerous cases have been reported in which CP has been used successfully for treatment and/or postexposure prophylaxis against infectious diseases, including in prior coronavirus outbreaks (i.e., SARS-CoV-1 and MERS-CoV).<xref rid="bib128" ref-type="bibr"><sup>175</sup></xref></p><p id="p0165">The development and implementation of CP therapy is less complicated than that of vaccines and monoclonal antibodies. In addition, CP can adapt to a variety of conditions. The only requirements are the availability of disease survivors who can donate plasma and a standard blood collection infrastructure to collect and distribute the CP.<xref rid="bib128" ref-type="bibr"><sup>175</sup></xref> Individuals who are eligible to donate CP must have a history of COVID-19, as confirmed by approved molecular testing (e.g., nasopharyngeal swab) or the presence of antibodies against SARS-CoV-2. In addition, symptoms including fever, cough and shortness of breath must have resolved at least 14 days before donation of CP.<xref rid="bib128" ref-type="bibr"><sup>175</sup></xref> In light of the emergence of variant SARS-CoV-2 strains, CP donated by survivors of infections with variant strains is an immediately deployable treatment option for patients who have been identified as having a variant infection, whereas other immune treatments may require (re)development of more specific mechanisms to target new viral strains.<xref rid="bib129" ref-type="bibr">176</xref>, <xref rid="bib130" ref-type="bibr">177</xref>, <xref rid="bib131" ref-type="bibr">178</xref></p><p id="p0170">Three essential principles of passive antibody therapy must be met by CP. To be effective against SARS-CoV-2 infection: i) CP must contain specific antibodies against the SARS-CoV-2 virus; ii) a sufficient quantity of anti-SARS-CoV-2 antibodies must be produced in the plasma to improve the outcome of the disease; iii) for optimal benefits, the plasma must be administered early after the onset of symptoms.<xref rid="bib132" ref-type="bibr"><sup>179</sup></xref></p><p id="p0175">CP therapy was first recognized as a potential antiviral therapy during the Spanish influenza pandemic approximately 100 years ago.<xref rid="bib133" ref-type="bibr"><sup>180</sup></xref> CP administration substantially decreases mortality among patients with severe acute respiratory infections, by 75%.<xref rid="bib134" ref-type="bibr"><sup>181</sup></xref> Beyond SARS-CoV, CP therapy has been successful in the treatment of MERS-CoV-2 and H1N1 viral infections.<xref rid="bib135" ref-type="bibr"><sup>182</sup></xref> Despite the effectiveness of the CP therapy against previous viral infections, this type of therapy was unable to improve the survival rate during an Ebola virus outbreak (141). Because SARS-CoV-2 shares similar genomic sequences with SARS-CoV and MERS-CoV, CP therapy can be considered a promising treatment strategy with the potential to help the infected patients develop immediate short-term passive immunization before the availability of a new generation of COVID-19 vaccines. In addition, owing to the rise of different strains of the COVID-19 pathogen arising from genetic modifications with consequences in mutability, CP therapy offers an advantage in providing artificially acquired, passive immunity against the local infections in communities.<xref rid="bib126" ref-type="bibr"><sup>173</sup></xref> Recent studies on CP therapy for COVID-19 have reported that CP with high levels of NAb titers from recovered patients with COVID-19 ameliorates clinical symptoms by decreasing viral load, while posing low risk of treatment<xref rid="bib136" ref-type="bibr"><sup>183</sup></xref> and no significant transfusion-associated morbidity or mortality.<xref rid="bib137" ref-type="bibr"><sup>184</sup></xref> A recent study has found that 15% of 2341 enrolled men and women were less likely to die from COVID-19 within 1 month after receiving an injection of CP than patients who received an inactive saline placebo or did not receive the CP therapy.<xref rid="bib138" ref-type="bibr"><sup>185</sup></xref></p><p id="p0180">Moreover, a meta-analysis of international randomized clinical trials (RCTs) among hospitalized, non-critically ill patients with COVID-19 has been conducted to evaluate the effects of CP on patients with COVID-19. The findings were derived from eight recently completed studies conducted in Belgium, the United States, India, Brazil, Spain and the Netherlands. The COVID-19 CP was not consistently associated with either benefits or harms in therapy.<xref rid="bib139" ref-type="bibr"><sup>186</sup></xref> In addition, CP was not found to have an effect on clinical outcomes for typical patients.<xref rid="bib139" ref-type="bibr"><sup>186</sup></xref> However, patients with type A and AB blood groups, and patients with preexisting diseases such as diabetes or cardiovascular disease were most likely to benefit from the CP therapy.<xref rid="bib139" ref-type="bibr"><sup>186</sup></xref> However, another study has reported the benefits of CP therapy for older outpatients within the first 72&#160;h of disease onset.<xref rid="bib140" ref-type="bibr"><sup>187</sup></xref> Monoclonal antibody-based therapy has been shown to be helpful, but only for outpatients who have recently been diagnosed with SARS-CoV-2 infection.<xref rid="bib141" ref-type="bibr"><sup>188</sup></xref><sup>,</sup><xref rid="bib142" ref-type="bibr"><sup>189</sup></xref> As a consequence, the lack of a clear benefit of CP even in patients with recent symptom onset has been rather unexpected, thus implying that the window of opportunity for antibody-based therapy may be limited and associated with the stage of illness rather than with symptom onset time.<xref rid="bib139" ref-type="bibr"><sup>186</sup></xref></p><p id="p0185">Furthermore, the Continuous Monitoring of Pooled International Trials of Convalescent Plasma (COMPILE) for COVID-19 Hospitalized Patients study has established and validated a CP treatment benefit index.<xref rid="bib143" ref-type="bibr"><sup>190</sup></xref> COMPILE included a total of 2369 hospitalized adult patients (18 years of age or older) who had COVID-19 and who might or might not have required oxygen supplementation, but did not require mechanical ventilation. The treatment benefit index score represents the estimated relative advantage that a patient is expected to gain from CP treatment compared with a treatment without CP.<xref rid="bib143" ref-type="bibr"><sup>190</sup></xref> Another recent CT study has been conducted on 941 patients who were hospitalized with COVID-19 for 3 or fewer days and required noninvasive oxygen supplementation.<xref rid="bib144" ref-type="bibr"><sup>191</sup></xref> In this trial, patients receiving large doses of CP who were not taking any other drugs, such as remdesivir or corticosteroids, were found to be likely to benefit from CP treatment.<xref rid="bib144" ref-type="bibr"><sup>191</sup></xref> These preliminary findings have reinforced the idea that CP may serve as a viable therapeutic option, particularly when alternative medicines are not yet available. However, the lack of an overall advantage from CP therapy in this trial,<xref rid="bib144" ref-type="bibr"><sup>191</sup></xref> as well as other trials on CP<xref rid="bib145" ref-type="bibr">192</xref>, <xref rid="bib146" ref-type="bibr">193</xref>, <xref rid="bib147" ref-type="bibr">194</xref> in hospitalized patients with severe to life-threatening disease, suggests that patients with less severe disease and older patients may benefit most from CP treatment. Moreover, CP obtained from donors who had been previously infected and vaccinated afterward has been found to possess antibodies with sufficient quantities and diversity to provide further protection against new COVID-19 strains.<xref rid="bib144" ref-type="bibr"><sup>191</sup></xref> Genetic mutations are typical of viral evolution during the course of the COVID-19 pandemic. Consequently CP has the potential to provide a successful treatment option that keeps pace with the mutations better than synthetic treatment options, such as monoclonal antibody therapies, which tend to become less effective over time because of mutations and must undergo redevelopment to address the new variants.<xref rid="bib138" ref-type="bibr"><sup>185</sup></xref></p><p id="p0190">Several key challenges in developing CP therapy that must be considered. First, plasma transfusions are associated with potential risks of adverse effects. Previously, a patient with Ebola virus disease had developed acute respiratory distress syndrome after plasma transfusion from the recovered patients, possibly because of transfusion-associated acute lung injury.<xref rid="bib148" ref-type="bibr"><sup>195</sup></xref> A recent case study on CP for COVID-19 has also reported that a patient developed erythema, hypoxia and hypotensivity with increased dyspnea within 10&#160;min of plasma transfusion.<xref rid="bib149" ref-type="bibr"><sup>196</sup></xref> Limitations also exist regarding the risk of transfusion-transmitted diseases.<xref rid="bib150" ref-type="bibr"><sup>197</sup></xref>
<xref rid="tbl2" ref-type="table">Table&#160;2</xref> shows the characteristics of recent RCTs evaluating CP therapy for SARS-CoV-2 infection.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p>Characteristics of RCTs evaluating convalescent plasma therapy for SARS-CoV-2 infection.</p></caption><alt-text id="alttext0045">Table&#160;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Trial registration number</th><th colspan="1" rowspan="1">Study phase</th><th colspan="1" rowspan="1">Year</th><th colspan="1" rowspan="1">Location</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Number of enrolled patients</th><th colspan="1" rowspan="1">Patient setting</th><th colspan="1" rowspan="1">Primary outcome measure</th><th colspan="1" rowspan="1">Mortality rate, planned mortality time point</th><th colspan="1" rowspan="1">Plasma titer, assay</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04385199" id="intref0360">NCT04385199</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Italy</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">182</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">Proportion of patients without progression in severity of pulmonary disease, defined as worsening of 2 points in the ordinal scale of WHO within 14 days</td><td colspan="1" rowspan="1">16.67%, 28 days</td><td colspan="1" rowspan="1">Low titer:<break/>&#8805;1:200 S-RBD IgG</td><td colspan="1" rowspan="1"><xref rid="bib298" ref-type="bibr"><sup>198</sup></xref></td></tr><tr><td colspan="1" rowspan="1">CTRI/2020/04/024775</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">India</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">464</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">1. Progression to severe ARDS (P/F ratio 100) or 2. All-cause mortality at 28 days</td><td colspan="1" rowspan="1">14.01%, 28 days</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib299" ref-type="bibr"><sup>199</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04356534" id="intref0365">NCT04356534</ext-link></td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Bahrain</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">Requirement for invasive ventilation</td><td colspan="1" rowspan="1">7.5%, 28 days</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib300" ref-type="bibr"><sup>200</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04345523" id="intref0370">NCT04345523</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Spain</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">350</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">Category changes in the &#8220;7-Ordinal Scale&#8221; ranging from 1 (not hospitalized, no limitations on activities) to 7 (death)</td><td colspan="1" rowspan="1">4.9%, 29 days</td><td colspan="1" rowspan="1">Confirmed<break/>High-titer: &gt;1:80, neutralizing assay</td><td colspan="1" rowspan="1"><xref rid="bib301" ref-type="bibr"><sup>201</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04346446" id="intref0375">NCT04346446</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">India</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">13.7%, 28 days</td><td colspan="1" rowspan="1">Proportion of patients remaining free of mechanical ventilation</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib302" ref-type="bibr"><sup>202</sup></xref></td></tr><tr><td colspan="1" rowspan="1">CTRI/2020/05/025209</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">India</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">All-cause mortality on day 30 after enrollment and identification of immunological correlates of response to CP</td><td colspan="1" rowspan="1">30%, 30 days</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib303" ref-type="bibr"><sup>203</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04381858" id="intref0380">NCT04381858</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Mexico</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">196</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">1. Mean hospitalization time<break/>2. Mean oxygenation index evolution<break/>3. Rate of severe acute respiratory distress syndrome (ARDS)<break/>4. Rate and time to death<break/>5. Mean time with invasive mechanical ventilation</td><td colspan="1" rowspan="1">45.2%, 28 days</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib304" ref-type="bibr"><sup>204</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04433910" id="intref0385">NCT04433910</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Germany</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">106</td><td colspan="1" rowspan="1">ICU</td><td colspan="1" rowspan="1">Composite endpoint of survival and no longer meeting criteria for severe COVID-19</td><td colspan="1" rowspan="1">14.3%, 21.0%, and 26.7%, 21, 35 and 60 days, respectively</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:20 neutralizing antibodies</td><td colspan="1" rowspan="1"><xref rid="bib305" ref-type="bibr"><sup>205</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04359810" id="intref0390">NCT04359810</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">USA and Brazil</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">223</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">Day 28 severity outcome</td><td colspan="1" rowspan="1">28 days</td><td colspan="1" rowspan="1">Low titer:<break/>&#8805;1:400 S-RBD IgG, quantitative ELISA</td><td colspan="1" rowspan="1"><xref rid="bib306" ref-type="bibr"><sup>206</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04441424" id="intref0395">NCT04441424</ext-link></td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Iraq</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">Death versus survival of treated patients</td><td colspan="1" rowspan="1">6.1%, Up to 8 weeks</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib307" ref-type="bibr"><sup>207</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04383535" id="intref0400">NCT04383535</ext-link></td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Argentina</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">333</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">Ordinal outcome with six mutually exclusive categories describing the patient's clinical status during follow-up (ranging from 1 (death) to 6 (discharge))</td><td colspan="1" rowspan="1">11.1%, 30 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:800 S-RBD IgG, COV-IDAR IgG test</td><td colspan="1" rowspan="1"><xref rid="bib308" ref-type="bibr"><sup>208</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04392414" id="intref0405">NCT04392414</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Russia</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">Number and proportion of patients with normal body temperature (&#8804;37.2&#160;&#176;C) at day 1, 2, 3, 4, 5, 6, 7 after the start of therapy</td><td colspan="1" rowspan="1">6.06%, 30 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:1000 S-RBD IgG, in-house assay</td><td colspan="1" rowspan="1"><xref rid="bib309" ref-type="bibr"><sup>209</sup></xref>,<xref rid="bib310" ref-type="bibr"><sup>210</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04332835" id="intref0410">NCT04332835</ext-link></td><td colspan="1" rowspan="1">2&#8211;3</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Colombia</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1"><list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0375">Change in viral load</p></list-item><list-item id="o0015"><p id="p0380">2. Change in immunoglobulin G COVID-19 titers</p></list-item></list></td><td colspan="1" rowspan="1">8.0%, 7, 14 and 28 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>IgG&#160;&#8805;&#160;1/3200 and IgA&#160;&#8805;&#160;1/800 by EUROIMMUN; all transfused plasma presented neutralizing antibodies &#8805;1/256</td><td colspan="1" rowspan="1"><xref rid="bib309" ref-type="bibr"><sup>209</sup></xref>,<xref rid="bib311" ref-type="bibr"><sup>211</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04366245" id="intref0415">NCT04366245</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Spain</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1"><list list-type="simple" id="olist0015"><list-item id="o0020"><label>1.</label><p id="p0385">Incidence of adverse events and serious adverse events, grade 3 and 4, associated with the product under investigation or the administration procedure, graduated according to CTCAE.</p></list-item><list-item id="o0025"><p id="p0390">2. Death from any cause</p></list-item><list-item id="o0030"><p id="p0395">3. Need for mechanical ventilation</p></list-item><list-item id="o0035"><p id="p0400">4. SOFA scale &#8805;3&#160;at 72&#160;h after randomization or an increase in 2 points or more from the basal level</p></list-item></list></td><td colspan="1" rowspan="1">2.44%, 14 and 28 days</td><td colspan="1" rowspan="1">Low titer: Vircell<break/>SL (Spain) test, correlates to&#160;&#8805;1:320 S-RBD IgG</td><td colspan="1" rowspan="1"><xref rid="bib309" ref-type="bibr"><sup>209</sup></xref>,<xref rid="bib312" ref-type="bibr"><sup>212</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04362176" id="intref0420">NCT04362176</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">COVID-19 7-point Ordinal Clinical Progression Outcomes Scale (ranging from 1 (not hospitalized with resumption of normal activities) to 7 (death))</td><td colspan="1" rowspan="1">Not defined, 14 and 28 days</td><td colspan="1" rowspan="1">50% neutralization titer &gt;1:50 (neutralizing antibodies) are selected for transfusion in the trial, Abbott&#8482; ARCHITECT&#8482; platform and the RBD Luminex assay</td><td colspan="1" rowspan="1"><xref rid="bib313" ref-type="bibr"><sup>213</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04323800" id="intref0425">NCT04323800</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">180</td><td colspan="1" rowspan="1">Outpatients</td><td colspan="1" rowspan="1"><list list-type="simple" id="olist0020"><list-item id="o0040"><p id="p0405">1. Efficacy of treatment at day 28</p></list-item><list-item id="o0045"><p id="p0410">2. Safety of treatment with high-titer anti- SARS-CoV-2 plasma versus control-1 and control-2</p></list-item></list></td><td colspan="1" rowspan="1">0%, 28 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:320 neutralizing antibodies, Euroimmun ELISA</td><td colspan="1" rowspan="1"><xref rid="bib314" ref-type="bibr"><sup>214</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04364737" id="intref0430">NCT04364737</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">941</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">The participant scores on the 11-point WHO Ordinal Scale for Clinical Improvement on day 14 after randomization (range from 0 to 10, with 0 indicating uninfected and no viral RNA detected and 10 indicating death)</td><td colspan="1" rowspan="1">4.0%, 14 and 28 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:100 neutralizing antibodies, ELISA</td><td colspan="1" rowspan="1"><xref rid="bib315" ref-type="bibr"><sup>215</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04373460" id="intref0435">NCT04373460</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">1225</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1"><list list-type="simple" id="olist0025"><list-item id="o0050"><p id="p0415">1. Cumulative incidence of hospitalization or death before hospitalization</p></list-item><list-item id="o0055"><p id="p0420">2. Cumulative incidence of treatment-associated serious adverse events</p></list-item><list-item id="o0060"><p id="p0425">3. Cumulative incidence of treatment-associated grade 3 or higher adverse events</p></list-item></list></td><td colspan="1" rowspan="1">0.2%, 28 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>1:320 SARS-CoV-2 spike protein titers, Euroimmun ELISA</td><td colspan="1" rowspan="1"><xref rid="bib24" ref-type="bibr"><sup>16</sup></xref>,<xref rid="bib316" ref-type="bibr"><sup>216</sup></xref></td></tr><tr><td colspan="1" rowspan="1">IRCT20200310046736N1</td><td colspan="1" rowspan="1">2&#8211;3</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Iran</td><td colspan="1" rowspan="1">Not yet recruiting</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">Outpatients</td><td colspan="1" rowspan="1">Improvement in the levels of cytokine storm indices</td><td colspan="1" rowspan="1">26.7%, 7&#8211;14 days</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib317" ref-type="bibr"><sup>217</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04338360" id="intref0440">NCT04338360</ext-link></td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Approved for marketing</td><td colspan="1" rowspan="1">3082</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">Death within 30 days after plasma transfusion</td><td colspan="1" rowspan="1">26.9%, 30 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:160 neutralizing antibodies</td><td colspan="1" rowspan="1"><xref rid="bib145" ref-type="bibr"><sup>192</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04381936" id="intref0445">NCT04381936</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">United Kingdom</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">11558</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">All-cause mortality</td><td colspan="1" rowspan="1">24.3%, 28 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:100 neutralizing antibodies</td><td colspan="1" rowspan="1"><xref rid="bib318" ref-type="bibr"><sup>218</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02735707" id="intref0450">NCT02735707</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Worldwide</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">2011</td><td colspan="1" rowspan="1">ICU</td><td colspan="1" rowspan="1"><list list-type="simple" id="olist0030"><list-item id="o0065"><p id="p0430">1. All-cause mortality</p></list-item><list-item id="o0070"><p id="p0435">2. Primary endpoint for patients with suspected or demonstrated SARS-CoV-2 infection</p></list-item></list></td><td colspan="1" rowspan="1">37.2%, 90 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:100 neutralizing or equivalent</td><td colspan="1" rowspan="1"><xref rid="bib319" ref-type="bibr"><sup>219</sup></xref>,<xref rid="bib320" ref-type="bibr"><sup>220</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04873414" id="intref0455">NCT04873414</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Indonesia</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">364</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">Mortality of patients with COVID-19 treated with CP (number of deaths from the initiation of CP treatment until hospital discharge or death)</td><td colspan="1" rowspan="1">Not defined, 82 days</td><td colspan="1" rowspan="1">No minimum cut-off described</td><td colspan="1" rowspan="1"><xref rid="bib321" ref-type="bibr"><sup>221</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04344535" id="intref0460">NCT04344535</ext-link></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">Inpatients with and without supplemental oxygen</td><td colspan="1" rowspan="1"><list list-type="simple" id="olist0035"><list-item id="o0075"><p id="p0440">1. Number of days of invasive mechanical ventilation through 28 days post randomization</p></list-item><list-item id="o0080"><p id="p0445">2. Patients who died during this time period were assigned 0 ventilator free days</p></list-item></list></td><td colspan="1" rowspan="1">16.1%, 90 days</td><td colspan="1" rowspan="1">Confirmed high-titer: &gt;1: 320, neutralizing<break/>assay</td><td colspan="1" rowspan="1"><xref rid="bib322" ref-type="bibr"><sup>222</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04342182" id="intref0465">NCT04342182</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Netherlands</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">Inpatients with or without supplemental oxygen</td><td colspan="1" rowspan="1">Comparison of mortality in the 300&#160;ml CP group and the control arm</td><td colspan="1" rowspan="1">19.8%, 60 days</td><td colspan="1" rowspan="1">Confirmed high-titer: &gt;1:80, neutralizing assay</td><td colspan="1" rowspan="1"><xref rid="bib323" ref-type="bibr"><sup>223</sup></xref></td></tr><tr><td colspan="1" rowspan="1">ChiCTR2000029757</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">China</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">Patient discharged alive or decrease of 2 points on a 6-point disease severity scale (ranging from 1 (discharge) to 6 (death))</td><td colspan="1" rowspan="1">19.4%, 28 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:640 S-RBD IgG, in-house assay</td><td colspan="1" rowspan="1"><xref rid="bib324" ref-type="bibr"><sup>224</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04479163" id="intref0470">NCT04479163</ext-link></td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Argentina</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">160</td><td colspan="1" rowspan="1">Outpatients</td><td colspan="1" rowspan="1">Development of severe respiratory disease defined as a respiratory rate &gt;30 and/or an O<sub>2</sub> saturation &lt;93%</td><td colspan="1" rowspan="1">3.8%, 25 days</td><td colspan="1" rowspan="1">Confirmed high-titer: &gt;1:1000 against SARS-CoV-2 spike protein (COVIDAR IgG)</td><td colspan="1" rowspan="1"><xref rid="bib325" ref-type="bibr"><sup>225</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04348656" id="intref0475">NCT04348656</ext-link></td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">940</td><td colspan="1" rowspan="1">Inpatients with supplemental oxygen</td><td colspan="1" rowspan="1">Endpoint of the need for intubation or patient death</td><td colspan="1" rowspan="1">30.3%, 30 days</td><td colspan="1" rowspan="1">Confirmed high-titer:<break/>&#8805;1:100 neutralizing antibodies</td><td colspan="1" rowspan="1"><xref rid="bib131" ref-type="bibr"><sup>178</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>ELISA, enzyme linked immunosorbent assay; N/A, not applicable; SOFA, sequential organ failure assessment; CTCAE, common toxicity criteria scale.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec6"><title>Herd immunity and COVID-19</title><p id="p0195">When a population is immune to an infectious disease, either through vaccination or immunity acquired through earlier infection, this is referred to as herd immunity or population immunity.<xref rid="bib14" ref-type="bibr"><sup>6</sup></xref> Herd immunity can offer indirect protection against the contraction of infectious disease, particularly for the most vulnerable people, such as those with comorbid conditions, as well as infants and older people. Before vaccination, herd immunity could be achieved only by exposing a very large number of people in the community to the disease in hopes that they would develop protective antibodies.<xref rid="bib151" ref-type="bibr"><sup>226</sup></xref> The phenomenon of herd immunity, which occurs naturally, was first observed in the 1930s, after many adolescents had developed immunity to measles.<xref rid="bib152" ref-type="bibr"><sup>227</sup></xref> Herd immunity is an important concept for understanding the short- and long-term effects of vaccination programs, and many existing examples illustrate this concept. In one of the most prominent examples, epidemics of common pediatric diseases, such as mumps, pertussis, polio, rubella, measles and chickenpox, occur at regular intervals.<xref rid="bib153" ref-type="bibr"><sup>228</sup></xref><sup>,</sup><xref rid="bib154" ref-type="bibr"><sup>229</sup></xref> In addition, an indirect herd protection has been documented after the introduction of conjugate vaccines against pneumococcal and Haemophilus infections.<xref rid="bib155" ref-type="bibr"><sup>230</sup></xref> Herd immunity is supported by existing examples and historical findings, and has again become the most hotly debated topic in science in the 21st century, in the midst of the SARS-CoV-2 pandemic. Concerns have been raised regarding the effectiveness of herd immunity in minimizing SARS-CoV-2 infection rates among susceptible populations.<xref rid="bib156" ref-type="bibr"><sup>231</sup></xref></p><p id="p0200">The basic reproduction number, or R<sub>0</sub> (pronounced &#8220;R naught&#8221;), is the main parameter of the herd immunity threshold. It describes the average number of secondary infections acquired by the introduction of a single infectious individual into a fully susceptible population.<xref rid="bib157" ref-type="bibr"><sup>232</sup></xref> If the population is not immune to the infection, then an infected person can theoretically infect as many as four more people throughout the infectious period if the R<sub>0</sub> is 4. For example, if R<sub>0</sub> is 4, the herd immunity threshold is 0.75, which can be calculated with the formula 1&#8211;1/R<sub>0</sub>.<xref rid="bib158" ref-type="bibr"><sup>233</sup></xref> The interaction between the host and pathogen determines R<sub>0</sub> in a given population, and this value may vary among pathogens. Variables such as population characteristics and the dynamics of disease transmission may affect R<sub>0</sub>.<xref rid="bib159" ref-type="bibr"><sup>234</sup></xref></p><p id="p0205">R<sub>0</sub> is widely used in the research of infectious disease dynamics, as one of the most fundamental metrics.<xref rid="bib160" ref-type="bibr">235</xref>, <xref rid="bib161" ref-type="bibr">236</xref>, <xref rid="bib162" ref-type="bibr">237</xref> In most cases, the R<sub>0</sub> for an infectious disease event is given as a single number or low-to-high range, and its interpretation is as follows: if R<sub>0</sub>&#160;&gt;&#160;1, the outbreak is predicted to continue, and if R<sub>0</sub>&#160;&lt;&#160;1, it is expected to cease.<xref rid="bib157" ref-type="bibr"><sup>232</sup></xref> R<sub>0</sub> can be used to estimate the percentage of a population that must be vaccinated to eliminate an infection; hence, it is commonly used to estimate the potential size of an outbreak or epidemic.<xref rid="bib159" ref-type="bibr"><sup>234</sup></xref> Many communicable diseases have reported R<sub>0</sub> values, including Ebola virus disease, measles, influenza, polio, acquired immunodeficiency syndrome (AIDS) and a variety of vector borne infectious diseases.<xref rid="bib163" ref-type="bibr">238</xref>, <xref rid="bib164" ref-type="bibr">239</xref>, <xref rid="bib165" ref-type="bibr">240</xref></p><p id="p0210">The threshold of herd immunity to alleviate or slow the COVID-19 pandemic depends on the R<sub>0</sub> for SARS-CoV-2. This threshold is described as the proportion of a population immune to an infectious disease, be it as the result of vaccination, natural infection or innate immunity, such that serial transmission of the infectious agent of the communicable disease is precluded or substantially decreased.<xref rid="bib151" ref-type="bibr"><sup>226</sup></xref> However, because COVID-19 remains actively spreading, the precise R<sub>0</sub> number is difficult to determine. Therefore, over time, the value of R<sub>0</sub> is inconstant, varying over a wide range of values at different areas in the interconnected world, depending on the outbreak stages and policymakers' strategies to control the infection, which differ across countries and often across regions within a single country.</p><p id="p0215">Initial R<sub>0</sub> predictions for COVID-19 differed among different populations. Most values have ranged from 1.66 to 3.58.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib166" ref-type="bibr">241</xref>, <xref rid="bib167" ref-type="bibr">242</xref>, <xref rid="bib168" ref-type="bibr">243</xref> For instance, the first R<sub>0</sub> value was reported in Wuhan, China, to be 2.2.<xref rid="bib169" ref-type="bibr"><sup>244</sup></xref> More recently, however, the team from the University of Oxford has estimated the R<sub>0</sub> to be 2.63.<xref rid="bib170" ref-type="bibr"><sup>245</sup></xref> Variants including Alpha, Gamma and Beta have reproductive numbers estimated at 4.7&#8211;4.9,<xref rid="bib171" ref-type="bibr"><sup>246</sup></xref> whereas the Delta variant has a reproductive number of approximately 5.<xref rid="bib172" ref-type="bibr"><sup>247</sup></xref><sup>,</sup><xref rid="bib173" ref-type="bibr"><sup>248</sup></xref> Preliminary estimates of reproductive numbers of the Omicron variant are 4.2 times greater than those of the Delta variant.<xref rid="bib174" ref-type="bibr"><sup>249</sup></xref> Thus, as R<sub>0</sub> values increase, estimates of the herd immunity threshold also increase. R<sub>0</sub> is influenced by demographic and social factors, including individual behavior, public health indicators, population density and cultural attitudes, thus leading to wide variations in herd immunity threshold estimations. In addition, the herd immunity threshold formula is dependent on the notion that COVID-19 has the ability to mutate to escape the immune system, and also on the nature of immune responses toward non-systemic respiratory viruses in general, which appear to be transient and only partially effective.<xref rid="bib175" ref-type="bibr"><sup>250</sup></xref><sup>,</sup><xref rid="bib176" ref-type="bibr"><sup>251</sup></xref> Thus, the central epidemiological question is what proportion of the population should be infected for herd immunity to be achieved and the community protected from contracting and/or spreading infectious SARS-CoV-2. However, given the relatively high number of people who should be infected and might potentially die from SARS-CoV-2 infection for herd immunity to be achieved, strategies to achieve the acquired immunity via natural COVID-19 infection would be difficult to accomplish. Therefore, the WHO recommends that herd immunity against COVID-19 be obtained through vaccination rather than by exposing people to the virus that causes the disease, to avoid unwanted new cases and increased mortality.<xref rid="bib14" ref-type="bibr"><sup>6</sup></xref></p><p id="p0220">In 2016, the annual number of deaths due to measles was less than 100,000, a number significantly lower than the more than 2 million deaths due to COVID-19 reported during the pre-vaccination period.<xref rid="bib177" ref-type="bibr"><sup>252</sup></xref> To achieve herd immunity, the WHO has set the limit of 95% of the population that should be immunized, because of the high infectivity of measles.<xref rid="bib178" ref-type="bibr"><sup>253</sup></xref> Accordingly, despite the lower mortality rate of COVID-19, its high infectivity requires a high proportion of the population to develop immunity to stop the spread of the infection, thereby reflecting the challenges in creating herd immunity. Deciding on priority groups to receive COVID-19 vaccination is challenging not only because of the limited supply of vaccines with early approval for HCWs, older people, and the middle-aged community,<xref rid="bib179" ref-type="bibr"><sup>254</sup></xref> but also because of direct effects on herd immunity. Another issue is the duration of immunity offered by the vaccination program. Because SARS-CoV-2 remains relatively new, the duration of the immunity memory, particularly in terms of epitope stability due to viral mutation, remains a large unknown.<xref rid="bib180" ref-type="bibr"><sup>255</sup></xref></p><p id="p0225">Both vaccinated people and convalescent patients with COVID-19 have shown lower binding of NAbs,<xref rid="bib181" ref-type="bibr">256</xref>, <xref rid="bib182" ref-type="bibr">257</xref>, <xref rid="bib183" ref-type="bibr">258</xref> and vaccine effectiveness has been lower in regions where the Gamma and Beta strains are more widespread.<xref rid="bib184" ref-type="bibr"><sup>259</sup></xref><sup>,</sup><xref rid="bib185" ref-type="bibr"><sup>260</sup></xref> In addition, Omicron has 32 S protein mutations that decrease NAb titers by 27&#8211;127 times relative to that of wild-type COVID-19.<xref rid="bib186" ref-type="bibr"><sup>261</sup></xref> The Omicron variant of the coronavirus, which is spreading more quickly than previous variants, is unlikely to help countries achieve herd immunity against COVID-19, wherein individuals would become immune to the virus with decreased spreading rates.<xref rid="bib187" ref-type="bibr"><sup>262</sup></xref> The Omicron variant's transmissibility is enhanced because it is more effective than its predecessors at infecting people who have been vaccinated or have previously been infected. Growing evidence indicates that the coronavirus will continue to develop new ways to overcome immune responses.<xref rid="bib187" ref-type="bibr"><sup>262</sup></xref> According to recently published studies, vaccination effectiveness against Omicron-associated symptoms is lower than that for other variants, and it decreases over time. Consequently, more people who have been vaccinated against Omicron are at risk of developing severe disease.<xref rid="bib188" ref-type="bibr">263</xref>, <xref rid="bib189" ref-type="bibr">264</xref>, <xref rid="bib190" ref-type="bibr">265</xref></p><p id="p0230">However, these studies also suggest that vaccination continues to provide substantial protection against severe disease and hospitalization, owing to the variety of diseases caused by the Omicron variant. People who have received a booster dose may be more protected than those who have received only the initial course, as suggested by the most recent evidence, including real-world effectiveness data. In South Africa, individuals who have received two doses of the Pfizer&#8211;BioNTech vaccine, for example, have been found to have as much as 70% protection against hospitalization.<xref rid="bib189" ref-type="bibr"><sup>264</sup></xref> Additionally, during the proxy Omicron period, the BNT162b2 vaccine maintained its effectiveness, albeit at a lower level, against hospital admission due to COVID-19 thought to have been caused by the Omicron variant than the Delta variant. The UK surveillance report has also revealed that after a booster dose of either the Pfizer or Moderna vaccine, the vaccination effectiveness against symptomatic disease among Omicron-infected patients was 60%&#8211;75% in the first 2&#8211;4 weeks, after which it decreased to 25%&#8211;40% in the next 15+ weeks.<xref rid="bib190" ref-type="bibr"><sup>265</sup></xref></p><p id="p0235">Despite the high infection rates, the two-dose COVID-19 vaccine strategy has significantly decreased hospitalizations and deaths.<xref rid="bib191" ref-type="bibr"><sup>266</sup></xref><sup>,</sup><xref rid="bib192" ref-type="bibr"><sup>267</sup></xref> Similarly to other vaccines, the second dose loses some of its protective efficacy within several months.<xref rid="bib193" ref-type="bibr"><sup>268</sup></xref><sup>,</sup><xref rid="bib194" ref-type="bibr"><sup>269</sup></xref> Previous studies have shown that, as any with other vaccine, COVID-19 vaccines show a decline in the levels of binding and NAbs with time.<xref rid="bib193" ref-type="bibr">268</xref>, <xref rid="bib194" ref-type="bibr">269</xref>, <xref rid="bib195" ref-type="bibr">270</xref> A preprint has indicated that at least 20 weeks after the second dose of the SARS-CoV-2 vaccine, the efficiency of ChAdOx1 nCoV-19 (Oxford-AstraZeneca) was 44.1%, and that of BNT162b2 (Pfizer-BioNtech) was 62.5%.<xref rid="bib196" ref-type="bibr"><sup>271</sup></xref><sup>,</sup><xref rid="bib197" ref-type="bibr"><sup>272</sup></xref> In Qatar, researchers have observed similar findings, with the exception that the effectiveness against hospitalization and death remained strong even after 6 months.<xref rid="bib198" ref-type="bibr">273</xref>, <xref rid="bib199" ref-type="bibr">274</xref>, <xref rid="bib200" ref-type="bibr">275</xref> Similarly, a large study conducted in the USA has found that the risk of infection significantly increases 6 months after vaccination, and mRNA-based vaccines have a substantially lower increase in risk than the viral vector-based vaccine Ad.26.COV2.S (Janssen).<xref rid="bib201" ref-type="bibr"><sup>276</sup></xref> Booster doses of BNT162b2 after vaccination have been shown in two Israeli studies to increase protection against symptomatic infection by 93.1%.<xref rid="bib202" ref-type="bibr"><sup>277</sup></xref><sup>,</sup><xref rid="bib203" ref-type="bibr"><sup>278</sup></xref> Both humoral and cellular responses to SARS-CoV-2 have been reported to be enhanced by booster doses in the COV-BOOST randomized controlled trial in the UK, with adverse effects similar to those seen after initial vaccination.<xref rid="bib204" ref-type="bibr"><sup>279</sup></xref> Moreover, the effectiveness against infection for both mRNA (mRNA-1273 [Moderna] and BNT162b2) and viral vector (ChAdOx1 nCov-19) COVID-19 vaccines has been shown to dramatically decline over 5&#8211;8 months, with respect to that 1 month after the second dose.<xref rid="bib205" ref-type="bibr"><sup>280</sup></xref> Moreover, a booster dose administered 6 months after the second vaccination has been found to restore the vaccine's efficacy to levels greater than those reported 1 month after the second vaccination. Those who received a heterologous booster schedule experienced a higher rate of systemic reactogenicity after vaccination than those who received a homologous booster, although both groups experienced very mild adverse effects after the booster vaccination.<xref rid="bib205" ref-type="bibr"><sup>280</sup></xref> Moreover, according to a study conducted in Canada, the effectiveness of vaccines in vaccinated individuals (compared with unvaccinated individuals) increased with each additional dose, and provided 49% (95% confidence interval 43%&#8211;54%) protection against infection, 69% (61%&#8211;76%) protection against symptomatic infection and 86% (81%&#8211;90%) protection against severe outcomes after the fourth dose.<xref rid="bib206" ref-type="bibr"><sup>281</sup></xref> During the Omicron dominant era, results have suggested that a fourth dose of the mRNA COVID-19 vaccine (mRNA-1273) provides better protection against infection, symptomatic infection and severe outcomes for people living in long-term care centers.<xref rid="bib206" ref-type="bibr"><sup>281</sup></xref> According to the available findings, vaccine boosters are safe for the general public and effective at restoring immunity after a period of waning protection. Homologous booster schedules have more favorable safety profiles than heterologous booster schedules.</p><p id="p0240">The efficacy of COVID-19 vaccines against asymptomatic infection may still be associated with transmission and is generally less efficient and may be less adequately estimated than that against symptomatic infection.<xref rid="bib207" ref-type="bibr"><sup>282</sup></xref><sup>,</sup><xref rid="bib208" ref-type="bibr"><sup>283</sup></xref> In a retrospective study conducted on HCWs who received the Pfizer vaccine, the vaccine efficiency for avoiding symptomatic infection was 97%, but was only 86% for avoiding asymptomatic disease.<xref rid="bib209" ref-type="bibr"><sup>284</sup></xref> The efficacy of the Moderna vaccine against asymptomatic disease was only 63%, as compared with 93.2% against symptomatic infection, whereas the efficacy of the AstraZeneca vaccine with the original dose regimen was only 3.8%.<xref rid="bib185" ref-type="bibr"><sup>260</sup></xref><sup>,</sup><xref rid="bib210" ref-type="bibr"><sup>285</sup></xref> Therefore, &#8220;universal vaccinations&#8221; as vaccine regimens that generate longer-lasting immunity and cover a wider range of potential future mutations may help decrease some of the problems associated with herd immunity against respiratory viruses. However, this type of vaccine remains under investigation.<xref rid="bib211" ref-type="bibr"><sup>286</sup></xref></p><p id="p0245">Herd immunity against COVID-19 can be safely achieved only by vaccinating large numbers of people, thereby decreasing overall viral transmission in the entire population. On the basis of the opinion of many experts, increasing evidence suggests that 80%&#8211;90% of the population would be required to have COVID-19 immunity for herd immunity to be effective.<xref rid="bib212" ref-type="bibr"><sup>287</sup></xref> Vaccinations and prior infection will help enhance herd immunity against COVID-19, thus decreasing the severity of the disease for people who are infected or reinfected.<xref rid="bib187" ref-type="bibr"><sup>262</sup></xref> However, to determine vaccine effectiveness against various outcomes (such as severe disease and subsequent transmission), vaccine effectiveness in various population subgroups and against various variants, as well as vaccine duration of protection, real-world vaccine effectiveness studies after implementation are required.<xref rid="bib190" ref-type="bibr"><sup>265</sup></xref> Herd immunity threshold estimates must therefore consider not only partial vaccine effectiveness, but also changes in critical parameters associated with mutations and with dynamic and steadily declining immunity. <xref rid="tbl3" ref-type="table">Table&#160;3</xref> shows recent RCTs that have indicated assessment of efficacy of candidate vaccines against SARS-CoV-2 infection.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table&#160;3</label><caption><p>Assessment of efficacy of different vaccines against SARS-CoV-2 infection among RCTs (as of October 27, 2022).</p></caption><alt-text id="alttext0050">Table&#160;3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine candidate</th><th colspan="1" rowspan="1">Developers</th><th colspan="1" rowspan="1">Doses</th><th colspan="1" rowspan="1">Trial phase</th><th colspan="1" rowspan="1">Clinical trial numbers</th><th colspan="1" rowspan="1">Efficacy of vaccine against hospitalization for severe and non-severe SARS-CoV-2 infection</th><th colspan="1" rowspan="1">Efficacy of vaccine against emergency department visits associated with SARS-CoV-2 infection</th><th colspan="1" rowspan="1">Efficacy of vaccine against severe and non-severe SARS-CoV-2 infection</th><th colspan="1" rowspan="1">Seroconversion rates (efficacy)</th><th colspan="1" rowspan="1">Immunogenicity and safety of a booster dose</th></tr></thead><tbody><tr><td rowspan="12" colspan="1">CoronaVac; inactivated SARS-CoV-2 vaccine (Vero cells)</td><td rowspan="12" colspan="1">Sinovac Research and Development Co., Ltd</td><td rowspan="12" colspan="1">2</td><td rowspan="12" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04756830" id="intref0480">NCT04756830</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04789356" id="intref0485">NCT04789356</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04801888" id="intref0490">NCT04801888</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04894227?term=NCT04894227&amp;draw=2&amp;rank=1" id="intref0495">NCT04894227</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04892459?term=NCT04892459&amp;draw=2&amp;rank=1" id="intref0500">NCT04892459</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04953325?term=NCT04953325&amp;draw=2&amp;rank=1" id="intref0505">NCT04953325</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04962308?term=vaccine&amp;recrs=abdf&amp;cond=COVID-19&amp;phase=012345&amp;sort=nwst&amp;draw=2&amp;rank=9" id="intref0510">NCT04962308</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05057169" id="intref0515">NCT05057169</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05148949" id="intref0520">NCT05148949</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05112913" id="intref0525">NCT05112913</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05165966" id="intref0530">NCT05165966</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">TCTR20210308003</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="7" colspan="1">Inactivated SARS-CoV-2 vaccine (Vero cells)<break/>WIBP COVID-19 vaccine</td><td rowspan="7" colspan="1">Sinopharm;<break/>China National Biotec Group Co;<break/>Wuhan Institute of Biological Products</td><td rowspan="7" colspan="1">2</td><td rowspan="7" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05065892" id="intref0535">NCT05065892</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05075044" id="intref0540">NCT05075044</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05075057" id="intref0545">NCT05075057</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04790851" id="intref0550">NCT04790851</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04863638" id="intref0555">NCT04863638</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05065879" id="intref0560">NCT05065879</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05075083" id="intref0565">NCT05075083</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="10" colspan="1">ChAdOx1-S (AZD1222)<break/>Covishield<break/>Vaxzevria</td><td rowspan="10" colspan="1">AstraZeneca + University of Oxford</td><td rowspan="10" colspan="1">1&#8211;2</td><td rowspan="7" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04760132" id="intref0570">NCT04760132</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04775069" id="intref0575">NCT04775069</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">EUCTR2021-002327-38-NL</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04914832?term=vaccine&amp;type=Intr&amp;draw=2&amp;rank=42" id="intref0580">NCT04914832</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000661875" id="intref0585">ACTRN12621000661875</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">RBR-4vmh6xg</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-004419-14/FI" id="intref0590">EUCTR2021-004419-14-FI</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="3" colspan="1">phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04864561" id="intref0595">NCT04864561</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04756271" id="intref0600">NCT04756271</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04536051" id="intref0605">NCT04536051</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">Recombinant novel coronavirus vaccine (adenovirus type 5 vector)<break/>Ad5-nCoV</td><td rowspan="2" colspan="1">CanSino Biological Inc./Beijing Institute of Biotechnology</td><td rowspan="2" colspan="1">1</td><td rowspan="2" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04892459?term=NCT04892459&amp;draw=2&amp;rank=1" id="intref0610">NCT04892459</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05303584" id="intref0615">NCT05303584</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="3" colspan="1">Recombinant COVID-19 vaccine (adenovirus type 5 vector) for inhalation (Ad5-nCoV-IH)</td><td rowspan="3" colspan="1">CanSino Biological Inc./Beijing Institute of Biotechnology</td><td rowspan="3" colspan="1">1</td><td colspan="1" rowspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05303584" id="intref0620">NCT05303584</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05169008" id="intref0625">NCT05169008</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05204589" id="intref0630">NCT05204589</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="7" colspan="1">Gam-COVID-Vac Adeno-based (rAd26-S&#160;+&#160;rAd5-S); Sputnik V COVID-19 vaccine</td><td rowspan="7" colspan="1">Gamaleya Research Institute; Health Ministry of the Russian Federation</td><td rowspan="7" colspan="1">2</td><td rowspan="7" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&amp;cond=covid-19&amp;draw=3" id="intref0635">NCT04530396</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04564716?term=vaccine&amp;cond=covid-19&amp;draw=3" id="intref0640">NCT04564716</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">CTRI/2022/04/041792</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT04642339" id="intref0645">NCT04642339</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04656613?term=vaccination&amp;cond=covid&amp;draw=2&amp;rank=53" id="intref0650">NCT04656613</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04741061?id=NCT04733807+OR+NCT04718467+OR+NCT04706156+OR+NCT04743947+OR+NCT04715997+OR+NCT04732468+OR+NCT04713488+OR+NCT04741061&amp;draw=2&amp;rank=2&amp;load=cart" id="intref0655">NCT04741061</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">PACTR202104601572565</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="8" colspan="1">Ad26.COV2.S</td><td rowspan="8" colspan="1">Janssen Pharmaceutical (Johnson &amp; Johnson)</td><td rowspan="8" colspan="1">1&#8211;2</td><td rowspan="3" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002327-38/NL" id="intref0660">EUCTR2021-002327-38-NL</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05037266" id="intref0665">NCT05037266</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05075538" id="intref0670">NCT05075538</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td rowspan="5" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04614948" id="intref0675">NCT04614948</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05047640" id="intref0680">NCT05047640</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05091307" id="intref0685">NCT05091307</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05142319" id="intref0690">NCT05142319</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=15686" id="intref0695">PACTR202102855526180</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="8" colspan="1">SARS-CoV-2 rS/matrix M1-adjuvant; full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with matrix M; NVX-CoV2373</td><td rowspan="8" colspan="1">Novavax</td><td rowspan="8" colspan="1">2</td><td rowspan="8" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04611802" id="intref0700">NCT04611802</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05463068" id="intref0705">NCT05463068</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2020-004123-16-GB" id="intref0710">EUCTR2020-004123-16-GB</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">CTRI/2022/04/042017</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05556720" id="intref0715">NCT05556720</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05249816" id="intref0720">NCT05249816</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05372588" id="intref0725">NCT05372588</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04583995" id="intref0730">NCT04583995</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="13" colspan="1">mRNA-1273; Spikevax</td><td rowspan="13" colspan="1">Moderna&#160;+&#160;National Institute of Allergy and Infectious Diseases (NIAID)</td><td rowspan="13" colspan="1">2</td><td rowspan="12" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04760132?term=vaccine%2C+phase+4&amp;cond=Covid19&amp;draw=2&amp;rank=1" id="intref0735">NCT04760132</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04885907" id="intref0740">NCT04885907</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002327-38/NL" id="intref0745">EUCTR2021-002327-38-NL</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003388-90/NL" id="intref0750">EUCTR2021-003388-90-NL</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">EUCTR2021-001202-30-NL</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04952402" id="intref0755">NCT04952402</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003618-37/NO" id="intref0760">EUCTR2021-003618-37-NO</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05030974" id="intref0765">NCT05030974</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05047718" id="intref0770">NCT05047718</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05079633" id="intref0775">NCT05079633</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05075538" id="intref0780">NCT05075538</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">EUCTR2021-004419-14-FI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05387317" id="intref0785">NCT05387317</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="14" colspan="1">BNT162b2 (3 LNP-mRNAs), also known as Comirnaty</td><td rowspan="14" colspan="1">Pfizer/BioNTech&#160;+&#160;Fosun Pharma</td><td rowspan="14" colspan="1">2</td><td rowspan="13" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04760132?term=vaccine%2C+phase+4&amp;cond=Covid19&amp;draw=2&amp;rank=1" id="intref0790">NCT04760132</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04780659?term=vaccine&amp;cond=Covid19&amp;draw=2&amp;rank=14" id="intref0795">NCT04780659</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://https/clinicaltrials.gov/ct2/show/NCT04775069" id="intref0800">NCT04775069</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000893-27/BE" id="intref0805">EUCTR2021-000893-27-BE</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000930-32/BE" id="intref0810">EUCTR2021-000930-32-BE</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">RBR-4vmh6xg</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04852861" id="intref0815">NCT04852861</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04878211" id="intref0820">NCT04878211</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003618-37/NO" id="intref0825">EUCTR2021-003618-37-NO</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04952766?term=vaccine&amp;recrs=abdf&amp;cond=COVID-19&amp;phase=012345&amp;sort=nwst&amp;draw=1&amp;rank=20" id="intref0830">NCT04952766</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04969250?term=NCT04969250&amp;draw=2&amp;rank=1" id="intref0835">NCT04969250</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05057169" id="intref0840">NCT05057169</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05160766" id="intref0845">NCT05160766</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05405283" id="intref0850">NCT05405283</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="3" colspan="1">Recombinant SARS-CoV-2 vaccine (CHO Cell); Zifivax (ZF2001)</td><td rowspan="3" colspan="1">Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.</td><td rowspan="3" colspan="1">2&#8211;3</td><td rowspan="3" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05091411" id="intref0855">NCT05091411</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04646590" id="intref0860">NCT04646590</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05128643" id="intref0865">NCT05128643</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="3" colspan="1">CVnCoV vaccine</td><td rowspan="3" colspan="1">CureVac AG</td><td rowspan="3" colspan="1">2</td><td rowspan="3" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04674189" id="intref0870">NCT04674189</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04838847" id="intref0875">NCT04838847</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04860258?term=NCT04860258&amp;draw=2&amp;rank=1" id="intref0880">NCT04860258</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="4" colspan="1">SARS-CoV-2 vaccine (Vero cells)</td><td rowspan="4" colspan="1">Institute of Medical Biology&#160;+&#160;Chinese Academy of Medical Sciences</td><td rowspan="4" colspan="1">2</td><td rowspan="4" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04659239" id="intref0885">NCT04659239</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05163652" id="intref0890">NCT05163652</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05033847" id="intref0895">NCT05033847</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05164731" id="intref0900">NCT05164731</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">QazCovid-in&#174;; COVID-19 inactivated vaccine</td><td colspan="1" rowspan="1">Research Institute for Biological Safety Problems, Rep of Kazakhstan</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04691908" id="intref0905">NCT04691908</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">INO-4800+electroporation</td><td colspan="1" rowspan="1">Inovio Pharmaceuticals&#160;+&#160;International Vaccine Institute&#160;+&#160;Advaccine (Suzhou) Biopharmaceutical Co., Ltd</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.isrctn.com/ISRCTN15779782" id="intref0910">ISRCTN15779782</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">AG0301-COVID19</td><td colspan="1" rowspan="1">AnGes&#160;+&#160;Takara Bio&#160;+&#160;Osaka University</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 2/3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04655625?term=vaccination&amp;cond=covid&amp;draw=1&amp;rank=129" id="intref0915">NCT04655625</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">nCov vaccine</td><td colspan="1" rowspan="1">Zydus Cadila</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1">CTRI/2020/07/026352</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">BBV152 vaccine; COVAXIN</td><td colspan="1" rowspan="1">Bharat Biotech International Limited</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04641481" id="intref0920">NCT04641481</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="4" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VAT00008">VAT00008</ext-link>: SARS-CoV-2 S protein with adjuvant</td><td rowspan="4" colspan="1">Sanofi Pasteur&#160;+&#160;GSK</td><td rowspan="4" colspan="1">2</td><td rowspan="4" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13475" id="intref0925">PACTR202011523101903</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05124171" id="intref0930">NCT05124171</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05405283" id="intref0935">NCT05405283</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT04904549" id="intref0940">NCT04904549</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Inactivated SARS-CoV-2 vaccine (Vero cells)</td><td colspan="1" rowspan="1">Shenzhen Kangtai Biological Products Co., Ltd.</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04852705?term=vaccine&amp;recrs=abdf&amp;cond=COVID-19&amp;phase=0123&amp;sort=nwst&amp;draw=2&amp;rank=1" id="intref0945">NCT04852705</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">GRAd-COV2; replication defective simian adenovirus (GRAd) encoding S</td><td colspan="1" rowspan="1">ReiThera&#160;+ Leukocare&#160;+&#160;Univercells</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Phase 2/3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04791423" id="intref0950">NCT04791423</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">CpG 1018/alum-adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019)</td><td colspan="1" rowspan="1">Clover Biopharmaceuticals Inc./Dynavax</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05012787" id="intref0955">NCT05012787</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="3" colspan="1">MVC-COV1901; spike-2P protein&#160;+&#160;adjuvant CpG 1018; MVC-COV1901(Beta)</td><td rowspan="3" colspan="1">Medigen Vaccine Biologics&#160;+&#160;Dynavax&#160;+&#160;National Institute of Allergy and Infectious Diseases</td><td rowspan="3" colspan="1">2</td><td rowspan="2" colspan="1">Phase 4</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05079633" id="intref0960">NCT05079633</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05097053" id="intref0965">NCT05097053</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05198596" id="intref0970">NCT05198596</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">FINLAY-FR-2 anti-SARS-CoV-2 vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant)<break/>Soberana 02</td><td colspan="1" rowspan="1">Instituto Finlay de Vacunas</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://https/rpcec.sld.cu/en/trials/RPCEC00000354-En" id="intref0975">RPCEC00000354</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)</td><td colspan="1" rowspan="1">Federal Budgetary Research Institution State Research Center of Virology and Biotechnology &#8220;Vector&#8221;</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04780035?term=vaccine&amp;cond=Covid19&amp;draw=2" id="intref0980">NCT04780035</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">RBD (baculovirus production expressed in Sf9 cells); recombinant SARS-CoV-2 vaccine (Sf9 cells)</td><td rowspan="2" colspan="1">West China Hospital&#160;+&#160;Sichuan University<break/>WestVac Biopharma Co., Ltd.</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04887207" id="intref0985">NCT04887207</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04904471?term=NCT04904471&amp;draw=2&amp;rank=1" id="intref0990">NCT04904471</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">UB-612 (Multitope peptide based S1-RBD-protein based vaccine)</td><td colspan="1" rowspan="1">Vaxxinity</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05293665" id="intref0995">NCT05293665</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD)</td><td rowspan="2" colspan="1">University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1">ChiCTR2100051391</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=17163" id="intref1000">PACTR202110872285345</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2 mRNA vaccine (ARCoV)</td><td colspan="1" rowspan="1">Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04847102" id="intref1005">NCT04847102</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">Coronavirus-like particle COVID-19 (CoVLP); MT-2766</td><td rowspan="2" colspan="1">Medicago Inc.</td><td rowspan="2" colspan="1">2</td><td colspan="1" rowspan="1">Phase 2/3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04636697" id="intref1010">NCT04636697</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05040789" id="intref1015">NCT05040789</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">COVI-VAC</td><td colspan="1" rowspan="1">Codagenix/Serum Institute of India</td><td colspan="1" rowspan="1">1&#8211;2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.isrctn.com/ISRCTN15779782" id="intref1020">ISRCTN15779782</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">CIGB-66 (RBD&#160;+&#160;aluminum hydroxide)</td><td colspan="1" rowspan="1">Center for Genetic Engineering and Biotechnology (CIGB)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://rpcec.sld.cu/trials/RPCEC00000359-En" id="intref1025">RPCEC00000359</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">VLA2001</td><td rowspan="2" colspan="1">Valneva&#160;+&#160;National Institute for Health Research, UK</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04864561" id="intref1030">NCT04864561</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04956224?term=vaccine&amp;recrs=abdf&amp;cond=COVID-19&amp;phase=012345&amp;sort=nwst&amp;draw=1&amp;rank=12" id="intref1035">NCT04956224</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">BECOV2</td><td colspan="1" rowspan="1">Biological E. Limited</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=59772" id="intref1040">CTRI/2021/08/036074</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Recombinant SARS-CoV-2 spike protein, aluminum adjuvanted (Nanocovax)</td><td colspan="1" rowspan="1">Nanogen Pharmaceutical Biotechnology</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04922788" id="intref1045">NCT04922788</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">Recombinant protein vaccine&#160;S-268019 (using baculovirus expression vector system)</td><td rowspan="2" colspan="1">Shionogi</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05212948" id="intref1050">NCT05212948</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">JPRN-jRCT2031210613</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">TURKOVAC; inactivated virus</td><td rowspan="2" colspan="1">Erciyes University and the Health Institutes of Turkey (TUSEB)</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04942405?term=TURKOVAC&amp;draw=1&amp;rank=1" id="intref1055">NCT04942405</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05077176" id="intref1060">NCT05077176</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminum hydroxide)</td><td colspan="1" rowspan="1">SK Bioscience Co., Ltd. and CEPI</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05007951" id="intref1065">NCT05007951</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Razi Cov Pars, recombinant spike protein</td><td colspan="1" rowspan="1">Razi Vaccine and Serum Research Institute</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://en.irct.ir/trial/57980" id="intref1070">IRCT20210206050259N3</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">COVID-19 inactivated vaccine, (CovIran-Barkat)</td><td colspan="1" rowspan="1">Shifa Pharmed Industrial Co</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 2/3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://en.irct.ir/trial/54881" id="intref1075">IRCT20201202049567N3</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">ReCOV: recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cells)</td><td colspan="1" rowspan="1">Jiangsu Rec-Biotechnology</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05398848" id="intref1080">NCT05398848</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">ABNCoV2 capsid virus-like particle (cVLP)&#160;&#177;&#160;adjuvant MF59</td><td colspan="1" rowspan="1">Radboud University</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05329220" id="intref1085">NCT05329220</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">Recombinant SARS-CoV-2 fusion protein vaccine (V-01)</td><td rowspan="2" colspan="1">Livzon Pharmaceutical</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05096832" id="intref1090">NCT05096832</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05096845" id="intref1095">NCT05096845</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Inactivated COVID-19 vaccine</td><td colspan="1" rowspan="1">KM Biologics Co., Ltd.</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1">JRCT2031210679</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">RBD protein recombinant SARS-CoV-2 vaccine (Noora vaccine)</td><td colspan="1" rowspan="1">Bagheiat-allah University of Medical Sciences/AmitisGen</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://en.irct.ir/trial/60796" id="intref1100">IRCT20210620051639N3</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">Recombinant protein RBD fusion dimer adjuvanted vaccine; COVID-19 vaccine Hipra; PHH-1V</td><td rowspan="2" colspan="1">Laboratorios Hipra, S.A.</td><td rowspan="2" colspan="1">2</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05246137" id="intref1105">NCT05246137</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05303402" id="intref1110">NCT05303402</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ARCT-154 mRNA Vaccine</td><td colspan="1" rowspan="1">Arcturus Therapeutics, Inc.</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.isrctn.com/ISRCTN15779782" id="intref1115">ISRCTN15779782</ext-link></td><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td rowspan="2" colspan="1">SCTV01C; bivalent recombinant trimeric S protein vaccine against SARS-CoV-2 variants</td><td rowspan="2" colspan="1">Sinocelltech Ltd.</td><td rowspan="2" colspan="1">1</td><td rowspan="2" colspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05308576" id="intref1120">NCT05308576</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05323461" id="intref1125">NCT05323461</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1">&#10003;</td></tr><tr><td colspan="1" rowspan="1">Inactivated whole virion concentrated purified vaccine (CoviVac)</td><td colspan="1" rowspan="1">Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Phase 3</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05407142" id="intref1130">NCT05407142</ext-link></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#10003;</td></tr></tbody></table><table-wrap-foot><fn><p>NCT, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov" id="intref1135">clinicaltrials.gov</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/home" id="intref1140">https://clinicaltrials.gov/ct2/home</ext-link>); IRCT, Iranian Registry of Clinical Trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://en.irct.ir/" id="intref1145">https://en.irct.ir/</ext-link>); ChiCTR, Chinese Clinical Trial Registry (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.chictr.org.cn/searchprojen.aspx" id="intref1150">https://www.chictr.org.cn/searchprojen.aspx</ext-link>); EUCTR, European Union Clinical Trials Register (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/search" id="intref1155">https://www.clinicaltrialsregister.eu/ctr-search/search</ext-link>); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://anzctr.org.au/Default.aspx" id="intref1160">ANZCTR</ext-link>, Australian New Zealand Clinical Trials Registry (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://anzctr.org.au/Default.aspx" id="intref1165">https://anzctr.org.au/Default.aspx</ext-link>); PACTR, Pan African Clinical Trials Registry (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pactr.samrc.ac.za/Search.aspx" id="intref1170">https://pactr.samrc.ac.za/Search.aspx</ext-link>); ISRCTN, International Standard Randomized Controlled (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.isrctn.com" id="intref1175">https://www.isrctn.com</ext-link>); CTRI, Clinical Trials Registry-India (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ctri.nic.in/Clinicaltrials/login.php" id="intref1180">http://ctri.nic.in/Clinicaltrials/login.php</ext-link>); RPCEC, Cuban Public Registry of Clinical Trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://rpcec.sld.cu/trials" id="intref1185">https://rpcec.sld.cu/trials</ext-link>); JPRN, Japan Primary Registries Network (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://rctportal.niph.go.jp/en/link" id="intref1190">https://rctportal.niph.go.jp/en/link</ext-link>); JRCT, Japan Registry of Clinical Trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jrct.niph.go.jp/" id="intref1195">https://jrct.niph.go.jp/</ext-link>); RBR, Brazilian Registry of Clinical Trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ensaiosclinicos.gov.br/" id="intref1200">https://ensaiosclinicos.gov.br/</ext-link>).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec7"><title>SARS-CoV-2 reinfection</title><p id="p0250">One of the largest enigmas surrounding COVID-19 is the probability of reinfection and/or reactivation of latent viral hideouts in the body, as well as the potential negative effects of some drugs on the formation of acquired immunity to the virus. These questions can be considered central for biomedical scientists fighting the outbreak of SARS-CoV-2.<xref rid="bib213" ref-type="bibr"><sup>288</sup></xref> Until nearly the third month of the COVID-19 pandemic, scientists expected that the disease would be non-relapsing and would be eliminated through immunization, such that all recovered patients would gain sufficient acquired immunity to SARS-CoV-2. However, as the number of patients with COVID-19 increased, some recovered patients reported relapse of COVID-19 signs and symptoms after they were completely cured and discharged from hospitals after displaying repeatedly positive SARS-CoV-2 RT-PCR tests. Hence, the dilemma of COVID-19 reinfection versus acquired immunity to SARS-CoV-2 has been raised and requires further research.</p><p id="p0255">The first report showing a positive SARS-CoV-2 RT-PCR assay for a convalescent case (after two consecutive negative results) was from China.<xref rid="bib214" ref-type="bibr"><sup>289</sup></xref> Another case report described three patients with COVID-19 who were readmitted in March 2020 to a hospital in Wuhan, China, after having recovered with positive SARS-CoV-2 IgG antibody, negative SARS-CoV-2 RT-PCR and negative SARS-CoV-2 IgM antibody tests.<xref rid="bib215" ref-type="bibr"><sup>290</sup></xref> Those patients were readmitted because of positive SARS-CoV-2 RT-PCR results after convalescence, although they did not display any of the characteristic COVID-19 signs or symptoms again, and the results of their IgG and IgM tests remained stable.<xref rid="bib215" ref-type="bibr"><sup>290</sup></xref> Thereafter, in April 2020, a total of 116 COVID-19 survivors from South Korea tested positive with SARS-CoV-2 RT-PCR tests after recovery.<xref rid="bib216" ref-type="bibr"><sup>291</sup></xref> These positive tests were confirmed according to the Korean criteria, wherein patients must have two consecutive SARS-CoV-2 negative samples within 24&#160;h to be considered to have recovered from COVID-19.<xref rid="bib217" ref-type="bibr"><sup>292</sup></xref> In these two reports, the possibility of reinfection was excluded because of the absence of evidence that the detected SARS-CoV-2 RNA was from replication-competent viruses that could be contagious.</p><p id="p0260">Moreover, a case report has described 11 patients with COVID-19 from France in April and May 2020, who experienced second separate symptomatic SARS-CoV-2 infections after recovery, as confirmed by RT-PCR.<xref rid="bib213" ref-type="bibr"><sup>288</sup></xref> In May 2020, another case of possible COVID-19 reinfection emerged in the USA.<xref rid="bib17" ref-type="bibr"><sup>9</sup></xref> In that case, 1 week after confirmed recovery and discharge, the patient was readmitted with both radiologically and virologically (RT-PCR) confirmed reinfection.<xref rid="bib17" ref-type="bibr"><sup>9</sup></xref> Although two similar cases have been reported in South Korea,<xref rid="bib218" ref-type="bibr"><sup>293</sup></xref> none of these reports have confirmed whether the convalescence was due to viral reactivation from a hideout in the body or to viral reinfection.</p><p id="p0265">In a retrospective study of 55 patients with COVID-19 who had been admitted to a hospital in Wuhan, five were readmitted after recovery and discharge.<xref rid="bib219" ref-type="bibr"><sup>294</sup></xref> All five patients returned with confirmed SARS-CoV-2 infection, as diagnosed on the basis of clinical, laboratory and CT examinations after 4&#8211;17 days; the authors hypothesized that SARS-CoV-2 reactivation was the reason.<xref rid="bib219" ref-type="bibr"><sup>294</sup></xref> The first SARS-CoV-2 reactivation case in Italy was reported 2 weeks after primary infection; the patient was cured, as confirmed by radiology and two consecutive RT-PCR tests. Interestingly, the results indicated the presence of SARS-CoV-2 IgG antibodies in the patient's serum, but not IgM, thus revealing that his immune system was beyond the acute phase of COVID-19.<xref rid="bib220" ref-type="bibr"><sup>295</sup></xref></p><p id="p0270">To investigate the scope of acquired immunity to SARS-CoV-2, another early study conducted by researchers from China infected Rhesus macaques with SARS-CoV-2, then reinfected them after confirmed recovery.<xref rid="bib221" ref-type="bibr"><sup>296</sup></xref> Viral replication was detected (nasopharyngeal and anal swabs), and COVID-19 symptoms were recorded in the primary infection, and neutralizing activity against SARS-CoV-2 was confirmed after recovery. However, the viral replication and signs of COVID-19 were not detected after reinfection, thus suggesting that acquired immunity to SARS-CoV-2 may protect against reinfection.<xref rid="bib221" ref-type="bibr"><sup>296</sup></xref> However, how long the acquired immunity to SARS-CoV-2 lasts is uncertain. A study on individuals infected with COVID-19, for example, has indicated a consistent decrease in neutralizing SARS-CoV-2 antibody levels over a 2&#8211;3 month period following recovery.<xref rid="bib222" ref-type="bibr"><sup>297</sup></xref></p><p id="p0275">These early studies have clarified that reinfection with SARS-CoV-2 is a realistic scenario and not a mere possibility. According to a recent study in Tunisia, reinfection has been detected in four women and HCWs 32&#8211;46 years of age.<xref rid="bib16" ref-type="bibr"><sup>8</sup></xref> Whole-genome sequencing of the viral RNA was performed on the clinical specimens that retested positive for SARS-CoV-2 by RT-PCR after recovery from the first infection and also on samples collected during the initial infection. A reinfection episode was detected in all four patients. Through comparative genome analysis, unique viral lineages were detected among the four patients.<xref rid="bib16" ref-type="bibr"><sup>8</sup></xref> The duration between infection episodes ranged between 45 and 141 days, and symptoms were milder in two patients during the second infection and more severe in the other two patients. Despite the presence of antibodies in three of the patients, all four patients had reinfection.<xref rid="bib16" ref-type="bibr"><sup>8</sup></xref></p><p id="p0280">However, Lumley and colleagues have reported no symptomatic reinfections in HCWs who had anti-spike antibodies, thus indicating that previous SARS-CoV-2 infection may result in anti-spike antibodies that protect against reinfection in most people, at least for the first 6 months.<xref rid="bib223" ref-type="bibr"><sup>298</sup></xref> Recently, in contrast to that after two rounds of vaccination, the IgG response in COVID-19 infected people has been demonstrated to be characterized by insufficient avidity maturation. Insufficient avidity maturation may promote SARS-CoV-2 reinfection and consequently impede the development of herd immunity in susceptible individuals.<xref rid="bib224" ref-type="bibr"><sup>299</sup></xref><sup>,</sup><xref rid="bib225" ref-type="bibr"><sup>300</sup></xref> Remarkably, the conjunction of natural infection and one step of vaccination resulted in the same degree of high IgG avidity as two rounds of vaccination, hence increasing the protective immune response.<xref rid="bib225" ref-type="bibr"><sup>300</sup></xref> According to these findings, individuals who have been exposed to different COVID-19 strains may not be able to develop sufficiently protective immune responses through natural infection, thus highlighting the importance of vaccination and regular monitoring of their immune status, both qualitatively and quantitatively.</p><p id="p0285">A prospective cohort study has recently been conducted among staff at the International Centre for Diarrheal Disease Research in Bangladesh, who had been registered for COVID-19 testing by real-time RT-PCR.<xref rid="bib15" ref-type="bibr"><sup>7</sup></xref> In this study, 750 positive patients were identified to have reinfection, 27.6% of whom required hospitalization and 2.5% of whom died. Among the positive cohort, 731 patients, excluding those who died, who tested positive for COVID-19 (episode 1) were followed up for 0.91 person-years, and 38 (5.7 reinfections/100 person-year) were identified as having reinfection (episode 2). The probability of infection was 80.2% lower in the positive cohort than the negative cohort. Genome sequencing revealed that reinfections were caused by genetically different COVID-19 strains. Naturally infected populations had a lower risk of reinfection with COVID-19 than vaccinated and infection-naive groups. Additionally, the lower mean Ct-value detected among symptomatic patients than asymptomatic patients suggested that the development of COVID-19-like symptoms and seroconversion were due to either a low Ct value or a high viral load.<xref rid="bib15" ref-type="bibr"><sup>7</sup></xref> Although reinfected patients did not develop severe disease, a substantial number of naturally infected or vaccinated people were more likely to be reinfected by emerging strains.</p><p id="p0290">Moreover, another prospective cohort study has reported that among 2625 patients who had at least one SARS-CoV-2 infection across the 10-month study period, 5.94% experienced reinfection, and 20.57% experienced recurrence following the first infection.<xref rid="bib226" ref-type="bibr"><sup>301</sup></xref> The average number of days to reinfection was 126.50 days, whereas the average number of days to recurrence was 31.50 days. The incidence rate of reinfection and recurrence was 0.35 cases/1000 person-days and 1.47 cases/1000 person-days, respectively, and most recurrences was detected within 30 and 60 days after the first infection. Moreover, people working in clinical units were at greater risk of reinfection than those working in non-clinical facilities.<xref rid="bib226" ref-type="bibr"><sup>301</sup></xref> This study contributes to the growing consensus that COVID-19 reinfection, defined as second infection &gt;90 days after initial infection, is uncommon, even among a HCWs who are regularly exposed to the virus. In addition, this study has emphasized the urgent need for widespread vaccination and booster doses to alleviate public health costs.</p><p id="p0295">Although the current vaccines have been demonstrated to be less effective against one or more variants than the original strain, studies have shown that full vaccination is reasonably effective in preventing COVID-19 associated hospitalization and death among vaccinated people compared with non-vaccinated people.<xref rid="bib15" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib185" ref-type="bibr"><sup>260</sup></xref><sup>,</sup><xref rid="bib227" ref-type="bibr">302</xref>, <xref rid="bib228" ref-type="bibr">303</xref>, <xref rid="bib229" ref-type="bibr">304</xref>, <xref rid="bib230" ref-type="bibr">305</xref>, <xref rid="bib231" ref-type="bibr">306</xref> Studies have demonstrated that Pfizer-BioNTech or Moderna vaccination effectively provides cross-variant neutralization against both the Beta (B.1.351) and Alpha variants following a natural infection by boosting the responses of neutralizing antibody elicited by COVID-19 variants.<xref rid="bib232" ref-type="bibr"><sup>307</sup></xref><sup>,</sup><xref rid="bib233" ref-type="bibr"><sup>308</sup></xref> According to these findings, complete vaccination against COVID-19 confers additional protection for people with a previous SARS-CoV-2 infection. In contrast, the molecular evidence for reinfection has indicated that genetically different strains or novel variants can evade the immune response regardless of whether they were acquired from vaccination or natural infection.<xref rid="bib234" ref-type="bibr"><sup>309</sup></xref> In a study by Tan et&#160;al., all patients, even those with minimal symptoms, exhibited a cellular response to COVID-19 antigens, thus providing cause for optimism in terms of preventing reinfections.<xref rid="bib235" ref-type="bibr"><sup>310</sup></xref> In contrast, some authors have postulated mechanisms explaining severe second reinfections, including a larger viral load and acquiring a more pathogenic variant.<xref rid="bib236" ref-type="bibr"><sup>311</sup></xref></p><p id="p0300">In addition, several studies have found lower vaccination effectiveness against the Delta (B.1.617.2) variant than against the Alpha (B.1.1.7) or Wuhan (B.1) variants.<xref rid="bib239" ref-type="bibr">41</xref>, <xref rid="bib237" ref-type="bibr">312</xref>, <xref rid="bib238" ref-type="bibr">313</xref> One of these studies, conducted in Massachusetts, has reported that more than 74% of 469 patients who were predominantly affected by the Delta variant had been fully vaccinated.<xref rid="bib240" ref-type="bibr"><sup>314</sup></xref> Therefore, full understanding of immunity against SARS-CoV-2 infection is urgently needed, to determine the likelihood of second infection and the longevity of vaccine protection. Consequently, assessing the vaccine's effectiveness against newly emerging strains will be critical.</p><p id="p0305">At this point in the discussion, an etymological clarification of the terms &#8220;reinfection&#8221; and &#8220;recrudescence/reactivation&#8221; should be made. These two terms have similar outcomes (i.e., viral infection and outbreak) but differ in the origin/cause. In the case of reinfection, recovered patients are susceptible to infection again by an identical or a new strain of the virus. In contrast, in reactivation, although they are immunologically protected, recovered patients are susceptible to the reappearance of disease symptoms due to the persistence of the virus.<xref rid="bib241" ref-type="bibr"><sup>315</sup></xref> To further understand the underlying mechanisms in cases of COVID-19 reinfection or reactivation, researchers have highlighted the importance of the assessment of adaptive immunity to SARS-CoV-2, and of the genomic comparison of SARS-CoV-2 strains in both episodes.<xref rid="bib213" ref-type="bibr"><sup>288</sup></xref></p><p id="p0310">In general, the occurrence of SARS-CoV-2 reactivation has been suggested to depend on three key risk factors: health status of the host, virological factors (e.g., the viral load and the mutation rate) and whether the host is taking an immunosuppressive medication.<xref rid="bib219" ref-type="bibr"><sup>294</sup></xref> Notably, the false-negative RT-PCR results can be obtained due to a low viral load and technical or human errors.<xref rid="bib214" ref-type="bibr"><sup>289</sup></xref> False-positive results after recovery can also occur because of the recurrence of SARS-CoV-2 RNA fragments as a result of the detoxification process, or because of human or technical errors during sampling, transport, analysis and recording.<xref rid="bib242" ref-type="bibr"><sup>316</sup></xref></p><p id="p0315">In contrast, because the duration of RT-PCR positivity may vary among patients,<xref rid="bib243" ref-type="bibr"><sup>317</sup></xref> viral replication may persist for longer periods than expected, thus resulting in late reactivation. Questions regarding whether SARS-CoV-2 can remain active for longer periods than expected, or can subside and reactivate again, lack clear answers, thus increasing the possibility of silent carrier status development.<xref rid="bib242" ref-type="bibr"><sup>316</sup></xref> Therefore, patients with COVID-19 must crucially be followed during the convalescence period, with a commitment of 14 days quarantine post-discharge. These cases highlight the importance of continuous surveillance of the results of SARS-CoV-2 molecular tests (i.e., quantitative RT-PCR) for the possibility of reinfection and infectivity assessment in patients at convalescence. In addition, the probability of reinfection by the same strain or another genetically mutated strain should be considered.</p><p id="p0320">In addition to the paucity of reports addressing the reinfection dilemma, these reports did not perform crucial comparisons between the genome sequences of SARS-CoV-2 in primary infection and reinfection, and thus could not confirm whether the detected cases of convalescence were due to reinfection or reactivation. Because RT-PCR detects the virus on the basis of a specific small sequence of the viral genome rather than its whole sequence, the test cannot differentiate between reactivation and reinfection, nor can they indicate which strain has caused the reinfection. With this in mind, researchers from the University of Hong Kong have recently followed a case of a confirmed second episode of SARS-CoV-2 infection after more than 4 months of recovery<xref rid="bib244" ref-type="bibr"><sup>318</sup></xref> and performed a genomic comparison of SARS-CoV-2 genome sequences in both episodes. Interestingly, the genome sequence of the SARS-CoV-2 in the second episode of infection significantly differed from that in the first episode.<xref rid="bib244" ref-type="bibr"><sup>318</sup></xref> Therefore, this report has suggested that COVID-19 convalescence is due to reinfection, possibly because SARS-CoV-2 is a positive-sense RNA virus with a comparatively high mutation rate. In the environment, the variability of SARS-CoV-2 is likely to resemble that of the common cold, another RNA virus in constant circulation. Although SARS-CoV-2 may share the high transmissibility and high asymptomatic rates of its relatively benign genetic relative, it is bound to have a far higher fatality rate than the latter.</p><p id="p0325">According to the data available to date, the potential explanations for the positive SARS-CoV-2 RT-PCR results in COVID-19 survivors can be summarized as shown in <xref rid="fig6" ref-type="fig">Figure&#160;6</xref>.<fig id="fig6" position="float" orientation="portrait"><label>Figure&#160;6</label><caption><p>Illustration of potential explanations for positive SARS-CoV-2 RT-PCR tests in recovered patients with COVID-19.</p></caption><alt-text id="alttext0035">Figure&#160;6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec><sec id="sec8"><title>Future directions</title><p id="p0330">As SARS-CoV-2 variants have continued to evolve and spread, the risk of COVID-19 reinfection has grown. Hence, caution should be exercised even after confirmed recovery, particularly in older people who are more susceptible to severe COVID-19, and for those with preexisting chronic diseases and/or pneumonia. To ensure a complete cure and prevent recurrence, post-recovery monitoring and stratified management should be implemented whenever possible. Reports on COVID-19 reinfection are limited, owing to the negligible number of these reports and their small sample sizes. Given the global emergency caused by this pandemic, comprehensive studies involving further immunological, virological and epidemiological data are needed to provide further understanding of the underlying pathophysiology of SARS-CoV-2 reinfection.</p><p id="p0335">Owing to the dramatic increase in the number of both active and recovered cases globally, the issue of COVID-19 reinfection has been brought to the public's attention as a necessary factor to consider to properly predict the spread of SARS-CoV-2 and its expected pandemic trajectory. On the basis of the literature discussed above, both herd immunity and vaccines may not be able to eliminate COVID-19 and establish permanent immunity against SARS-CoV-2. Given the cost and time required to develop herd immunity and vaccines, scientists must seek further valuable and sustainable solutions requiring less time and cost rather than being satisfied with the current approaches.</p></sec><sec id="sec9"><title>Conclusions</title><p id="p0340">The current approval of several vaccines for COVID-19 has given the global population hope that the pandemic will be overcome. The urgency of the pandemic, the technological advances and existing vaccine candidates have contributed to the rapid development of vaccines for COVID-19. Nevertheless, much about COVID-19 and its causative agent, SARS-CoV-2, remains undiscovered, including the human response to vaccines and the emergence of reinfection or reactivation of infection, thus further complicating understanding of COVID-19. Hence, healthcare practices and the scientific community should be made aware of these issues for devising guidelines and future R&amp;D plans targeted to the eradication of the COVID-19 pandemic.</p></sec><sec id="sec10"><title>Source of funding</title><p id="p0345">This work was supported by a grant from the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003093</institution-id><institution>Ministry of Higher Education, Malaysia</institution></institution-wrap></funding-source> (grant number: FRGS/1/2020/SKK06/USM/03/2).</p></sec><sec id="sec11"><title>Conflict of interest</title><p id="p0350">The authors have no conflict of interest to declare.</p></sec><sec id="sec12"><title>Ethical approval</title><p id="p0355">Not applicable.</p></sec><sec id="sec13"><title>Authors contributions</title><p id="p0360">MAIA-H and RM conceived and designed the study, and conducted the preliminary review of articles. MAIA-H, MAHA, MHM-Z and ENSEAR determined the research scope, and collected and organized the extracted data. MAIA-H and MAHA analyzed and interpreted the data. MAIA-H, MAHA, MHM-Z, ENSEAR, MMH, WA, SA, CYY, IZA, VU and RM wrote the initial and final drafts of the article, and provided logistic support. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.</p></sec><sec id="sec14a"><title>Acknowledgment</title><p id="p0370">Both MAIA-H and ENSEAR would like to acknowledge the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004595</institution-id><institution>Universiti Sains Malaysia</institution></institution-wrap></funding-source> (USM) Fellowship Scheme for providing financial support. MHM-Z would like to acknowledge the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003971</institution-id><institution>Islamic Development Bank</institution></institution-wrap></funding-source> (IsDB) for providing financial support under the PhD Scholarship Program.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>C.-Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.-X.</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N&#160;Engl J Med</source><volume>382</volume><issue>18</issue><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id><pub-id pub-id-type="pmcid">PMC7092819</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lipkin</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>R.F.</given-names></name></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nat Med</source><volume>26</volume><issue>4</issue><year>2020</year><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmid">32284615</pub-id><pub-id pub-id-type="pmcid">PMC7095063</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Hatmal</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Alshaer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Al-Hatamleh</surname><given-names>M.A.I.</given-names></name><name name-style="western"><surname>Hatmal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smadi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Taha</surname><given-names>M.O.</given-names></name><etal/></person-group><article-title>Comprehensive structural and molecular comparison of spike proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and their interactions with ACE2</article-title><source>Cells</source><volume>9</volume><issue>12</issue><year>2020</year><fpage>2638</fpage><pub-id pub-id-type="doi">10.3390/cells9122638</pub-id><pub-id pub-id-type="pmid">33302501</pub-id><pub-id pub-id-type="pmcid">PMC7763676</pub-id></element-citation></ref><ref id="bib12"><label>4</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Niknam</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Golchin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Danesh Pouya</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nemati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezaei-Tavirani</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Potential therapeutic options for COVID-19: an update on current evidence</article-title><source>Eur J Med Res</source><volume>27</volume><issue>1</issue><year>2022</year><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s40001-021-00626-3</pub-id><pub-id pub-id-type="pmid">35027080</pub-id><pub-id pub-id-type="pmcid">PMC8755901</pub-id></element-citation></ref><ref id="bib13"><label>5</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Klassen</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Senefeld</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Senese</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>Convalescent plasma therapy for COVID-19: a graphical mosaic of the worldwide evidence</article-title><source>Front Med</source><volume>8</volume><year>2021</year><object-id pub-id-type="publisher-id">684151</object-id><pub-id pub-id-type="doi">10.3389/fmed.2021.684151</pub-id><pub-id pub-id-type="pmcid">PMC8215127</pub-id><pub-id pub-id-type="pmid">34164419</pub-id></element-citation></ref><ref id="bib14"><label>6</label><element-citation publication-type="book" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>World Health Organization</surname></name></person-group><part-title>&#8220;Immunity passports&#8221; in the context of COVID-19</part-title><year>2020</year><publisher-name>World Health Organization</publisher-name><comment>Updated 24 April 2020. Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19" id="intref0015">https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19</ext-link></element-citation></ref><ref id="bib15"><label>7</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Miah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Begum</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Sarmin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahfuz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>COVID-19 reinfections among naturally infected and vaccinated individuals</article-title><source>Sci Rep</source><volume>12</volume><year>2022</year><fpage>1438</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-05325-5</pub-id><pub-id pub-id-type="pmid">35082344</pub-id><pub-id pub-id-type="pmcid">PMC8792012</pub-id></element-citation></ref><ref id="bib16"><label>8</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Gargouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Souissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abid</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chtourou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Feki-Berrajah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Karray</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Evidence of SARS-CoV-2 symptomatic reinfection in four health care professionals from the same hospital despite the presence of antibodies</article-title><source>Int J Infect Dis</source><volume>117</volume><year>2022</year><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2022.01.006</pub-id><pub-id pub-id-type="pmid">35017107</pub-id><pub-id pub-id-type="pmcid">PMC8743858</pub-id></element-citation></ref><ref id="bib17"><label>9</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Duggan</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Ludy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Reisner</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Wilcox</surname><given-names>S.R.</given-names></name></person-group><article-title>A&#160;case report of possible novel coronavirus 2019 reinfection</article-title><source>Am J Emerg Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ajem.2020.06.079</pub-id><pub-id pub-id-type="pmcid">PMC7335242</pub-id><pub-id pub-id-type="pmid">32703607</pub-id></element-citation></ref><ref id="bib18"><label>10</label><element-citation publication-type="book" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Pango lineages: latest epidemiological lineages of SARS-CoV-2</part-title><year>2022</year><publisher-name>Pango</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage_list.html" id="intref0020">https://cov-lineages.org/lineage_list.html</ext-link></element-citation></ref><ref id="bib19"><label>11</label><element-citation publication-type="book" id="sref19"><person-group person-group-type="author"><collab>Nextstrain</collab></person-group><part-title>Genomic epidemiology of SARS-CoV-2 with global subsampling</part-title><year>2022</year><publisher-name>Nextstrain</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://nextstrain.org/ncov/gisaid/global" id="intref0025">https://nextstrain.org/ncov/gisaid/global</ext-link></element-citation></ref><ref id="bib20"><label>12</label><element-citation publication-type="book" id="sref20"><person-group person-group-type="author"><collab>GISAID Fv</collab></person-group><part-title>hCoV-19 data sharing via GISAID</part-title><year>2022</year><publisher-name>GISAID</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gisaid.org/" id="intref0030">https://www.gisaid.org/</ext-link></element-citation></ref><ref id="bib21"><label>13</label><element-citation publication-type="book" id="sref21"><person-group person-group-type="author"><collab>National Library of Medicine</collab></person-group><part-title>SARS-CoV-2 data hub</part-title><year>2022</year><publisher-name>NCBI Virus</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&amp;VirusLineage_ss=Severe%20acute%20respiratory%20syndrome%20coronavirus%202,%20taxid:2697049" id="intref0035">https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&amp;VirusLineage_ss=Severe%20acute%20respiratory%20syndrome%20coronavirus%202,%20taxid:2697049</ext-link></element-citation></ref><ref id="bib22"><label>14</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>O'Toole</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>V.</given-names></name><name name-style="western"><surname>McCrone</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Ruis</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A&#160;dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology</article-title><source>Nat Microbiol</source><volume>5</volume><issue>11</issue><year>2020</year><fpage>1403</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0770-5</pub-id><pub-id pub-id-type="pmid">32669681</pub-id><pub-id pub-id-type="pmcid">PMC7610519</pub-id></element-citation></ref><ref id="bib23"><label>15</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Turo&#328;ov&#225;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sch&#252;rmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>W.J.H.</given-names></name><name name-style="western"><surname>Welsch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>F.E.C.</given-names></name><etal/></person-group><article-title>In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges</article-title><source>Science</source><volume>370</volume><issue>6513</issue><year>2020</year><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1126/science.abd5223</pub-id><pub-id pub-id-type="pmid">32817270</pub-id><pub-id pub-id-type="pmcid">PMC7665311</pub-id></element-citation></ref><ref id="bib24"><label>16</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Gebo</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Shoham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shenoy</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.12.10.21267485</pub-id></element-citation></ref><ref id="bib25"><label>17</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>On the origin and continuing evolution of SARS-CoV-2</article-title><source>Natl Sci Rev</source><volume>7</volume><issue>6</issue><year>2020</year><fpage>1012</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id><pub-id pub-id-type="pmid">34676127</pub-id><pub-id pub-id-type="pmcid">PMC7107875</pub-id></element-citation></ref><ref id="bib26"><label>18</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Winger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caspari</surname><given-names>T.</given-names></name></person-group><article-title>The spike of concern-the novel variants of SARS-CoV-2</article-title><source>Viruses</source><volume>13</volume><issue>6</issue><year>2021</year><pub-id pub-id-type="doi">10.3390/v13061002</pub-id><pub-id pub-id-type="pmcid">PMC8229995</pub-id><pub-id pub-id-type="pmid">34071984</pub-id></element-citation></ref><ref id="bib27"><label>19</label><element-citation publication-type="book" id="sref27"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><part-title>Tracking SARS-CoV-2 variants</part-title><year>2022</year><publisher-name>World Health Organization</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/" id="intref0040">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</ext-link></element-citation></ref><ref id="bib28"><label>20</label><element-citation publication-type="book" id="sref28"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control (ECDC)</collab></person-group><part-title>SARS-CoV-2 variants of concern as of 7 April 2022</part-title><year>2022</year><publisher-name>European Centre for Disease Prevention and Control</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/covid-19/variants-concern" id="intref0045">https://www.ecdc.europa.eu/en/covid-19/variants-concern</ext-link></element-citation></ref><ref id="bib29"><label>21</label><element-citation publication-type="other" id="sref29"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>SARS-CoV-2 variant classifications and definitions: centers for disease control and prevention</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html" id="intref0050">https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html</ext-link><year>2021</year></element-citation></ref><ref id="bib30"><label>22</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Gomez</surname><given-names>R.</given-names></name></person-group><article-title>The development of SARS-CoV-2 variants: the gene makes the disease</article-title><source>J&#160;Dev Biol</source><volume>9</volume><issue>4</issue><year>2021</year><fpage>58</fpage><pub-id pub-id-type="doi">10.3390/jdb9040058</pub-id><pub-id pub-id-type="pmid">34940505</pub-id><pub-id pub-id-type="pmcid">PMC8705434</pub-id></element-citation></ref><ref id="bib31"><label>23</label><element-citation publication-type="book" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Aleem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samad</surname><given-names>A.B.A.</given-names></name><name name-style="western"><surname>Slenker</surname><given-names>A.K.</given-names></name></person-group><part-title>Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)</part-title><year>2021</year><pub-id pub-id-type="pmid">34033342</pub-id></element-citation></ref><ref id="bib32"><label>24</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>McCallum</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lempp</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title><source>Cell</source><volume>184</volume><issue>9</issue><year>2021</year><fpage>2332</fpage><lpage>2347.e2316</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.028</pub-id><pub-id pub-id-type="pmid">33761326</pub-id><pub-id pub-id-type="pmcid">PMC7962585</pub-id></element-citation></ref><ref id="bib33"><label>25</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Suryadevara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shrihari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gilchuk</surname><given-names>P.</given-names></name><name name-style="western"><surname>VanBlargan</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Binshtein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zost</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein</article-title><source>Cell</source><volume>184</volume><issue>9</issue><year>2021</year><fpage>2316</fpage><lpage>2331.e2315</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.029</pub-id><pub-id pub-id-type="pmid">33773105</pub-id><pub-id pub-id-type="pmcid">PMC7962591</pub-id></element-citation></ref><ref id="bib34"><label>26</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Rincon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez-Romero</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Tonda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mendoza-Maldonado</surname><given-names>L.</given-names></name><name name-style="western"><surname>Claassen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garssen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Design of specific primer set for detection of B.1.1.7 SARS-CoV-2 variant using deep learning</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.12.29.424715</pub-id><pub-id pub-id-type="pmcid">PMC7806918</pub-id><pub-id pub-id-type="pmid">33441822</pub-id></element-citation></ref><ref id="bib35"><label>27</label><element-citation publication-type="book" id="sref35"><comment>[Internet]</comment><source>Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings</source><year>2021</year><comment>[cited 21 January 2021]. Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586" id="intref0055">https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586</ext-link></element-citation></ref><ref id="bib36"><label>28</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Wibmer</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Ayres</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hermanus</surname><given-names>T.</given-names></name><name name-style="western"><surname>Madzivhandila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kgagudi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lambson</surname><given-names>B.E.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.01.18.427166</pub-id><pub-id pub-id-type="pmid">33654292</pub-id></element-citation></ref><ref id="bib37"><label>29</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Carabelli</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title><source>Nat Rev Microbiol</source><volume>19</volume><issue>7</issue><year>2021</year><fpage>409</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id><pub-id pub-id-type="pmid">34075212</pub-id><pub-id pub-id-type="pmcid">PMC8167834</pub-id></element-citation></ref><ref id="bib38"><label>30</label><element-citation publication-type="book" id="sref38"><person-group person-group-type="author"><collab>UK Health Security Agency</collab></person-group><part-title>COVID-19 variants identified in the UK</part-title><year>2022</year><publisher-name>UK Health Security Agency</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/news/covid-19-variants-identified-in-the-uk" id="intref0060">https://www.gov.uk/government/news/covid-19-variants-identified-in-the-uk</ext-link></element-citation></ref><ref id="bib39"><label>31</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Greaney</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Loes</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>K.H.D.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.Y.</given-names></name><etal/></person-group><article-title>Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2020.12.31.425021</pub-id><pub-id pub-id-type="pmcid">PMC7869748</pub-id><pub-id pub-id-type="pmid">33592168</pub-id></element-citation></ref><ref id="bib245"><label>32</label><element-citation publication-type="book" id="sref245"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.617.2</part-title><year>2021</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.617.2" id="intref0170">https://cov-lineages.org/lineage.html?lineage=B.1.617.2</ext-link></element-citation></ref><ref id="bib246"><label>33</label><element-citation publication-type="book" id="sref246"><person-group person-group-type="author"><collab>Public Health England</collab></person-group><part-title>SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 16</part-title><year>2021</year><publisher-name>Public Health England</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001359/Variants_of_Concern_VOC_Technical_Briefing_16.pdf" id="intref0175">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001359/Variants_of_Concern_VOC_Technical_Briefing_16.pdf</ext-link></element-citation></ref><ref id="bib247"><label>34</label><element-citation publication-type="other" id="sref247"><person-group person-group-type="author"><name name-style="western"><surname>Stowe</surname><given-names>Julia</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>Nick</given-names></name><name name-style="western"><surname>Gower</surname><given-names>Charlotte</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>Eileen</given-names></name><name name-style="western"><surname>Utsi</surname><given-names>Lara</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>Ruth</given-names></name><etal/></person-group><article-title>Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431" id="intref0180">https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431</ext-link><year>2021</year></element-citation></ref><ref id="bib248"><label>35</label><element-citation publication-type="journal" id="sref248"><person-group person-group-type="author"><name name-style="western"><surname>Sheikh</surname><given-names>A.</given-names></name><name name-style="western"><surname>McMenamin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>C.</given-names></name></person-group><article-title>SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness</article-title><source>Lancet</source><volume>397</volume><issue>10293</issue><year>2021</year><fpage>2461</fpage><lpage>2462</lpage><pub-id pub-id-type="pmid">34139198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01358-1</pub-id><pub-id pub-id-type="pmcid">PMC8201647</pub-id></element-citation></ref><ref id="bib249"><label>36</label><element-citation publication-type="book" id="sref249"><person-group person-group-type="author"><collab>Public Health England</collab></person-group><part-title>SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 12</part-title><year>2021</year><publisher-name>Public Health England</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_England.pdf" id="intref0185">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_England.pdf</ext-link></element-citation></ref><ref id="bib250"><label>37</label><element-citation publication-type="book" id="sref250"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.1.7: cov-lineages</part-title><year>2020</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.1.7" id="intref0190">https://cov-lineages.org/lineage.html?lineage=B.1.1.7</ext-link></element-citation></ref><ref id="bib251"><label>38</label><element-citation publication-type="journal" id="sref251"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Kucharski</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Munday</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England</article-title><source>Science</source><volume>372</volume><issue>6538</issue><year>2021</year><object-id pub-id-type="publisher-id">eabg3055</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg3055</pub-id><pub-id pub-id-type="pmcid">PMC8128288</pub-id><pub-id pub-id-type="pmid">33658326</pub-id></element-citation></ref><ref id="bib252"><label>39</label><element-citation publication-type="journal" id="sref252"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Edmunds</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Diaz-Ordaz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Keogh</surname><given-names>R.H.</given-names></name></person-group><article-title>Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7</article-title><source>Nature</source><volume>593</volume><issue>7858</issue><year>2021</year><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">33723411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03426-1</pub-id><pub-id pub-id-type="pmcid">PMC9170116</pub-id></element-citation></ref><ref id="bib253"><label>40</label><element-citation publication-type="journal" id="sref253"><person-group person-group-type="author"><name name-style="western"><surname>Funk</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pharris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spiteri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bundle</surname><given-names>N.</given-names></name><name name-style="western"><surname>Melidou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Characteristics of SARS-CoV-2 variants of concern B. 1.1. 7, B. 1.351 or P. 1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021</article-title><source>Euro Surveill</source><volume>26</volume><issue>16</issue><year>2021</year><object-id pub-id-type="publisher-id">2100348</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2021.26.16.2100348</pub-id><pub-id pub-id-type="pmcid">PMC8063589</pub-id><pub-id pub-id-type="pmid">33890566</pub-id></element-citation></ref><ref id="bib239"><label>41</label><element-citation publication-type="journal" id="sref239"><person-group person-group-type="author"><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koen</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>20</issue><year>2021</year><fpage>1885</fpage><lpage>1898</lpage><pub-id pub-id-type="pmid">33725432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102214</pub-id><pub-id pub-id-type="pmcid">PMC7993410</pub-id></element-citation></ref><ref id="bib254"><label>42</label><element-citation publication-type="book" id="sref254"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.351: cov-lineages</part-title><year>2020</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.351" id="intref0195">https://cov-lineages.org/lineage.html?lineage=B.1.351</ext-link></element-citation></ref><ref id="bib255"><label>43</label><element-citation publication-type="book" id="sref255"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>Carl A.B.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>Nicholas G.</given-names></name><name name-style="western"><surname>Kucharski</surname><given-names>Adam J.</given-names></name><collab>CMMID COVID-19 working group</collab><name name-style="western"><surname>Edmunds</surname><given-names>W. John</given-names></name><name name-style="western"><surname>Eggo</surname><given-names>Rosalind M.</given-names></name></person-group><part-title>Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2</part-title><year>2021</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf" id="intref0200">https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf</ext-link></element-citation></ref><ref id="bib256"><label>44</label><element-citation publication-type="journal" id="sref256"><person-group person-group-type="author"><name name-style="western"><surname>Cele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gazy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hwa</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Tegally</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma</article-title><source>Nature</source><volume>593</volume><issue>7857</issue><year>2021</year><fpage>142</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">33780970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03471-w</pub-id><pub-id pub-id-type="pmcid">PMC9867906</pub-id></element-citation></ref><ref id="bib257"><label>45</label><element-citation publication-type="journal" id="sref257"><person-group person-group-type="author"><name name-style="western"><surname>Tegally</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iranzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Giandhari</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Detection of a SARS-CoV-2 variant of concern in South Africa</article-title><source>Nature</source><volume>592</volume><issue>7854</issue><year>2021</year><fpage>438</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">33690265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03402-9</pub-id></element-citation></ref><ref id="bib258"><label>46</label><element-citation publication-type="book" id="sref258"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage P.1: cov-lineages</part-title><year>2020</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=P.1" id="intref0205">https://cov-lineages.org/lineage.html?lineage=P.1</ext-link></element-citation></ref><ref id="bib259"><label>47</label><element-citation publication-type="journal" id="sref259"><person-group person-group-type="author"><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>Antibody evasion by the P. 1 strain of SARS-CoV-2</article-title><source>Cell</source><volume>184</volume><issue>11</issue><year>2021</year><fpage>2939</fpage><lpage>2954</lpage><comment>e2939</comment><pub-id pub-id-type="pmid">33852911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.03.055</pub-id><pub-id pub-id-type="pmcid">PMC8008340</pub-id></element-citation></ref><ref id="bib260"><label>48</label><element-citation publication-type="journal" id="sref260"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Mellan</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Claro</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Candido</surname><given-names>D.d.S.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus, Brazil</article-title><source>Science</source><volume>372</volume><issue>6544</issue><year>2021</year><fpage>815</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">33853970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abh2644</pub-id><pub-id pub-id-type="pmcid">PMC8139423</pub-id></element-citation></ref><ref id="bib261"><label>49</label><element-citation publication-type="book" id="sref261"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.429</part-title><year>2020</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.429" id="intref0210">https://cov-lineages.org/lineage.html?lineage=B.1.429</ext-link></element-citation></ref><ref id="bib262"><label>50</label><element-citation publication-type="book" id="sref262"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.427</part-title><year>2020</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.427" id="intref0215">https://cov-lineages.org/lineage.html?lineage=B.1.427</ext-link></element-citation></ref><ref id="bib263"><label>51</label><element-citation publication-type="journal" id="sref263"><person-group person-group-type="author"><name name-style="western"><surname>Collier</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Datir</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies</article-title><source>Nature</source><volume>593</volume><issue>7857</issue><year>2021</year><fpage>136</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">33706364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03412-7</pub-id><pub-id pub-id-type="pmcid">PMC7616976</pub-id></element-citation></ref><ref id="bib264"><label>52</label><element-citation publication-type="book" id="sref264"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.525</part-title><year>2020</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.525" id="intref0220">https://cov-lineages.org/lineage.html?lineage=B.1.525</ext-link></element-citation></ref><ref id="bib265"><label>53</label><element-citation publication-type="journal" id="sref265"><person-group person-group-type="author"><name name-style="western"><surname>Jangra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rathnasinghe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stadlbauer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alshammary</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amoako</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike E484K mutation reduces antibody neutralisation</article-title><source>Lancet Microbe</source><volume>2</volume><issue>7</issue><year>2021</year><fpage>e283</fpage><lpage>e284</lpage><pub-id pub-id-type="pmid">33846703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(21)00068-9</pub-id><pub-id pub-id-type="pmcid">PMC8026167</pub-id></element-citation></ref><ref id="bib266"><label>54</label><element-citation publication-type="journal" id="sref266"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants</article-title><source>Lancet Microbe</source><volume>2</volume><issue>10</issue><year>2021</year><fpage>e494</fpage><pub-id pub-id-type="pmid">34458880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(21)00217-2</pub-id><pub-id pub-id-type="pmcid">PMC8378832</pub-id></element-citation></ref><ref id="bib267"><label>55</label><element-citation publication-type="book" id="sref267"><person-group person-group-type="author"><collab>Public Health England</collab></person-group><part-title>SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 11</part-title><year>2021</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_England.pdf" id="intref0225">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_England.pdf</ext-link></element-citation></ref><ref id="bib268"><label>56</label><element-citation publication-type="journal" id="sref268"><person-group person-group-type="author"><name name-style="western"><surname>Tut</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>T.</given-names></name><name name-style="western"><surname>Krutikov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sylla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study</article-title><source>Lancet Healthy Longev</source><volume>2</volume><issue>9</issue><year>2021</year><fpage>e544</fpage><lpage>e553</lpage><pub-id pub-id-type="pmid">34430954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(21)00168-9</pub-id><pub-id pub-id-type="pmcid">PMC8376213</pub-id></element-citation></ref><ref id="bib269"><label>57</label><element-citation publication-type="journal" id="sref269"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>G.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>D.Y.</given-names></name><etal/></person-group><article-title>Neutralization of variant under investigation B. 1.617. 1 with sera of BBV152 vaccinees</article-title><source>Clin Infect Dis</source><volume>74</volume><issue>2</issue><year>2022</year><fpage>366</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">33961693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciab411</pub-id></element-citation></ref><ref id="bib270"><label>58</label><element-citation publication-type="book" id="sref270"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.617.1: cov-lineages</part-title><year>2020</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.617.1" id="intref0230">https://cov-lineages.org/lineage.html?lineage=B.1.617.1</ext-link></element-citation></ref><ref id="bib271"><label>59</label><element-citation publication-type="book" id="sref271"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage P.2</part-title><year>2020</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=P.2" id="intref0235">https://cov-lineages.org/lineage.html?lineage=P.2</ext-link></element-citation></ref><ref id="bib272"><label>60</label><element-citation publication-type="journal" id="sref272"><person-group person-group-type="author"><name name-style="western"><surname>Acevedo</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gaete-Argel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alonso-Palomares</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Oca</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bustamante</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gaggero</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile</article-title><source>Nat Microbiol</source><volume>7</volume><issue>4</issue><year>2022</year><fpage>524</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01092-1</pub-id><pub-id pub-id-type="pmid">35365787</pub-id></element-citation></ref><ref id="bib273"><label>61</label><element-citation publication-type="journal" id="sref273"><person-group person-group-type="author"><name name-style="western"><surname>Tada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dcosta</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Samanovic</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Landau</surname><given-names>N.R.</given-names></name></person-group><article-title>SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.07.02.450959</pub-id></element-citation></ref><ref id="bib274"><label>62</label><element-citation publication-type="book" id="sref274"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage C.37</part-title><year>2020</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=C.37" id="intref0240">https://cov-lineages.org/lineage.html?lineage=C.37</ext-link></element-citation></ref><ref id="bib275"><label>63</label><element-citation publication-type="book" id="sref275"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.621</part-title><year>2020</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.621" id="intref0245">https://cov-lineages.org/lineage.html?lineage=B.1.621</ext-link></element-citation></ref><ref id="bib276"><label>64</label><element-citation publication-type="book" id="sref276"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage B.1.526</part-title><year>2020</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=B.1.526" id="intref0250">https://cov-lineages.org/lineage.html?lineage=B.1.526</ext-link></element-citation></ref><ref id="bib277"><label>65</label><element-citation publication-type="book" id="sref277"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage XD</part-title><year>2022</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=XD" id="intref0255">https://cov-lineages.org/lineage.html?lineage=XD</ext-link></element-citation></ref><ref id="bib278"><label>66</label><element-citation publication-type="book" id="sref278"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage XE</part-title><year>2022</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=XE" id="intref0260">https://cov-lineages.org/lineage.html?lineage=XE</ext-link></element-citation></ref><ref id="bib279"><label>67</label><element-citation publication-type="book" id="sref279"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage XF</part-title><year>2022</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=XF" id="intref0265">https://cov-lineages.org/lineage.html?lineage=XF</ext-link></element-citation></ref><ref id="bib280"><label>68</label><element-citation publication-type="book" id="sref280"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage BA.1</part-title><year>2021</year><publisher-name>cov-lineages</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=BA.1" id="intref0270">https://cov-lineages.org/lineage.html?lineage=BA.1</ext-link></element-citation></ref><ref id="bib281"><label>69</label><element-citation publication-type="book" id="sref281"><person-group person-group-type="author"><collab>Agency UHS</collab></person-group><part-title>COVID-19 vaccine surveillance report, week 6</part-title><year>2022</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6.pdf" id="intref0275">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6.pdf</ext-link></element-citation></ref><ref id="bib282"><label>70</label><element-citation publication-type="book" id="sref282"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control (ECDC)</collab></person-group><part-title>Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU, EU/EEA, 19th update</part-title><year>2022</year><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/sites/default/files/documents/RRA-19-update-27-jan-2022.pdf" id="intref0280">https://www.ecdc.europa.eu/sites/default/files/documents/RRA-19-update-27-jan-2022.pdf</ext-link></element-citation></ref><ref id="bib283"><label>71</label><element-citation publication-type="journal" id="sref283"><person-group person-group-type="author"><name name-style="western"><surname>Altarawneh</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Chemaitelly</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ayoub</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Qassim</surname><given-names>S.</given-names></name><name name-style="western"><surname>AlMukdad</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Protection against the omicron variant from previous SARS-CoV-2 infection</article-title><source>N&#160;Engl J Med</source><volume>386</volume><issue>13</issue><year>2022</year><fpage>1288</fpage><lpage>1290</lpage><pub-id pub-id-type="pmid">35139269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2200133</pub-id><pub-id pub-id-type="pmcid">PMC8849180</pub-id></element-citation></ref><ref id="bib284"><label>72</label><element-citation publication-type="journal" id="sref284"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K.-C.</given-names></name><name name-style="western"><surname>Ching</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>K.-L.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo</article-title><source>Nature</source><volume>603</volume><issue>7902</issue><year>2022</year><fpage>715</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04479-6</pub-id><pub-id pub-id-type="pmid">35104836</pub-id></element-citation></ref><ref id="bib285"><label>73</label><element-citation publication-type="journal" id="sref285"><person-group person-group-type="author"><name name-style="western"><surname>R&#246;ssler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Knabl</surname><given-names>L.</given-names></name><name name-style="western"><surname>von Laer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kimpel</surname><given-names>J.</given-names></name></person-group><article-title>Neutralization profile after recovery from SARS-CoV-2 Omicron infection</article-title><source><italic toggle="yes">N Engl J Med</italic></source><volume>386</volume><year>2022</year><fpage>1764</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2201607</pub-id><pub-id pub-id-type="pmid">35320661</pub-id><pub-id pub-id-type="pmcid">PMC9006769</pub-id></element-citation></ref><ref id="bib286"><label>74</label><element-citation publication-type="book" id="sref286"><person-group person-group-type="author"><collab>UK Health Security Agency (UKHSA) UHSA</collab></person-group><part-title>SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing: update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529)</part-title><year>2021</year><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf" id="intref0285">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf</ext-link></element-citation></ref><ref id="bib287"><label>75</label><element-citation publication-type="book" id="sref287"><person-group person-group-type="author"><name name-style="western"><surname>Ferguson</surname><given-names>N.G.A.</given-names></name><name name-style="western"><surname>Hinsley</surname><given-names>W.</given-names></name><name name-style="western"><surname>Volz</surname><given-names>E.</given-names></name><collab>team obotICC-r</collab></person-group><part-title>Report 50: hospitalisation risk for Omicron cases in England</part-title><year>2021</year><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf" id="intref0290">https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf</ext-link></element-citation></ref><ref id="bib288"><label>76</label><element-citation publication-type="book" id="sref288"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage BA.2</part-title><year>2021</year><publisher-name>cov-lineages</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=BA.2" id="intref0295">https://cov-lineages.org/lineage.html?lineage=BA.2</ext-link></element-citation></ref><ref id="bib289"><label>77</label><element-citation publication-type="book" id="sref289"><person-group person-group-type="author"><collab>UK Health Security Agency</collab></person-group><part-title>SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 35</part-title><year>2022</year><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022.pdf" id="intref0300">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022.pdf</ext-link></element-citation></ref><ref id="bib290"><label>78</label><element-citation publication-type="book" id="sref290"><person-group person-group-type="author"><collab>UK Health Security Agency</collab></person-group><part-title>SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 39</part-title><year>2022</year><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf" id="intref0305">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf</ext-link></element-citation></ref><ref id="bib291"><label>79</label><element-citation publication-type="journal" id="sref291"><person-group person-group-type="author"><name name-style="western"><surname>Fonager</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bennedb&#230;k</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bager</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wohlfahrt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ellegaard</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ingham</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Molecular epidemiology of the SARS-CoV-2 variant omicron BA. 2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022</article-title><source>Euro Surveill</source><volume>27</volume><issue>10</issue><year>2022</year><object-id pub-id-type="publisher-id">2200181</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2022.27.10.2200181</pub-id><pub-id pub-id-type="pmcid">PMC8915403</pub-id><pub-id pub-id-type="pmid">35272746</pub-id></element-citation></ref><ref id="bib292"><label>80</label><element-citation publication-type="book" id="sref292"><person-group person-group-type="author"><name name-style="western"><surname>Lyngse</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Kirkeby</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Denwood</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>M&#248;lbak</surname><given-names>K.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>C.H.</given-names></name><etal/></person-group><part-title>Transmission of SARS-CoV-2 Omicron VOC subvariants BA. 1 and BA. 2</part-title><comment>evidence from Danish Households</comment><year>2022</year><publisher-name>medRxiv</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-33498-0</pub-id><pub-id pub-id-type="pmcid">PMC9524324</pub-id><pub-id pub-id-type="pmid">36180438</pub-id></element-citation></ref><ref id="bib293"><label>81</label><element-citation publication-type="book" id="sref293"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage BA.3</part-title><year>2021</year><publisher-name>cov-lineages</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=BA.3" id="intref0310">https://cov-lineages.org/lineage.html?lineage=BA.3</ext-link></element-citation></ref><ref id="bib294"><label>82</label><element-citation publication-type="book" id="sref294"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage BA.4</part-title><year>2022</year><publisher-name>cov-lineages</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=BA.4" id="intref0315">https://cov-lineages.org/lineage.html?lineage=BA.4</ext-link></element-citation></ref><ref id="bib295"><label>83</label><element-citation publication-type="book" id="sref295"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage BA.5</part-title><year>2022</year><publisher-name>cov-lineages</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=BA.5" id="intref0320">https://cov-lineages.org/lineage.html?lineage=BA.5</ext-link></element-citation></ref><ref id="bib296"><label>84</label><element-citation publication-type="book" id="sref296"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control (ECDC)</collab></person-group><part-title>SARS-CoV-2 variants of concern as of 15 July 2022</part-title><year>2022</year><publisher-name>European Centre for Disease Prevention and Control</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/covid-19/variants-concern" id="intref0325">https://www.ecdc.europa.eu/en/covid-19/variants-concern</ext-link></element-citation></ref><ref id="bib297"><label>85</label><element-citation publication-type="book" id="sref297"><person-group person-group-type="author"><name name-style="western"><surname>O'Toole</surname><given-names>&#193;ine</given-names></name><name name-style="western"><surname>Scher</surname><given-names>Emily</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name></person-group><part-title>Lineage BA.2.75</part-title><year>2022</year><publisher-name>cov-lineages</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cov-lineages.org/lineage.html?lineage=BA.2.75" id="intref0330">https://cov-lineages.org/lineage.html?lineage=BA.2.75</ext-link></element-citation></ref><ref id="bib40"><label>86</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Soler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Houdebine</surname><given-names>L.M.</given-names></name></person-group><article-title>Preparation of recombinant vaccines</article-title><source>Biotechnol Annu Rev</source><volume>13</volume><year>2007</year><fpage>65</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/S1387-2656(07)13004-0</pub-id><pub-id pub-id-type="pmid">17875474</pub-id><pub-id pub-id-type="pmcid">PMC7106376</pub-id></element-citation></ref><ref id="bib41"><label>87</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Clem</surname><given-names>A.S.</given-names></name></person-group><article-title>Fundamentals of vaccine immunology</article-title><source>J&#160;Glob Infect Dis</source><volume>3</volume><issue>1</issue><year>2011</year><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4103/0974-777X.77299</pub-id><pub-id pub-id-type="pmid">21572612</pub-id><pub-id pub-id-type="pmcid">PMC3068582</pub-id></element-citation></ref><ref id="bib42"><label>88</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Immunological mechanisms of vaccination</article-title><source>Nat Immunol</source><volume>12</volume><issue>6</issue><year>2011</year><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></element-citation></ref><ref id="bib43"><label>89</label><element-citation publication-type="book" id="sref43"><person-group person-group-type="author"><collab>US Government Accountability Office</collab></person-group><part-title>Vaccine development; capabilities and challenges for addressing infectious diseases</part-title><year>2021</year><publisher-name>GAO, U.S. Government Accountability Office</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gao.gov/assets/720/717636.pdf" id="intref0065">https://www.gao.gov/assets/720/717636.pdf</ext-link></element-citation></ref><ref id="bib44"><label>90</label><element-citation publication-type="book" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>C.N.</given-names></name></person-group><part-title>Operation warp speed: accelerated COVID-19 vaccine development status and efforts to address manufacturing challenges</part-title><year>2021</year><publisher-name>GAO, U.S. Government Accountability Office</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gao.gov/products/gao-21-319" id="intref0070">https://www.gao.gov/products/gao-21-319</ext-link></element-citation></ref><ref id="bib45"><label>91</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Triggle</surname><given-names>C.R.</given-names></name></person-group><article-title>A&#160;review of the progress and challenges of developing a vaccine for COVID-19</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">585354</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.585354</pub-id><pub-id pub-id-type="pmcid">PMC7591699</pub-id><pub-id pub-id-type="pmid">33163000</pub-id></element-citation></ref><ref id="bib46"><label>92</label><element-citation publication-type="other" id="sref46"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>COVID-19 vaccine tracker and landscape</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" id="intref0075">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link><year>2022</year></element-citation></ref><ref id="bib47"><label>93</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Robert-Guroff</surname><given-names>M.</given-names></name></person-group><article-title>Replicating and non-replicating viral vectors for vaccine development</article-title><source>Curr Opin Biotechnol</source><volume>18</volume><issue>6</issue><year>2007</year><fpage>546</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.010</pub-id><pub-id pub-id-type="pmid">18063357</pub-id><pub-id pub-id-type="pmcid">PMC2245896</pub-id></element-citation></ref><ref id="bib48"><label>94</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Leitner</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>DNA and RNA-based vaccines: principles, progress and prospects</article-title><source>Vaccine</source><volume>18</volume><issue>9&#8211;10</issue><year>1999</year><fpage>765</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(99)00271-6</pub-id><pub-id pub-id-type="pmid">10580187</pub-id><pub-id pub-id-type="pmcid">PMC1986720</pub-id></element-citation></ref><ref id="bib49"><label>95</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Dan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Faliti</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection</article-title><source>Science</source><volume>371</volume><issue>6529</issue><year>2021</year><object-id pub-id-type="publisher-id">eabf4063</object-id><pub-id pub-id-type="doi">10.1126/science.abf4063</pub-id><pub-id pub-id-type="pmcid">PMC7919858</pub-id><pub-id pub-id-type="pmid">33408181</pub-id></element-citation></ref><ref id="bib50"><label>96</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kobokovich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Connell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gronvall</surname><given-names>G.K.</given-names></name></person-group><article-title>COVID-19 antibody tests: a valuable public health tool with limited relevance to individuals</article-title><source>Trends Microbiol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.tim.2020.11.002</pub-id><pub-id pub-id-type="pmcid">PMC7836413</pub-id><pub-id pub-id-type="pmid">33234439</pub-id></element-citation></ref><ref id="bib51"><label>97</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Firmal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ganguly</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name></person-group><article-title>Overview of immune response during SARS-CoV-2 infection: lessons from the past</article-title><source>Front Immunol</source><issue>1949</issue><year>2020</year><fpage>11</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01949</pub-id><pub-id pub-id-type="pmid">32849654</pub-id><pub-id pub-id-type="pmcid">PMC7426442</pub-id></element-citation></ref><ref id="bib52"><label>98</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Fatah</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Tawfeeq</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Rostam</surname><given-names>H.M.</given-names></name></person-group><article-title>SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.11.20.20234385</pub-id><pub-id pub-id-type="pmcid">PMC8327640</pub-id><pub-id pub-id-type="pmid">34367645</pub-id></element-citation></ref><ref id="bib53"><label>99</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Mustapha</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Abdullahi</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Ajagbe</surname><given-names>O.O.R.</given-names></name><name name-style="western"><surname>Emeribe</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Fasogbon</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Onoja</surname><given-names>S.O.</given-names></name><etal/></person-group><article-title>Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19</article-title><source>Heliyon</source><volume>7</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">e05951</object-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e05951</pub-id><pub-id pub-id-type="pmcid">PMC7810769</pub-id><pub-id pub-id-type="pmid">33490695</pub-id></element-citation></ref><ref id="bib54"><label>100</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.B.</given-names></name></person-group><article-title>A&#160;review of vaccine development and research for industry animals in Korea</article-title><source>Clin Exp Vaccine Res</source><volume>1</volume><issue>1</issue><year>2012</year><fpage>18</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.7774/cevr.2012.1.1.18</pub-id><pub-id pub-id-type="pmid">23596575</pub-id><pub-id pub-id-type="pmcid">PMC3623508</pub-id></element-citation></ref><ref id="bib55"><label>101</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J.</given-names></name></person-group><article-title>Developing covid-19 vaccines at pandemic speed</article-title><source>N&#160;Engl J Med</source><volume>382</volume><issue>21</issue><year>2020</year><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="bib326"><label>102</label><element-citation publication-type="journal" id="sref326"><person-group person-group-type="author"><name name-style="western"><surname>Forman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeurissen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mossialos</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19 vaccine challenges: what have we learned so far and what remains to be done?</article-title><source>Health Policy</source><volume>125</volume><issue>5</issue><year>2021</year><fpage>553</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">33820678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.healthpol.2021.03.013</pub-id><pub-id pub-id-type="pmcid">PMC7997052</pub-id></element-citation></ref><ref id="bib56"><label>103</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat Commun</source><volume>11</volume><issue>1</issue><year>2020</year><fpage>1620</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmid">32221306</pub-id><pub-id pub-id-type="pmcid">PMC7100515</pub-id></element-citation></ref><ref id="bib57"><label>104</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Wallis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shenton</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>R.C.</given-names></name></person-group><article-title>Novel approaches for the design, delivery and administration of vaccine technologies</article-title><source>Clin Exp Immunol</source><volume>196</volume><issue>2</issue><year>2019</year><fpage>189</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1111/cei.13287</pub-id><pub-id pub-id-type="pmid">30963549</pub-id><pub-id pub-id-type="pmcid">PMC6468175</pub-id></element-citation></ref><ref id="bib58"><label>105</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Karch</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Burkhard</surname><given-names>P.</given-names></name></person-group><article-title>Vaccine technologies: from whole organisms to rationally designed protein assemblies</article-title><source>Biochem Pharmacol</source><volume>120</volume><year>2016</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.05.001</pub-id><pub-id pub-id-type="pmid">27157411</pub-id><pub-id pub-id-type="pmcid">PMC5079805</pub-id></element-citation></ref><ref id="bib59"><label>106</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>D.</given-names></name></person-group><article-title>Vaccine adjuvants: why and how</article-title><source>Hum Vaccin Immunother</source><volume>12</volume><issue>10</issue><year>2016</year><fpage>2709</fpage><lpage>2711</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1219003</pub-id><pub-id pub-id-type="pmid">27551808</pub-id><pub-id pub-id-type="pmcid">PMC5084984</pub-id></element-citation></ref><ref id="bib60"><label>107</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Riese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prochnow</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name></person-group><article-title>Vaccine adjuvants: key tools for innovative vaccine design</article-title><source>Curr Top Med Chem</source><volume>13</volume><issue>20</issue><year>2013</year><fpage>2562</fpage><lpage>2580</lpage><pub-id pub-id-type="doi">10.2174/15680266113136660183</pub-id><pub-id pub-id-type="pmid">24066891</pub-id></element-citation></ref><ref id="bib61"><label>108</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Woodland</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name></person-group><article-title>Cellular immunity and memory to respiratory virus infections</article-title><source>Immunol Res</source><volume>24</volume><issue>1</issue><year>2001</year><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1385/IR:24:1:53</pub-id><pub-id pub-id-type="pmid">11485209</pub-id></element-citation></ref><ref id="bib62"><label>109</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Mullard</surname><given-names>A.</given-names></name></person-group><article-title>New drugs cost US$2.6 billion to develop</article-title><source>Nat Rev Drug Discov</source><volume>13</volume><issue>12</issue><year>2014</year><pub-id pub-id-type="doi">10.1038/nrd4507</pub-id><comment>877&#8211;877</comment></element-citation></ref><ref id="bib63"><label>110</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Uskokovic</surname><given-names>V.</given-names></name></person-group><article-title>Nanomedicine for the poor: a lost cause or an idea whose time has yet to come?</article-title><source>Nanomedicine</source><volume>16</volume><issue>14</issue><year>2021</year><fpage>1203</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.2217/nnm-2021-0024</pub-id><pub-id pub-id-type="pmid">33988035</pub-id><pub-id pub-id-type="pmcid">PMC8120867</pub-id></element-citation></ref><ref id="bib64"><label>111</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Yarlagadda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine challenges in developing and developed countries</article-title><source>Cureus</source><volume>14</volume><issue>4</issue><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.23951</pub-id><pub-id pub-id-type="pmcid">PMC9085716</pub-id><pub-id pub-id-type="pmid">35547442</pub-id></element-citation></ref><ref id="bib65"><label>112</label><element-citation publication-type="book" id="sref65"><person-group person-group-type="author"><collab>GAVI</collab></person-group><part-title>The 2021-2025 investment opportunity</part-title><year>2021</year><publisher-name>Gavi The vaccine Alliance</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gavi.org/investing-gavi/resource-mobilisation-process/gavis-3rd-donor-pledging-conference-june-2020" id="intref0080">https://www.gavi.org/investing-gavi/resource-mobilisation-process/gavis-3rd-donor-pledging-conference-june-2020</ext-link></element-citation></ref><ref id="bib66"><label>113</label><element-citation publication-type="book" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Harlan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pitrelli</surname><given-names>S.</given-names></name></person-group><part-title>From Oxford to an Italian lab, one race for coronavirus vaccine is gaining backers</part-title><year>2020</year><publisher-name>The Washington Post</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.washingtonpost.com/world/europe/vaccine-coronavirus-oxford-italy-trials/2020/06/20/4b8f5e0a-af1c-11ea-98b5-279a6479a1e4_story.html" id="intref0085">https://www.washingtonpost.com/world/europe/vaccine-coronavirus-oxford-italy-trials/2020/06/20/4b8f5e0a-af1c-11ea-98b5-279a6479a1e4_story.html</ext-link></element-citation></ref><ref id="bib67"><label>114</label><element-citation publication-type="book" id="sref67"><person-group person-group-type="author"><collab>United Nations</collab></person-group><part-title>UN analysis shows link between lack of vaccine equity and widening poverty gap</part-title><year>2022</year><publisher-name>UN News</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://news.un.org/en/story/2022/03/1114762" id="intref0090">https://news.un.org/en/story/2022/03/1114762</ext-link></element-citation></ref><ref id="bib68"><label>115</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Maxmen</surname><given-names>A.</given-names></name></person-group><article-title>The fight to manufacture COVID vaccines in lower-income countries</article-title><source>Nature</source><volume>597</volume><issue>7877</issue><year>2021</year><fpage>455</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-02383-z</pub-id><pub-id pub-id-type="pmid">34526695</pub-id></element-citation></ref><ref id="bib69"><label>116</label><element-citation publication-type="book" id="sref69"><person-group person-group-type="author"><collab>UNDP</collab></person-group><part-title>Vaccine equity and speed: data futures platform</part-title><year>2022</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://data.undp.org/vaccine-equity-archive/vaccine-equity-and-speed/" id="intref0095">https://data.undp.org/vaccine-equity-archive/vaccine-equity-and-speed/</ext-link></element-citation></ref><ref id="bib70"><label>117</label><element-citation publication-type="book" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Peter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>Rebecca</given-names></name><name name-style="western"><surname>Stevis-Gridneff</surname><given-names>Matina</given-names></name></person-group><part-title>What would it take to vaccinate the world against covid?</part-title><year>2021</year><publisher-name>The New York Times</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nytimes.com/2021/05/15/world/americas/covid-vaccine-patent-biden.html" id="intref0100">https://www.nytimes.com/2021/05/15/world/americas/covid-vaccine-patent-biden.html</ext-link></element-citation></ref><ref id="bib71"><label>118</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Kavanagh</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Gostin</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Sunder</surname><given-names>M.</given-names></name></person-group><article-title>Sharing technology and vaccine doses to address global vaccine inequity and end the COVID-19 pandemic</article-title><source>JAMA</source><volume>326</volume><issue>3</issue><year>2021</year><fpage>219</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.10823</pub-id><pub-id pub-id-type="pmid">34196659</pub-id></element-citation></ref><ref id="bib72"><label>119</label><element-citation publication-type="book" id="sref72"><person-group person-group-type="author"><collab>Center DUGHI</collab></person-group><part-title>COVID-19 vaccines and treatment: the race for global equity: launch and scale speedometer</part-title><year>2021</year><publisher-name>Duke University</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jamanetwork.com/journals/jama/fullarticle/2781756" id="intref0105">https://jamanetwork.com/journals/jama/fullarticle/2781756</ext-link></element-citation></ref><ref id="bib73"><label>120</label><element-citation publication-type="book" id="sref73"><person-group person-group-type="author"><collab>Global Health Centre at the Graduate Institute G</collab></person-group><part-title>COVID-19 vaccine access</part-title><year>2022</year><publisher-name>Global Health Centre at the Graduate Institute</publisher-name><publisher-loc>Geneva</publisher-loc><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.knowledgeportalia.org/covid19-vaccine-arrangements" id="intref0110">https://www.knowledgeportalia.org/covid19-vaccine-arrangements</ext-link></element-citation></ref><ref id="bib74"><label>121</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Nachega</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Sam-Agudu</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Masekela</surname><given-names>R.</given-names></name><name name-style="western"><surname>van der Zalm</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Nsanzimana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Condo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Addressing challenges to rolling out COVID-19 vaccines in African countries</article-title><source>Lancet Glob Health</source><volume>9</volume><issue>6</issue><year>2021</year><fpage>e746</fpage><lpage>e748</lpage><pub-id pub-id-type="pmid">33713633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(21)00097-8</pub-id><pub-id pub-id-type="pmcid">PMC7946417</pub-id></element-citation></ref><ref id="bib75"><label>122</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Agoramoorthy</surname><given-names>G.</given-names></name></person-group><article-title>India's cost-effective COVID-19 vaccine development initiatives</article-title><source>Vaccine</source><volume>38</volume><issue>50</issue><year>2020</year><fpage>7883</fpage><pub-id pub-id-type="pmid">33129610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.10.056</pub-id><pub-id pub-id-type="pmcid">PMC7574682</pub-id></element-citation></ref><ref id="bib76"><label>123</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Finch</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Hern&#225;ndez Finch</surname><given-names>M.E.</given-names></name></person-group><article-title>Poverty and Covid-19: rates of incidence and deaths in the United States during the first 10 weeks of the pandemic</article-title><source>Front Sociol</source><volume>5</volume><issue>47</issue><year>2020</year><pub-id pub-id-type="doi">10.3389/fsoc.2020.00047</pub-id><pub-id pub-id-type="pmcid">PMC8022686</pub-id><pub-id pub-id-type="pmid">33869454</pub-id></element-citation></ref><ref id="bib77"><label>124</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Wise</surname><given-names>J.</given-names></name></person-group><article-title>Covid-19: low skilled men have highest death rate of working age adults</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m1906</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1906</pub-id><pub-id pub-id-type="pmid">32398229</pub-id></element-citation></ref><ref id="bib78"><label>125</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>R.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>N.E.</given-names></name><collab>Hesitancy SWGoV</collab></person-group><article-title>Diagnosing the determinants of vaccine hesitancy in specific subgroups: the Guide to Tailoring Immunization Programmes (TIP)</article-title><source>Vaccine</source><volume>33</volume><issue>34</issue><year>2015</year><fpage>4176</fpage><lpage>4179</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.038</pub-id><pub-id pub-id-type="pmid">25896376</pub-id></element-citation></ref><ref id="bib79"><label>126</label><mixed-citation publication-type="other" id="sref79">Ten threats to global health in 2019: WHO; [Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019" id="intref0115">https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019</ext-link>.</mixed-citation></ref><ref id="bib80"><label>127</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Norhayati</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Che Yusof</surname><given-names>R.</given-names></name><name name-style="western"><surname>Azman</surname><given-names>Y.M.</given-names></name></person-group><article-title>Systematic review and meta-analysis of COVID-19 vaccination acceptance</article-title><source>Front Med</source><volume>8</volume><year>2021</year><object-id pub-id-type="publisher-id">783982</object-id><pub-id pub-id-type="doi">10.3389/fmed.2021.783982</pub-id><pub-id pub-id-type="pmcid">PMC8828741</pub-id><pub-id pub-id-type="pmid">35155467</pub-id></element-citation></ref><ref id="bib81"><label>128</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Mahmud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohsin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Muyeed</surname><given-names>A.</given-names></name></person-group><article-title>The acceptance of COVID-19 vaccine at early stage of development and approval: a global systematic review and meta-analysis</article-title><source>Heliyon</source><volume>8</volume><issue>9</issue><year>2022</year><object-id pub-id-type="publisher-id">e10728</object-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e10728</pub-id><pub-id pub-id-type="pmcid">PMC9499991</pub-id><pub-id pub-id-type="pmid">36168558</pub-id></element-citation></ref><ref id="bib82"><label>129</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Leigh</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>White</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Picchio</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Rabin</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Ratzan</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries</article-title><source>Vaccine</source><volume>40</volume><issue>31</issue><year>2022</year><fpage>4081</fpage><lpage>4089</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.04.097</pub-id><pub-id pub-id-type="pmid">35654620</pub-id><pub-id pub-id-type="pmcid">PMC9068669</pub-id></element-citation></ref><ref id="bib83"><label>130</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Terry</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cartledge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Damery</surname><given-names>S.</given-names></name><name name-style="western"><surname>Greenfield</surname><given-names>S.</given-names></name></person-group><article-title>Factors associated with COVID-19 vaccine intentions during the COVID-19 pandemic; a systematic review and meta-analysis of cross-sectional studies</article-title><source>BMC Public Health</source><volume>22</volume><issue>1</issue><year>2022</year><fpage>1667</fpage><pub-id pub-id-type="doi">10.1186/s12889-022-14029-4</pub-id><pub-id pub-id-type="pmid">36056325</pub-id><pub-id pub-id-type="pmcid">PMC9437387</pub-id></element-citation></ref><ref id="bib84"><label>131</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Thorsteinsdottir</surname><given-names>B.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>B.E.</given-names></name></person-group><article-title>Prioritizing health care workers and first responders for access to the COVID19 vaccine is not unethical, but both fair and effective &#8211; an ethical analysis</article-title><source>Scand J Trauma Resusc Emerg Med</source><volume>29</volume><issue>1</issue><year>2021</year><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s13049-021-00886-2</pub-id><pub-id pub-id-type="pmid">34088336</pub-id><pub-id pub-id-type="pmcid">PMC8177265</pub-id></element-citation></ref><ref id="bib85"><label>132</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Lazarus</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Wyka</surname><given-names>K.</given-names></name><name name-style="western"><surname>White</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Picchio</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Rabin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ratzan</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021</article-title><source>Nat Commun</source><volume>13</volume><issue>1</issue><year>2022</year><fpage>3801</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31441-x</pub-id><pub-id pub-id-type="pmid">35778396</pub-id><pub-id pub-id-type="pmcid">PMC9247969</pub-id></element-citation></ref><ref id="bib86"><label>133</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Hatmal</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Al-Hatamleh</surname><given-names>M.A.I.</given-names></name><name name-style="western"><surname>Olaimat</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Mohamud</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fawaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kateeb</surname><given-names>E.T.</given-names></name><etal/></person-group><article-title>Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors</article-title><source>Vaccines</source><volume>10</volume><issue>3</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/vaccines10030366</pub-id><pub-id pub-id-type="pmcid">PMC8955470</pub-id><pub-id pub-id-type="pmid">35334998</pub-id></element-citation></ref><ref id="bib87"><label>134</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pokorna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Antalova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Krobot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zviadadze</surname><given-names>N.</given-names></name><name name-style="western"><surname>Serdiuk</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Prevalence and drivers of COVID-19 vaccine hesitancy among Czech University students: national cross-sectional study</article-title><source>Vaccines</source><volume>9</volume><issue>9</issue><year>2021</year><fpage>948</fpage><pub-id pub-id-type="doi">10.3390/vaccines9090948</pub-id><pub-id pub-id-type="pmid">34579185</pub-id><pub-id pub-id-type="pmcid">PMC8470400</pub-id></element-citation></ref><ref id="bib88"><label>135</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Al-Qerem</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Jarab</surname><given-names>A.S.</given-names></name></person-group><article-title>COVID-19 vaccination acceptance and its associated factors among a middle Eastern population</article-title><source>Front Public Health</source><volume>9</volume><year>2021</year><object-id pub-id-type="publisher-id">632914</object-id><pub-id pub-id-type="doi">10.3389/fpubh.2021.632914</pub-id><pub-id pub-id-type="pmcid">PMC7902782</pub-id><pub-id pub-id-type="pmid">33643995</pub-id></element-citation></ref><ref id="bib89"><label>136</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jouzova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ustun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lagova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hruban</surname><given-names>L.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>P.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine acceptance of pregnant and lactating women (PLW) in Czechia: an analytical cross-sectional study</article-title><source>Int J Environ Res Public Health</source><volume>18</volume><issue>24</issue><year>2021</year><object-id pub-id-type="publisher-id">13373</object-id><pub-id pub-id-type="doi">10.3390/ijerph182413373</pub-id><pub-id pub-id-type="pmcid">PMC8708407</pub-id><pub-id pub-id-type="pmid">34948987</pub-id></element-citation></ref><ref id="bib90"><label>137</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Laurent</surname><given-names>S.M.</given-names></name></person-group><article-title>Psychological predictors of vaccination intentions among U.S. undergraduates and online panel workers during the 2020 COVID-19 pandemic</article-title><source>PLoS One</source><volume>16</volume><issue>11</issue><year>2021</year><object-id pub-id-type="publisher-id">e0260380</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0260380</pub-id><pub-id pub-id-type="pmcid">PMC8631617</pub-id><pub-id pub-id-type="pmid">34847162</pub-id></element-citation></ref><ref id="bib91"><label>138</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdulqader</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morgado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Domnori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Global prevalence and drivers of dental students' COVID-19 vaccine hesitancy</article-title><source>Vaccines</source><volume>9</volume><issue>6</issue><year>2021</year><fpage>566</fpage><pub-id pub-id-type="doi">10.3390/vaccines9060566</pub-id><pub-id pub-id-type="pmid">34072500</pub-id><pub-id pub-id-type="pmcid">PMC8226539</pub-id></element-citation></ref><ref id="bib92"><label>139</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Jennings</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stoker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bunting</surname><given-names>H.</given-names></name><name name-style="western"><surname>Valgarethsson</surname><given-names>V.O.</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Devine</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Lack of trust, conspiracy beliefs, and social media use predict COVID-19 vaccine hesitancy</article-title><source>Vaccines</source><volume>9</volume><issue>6</issue><year>2021</year><pub-id pub-id-type="doi">10.3390/vaccines9060593</pub-id><pub-id pub-id-type="pmcid">PMC8226842</pub-id><pub-id pub-id-type="pmid">34204971</pub-id></element-citation></ref><ref id="bib93"><label>140</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Lounis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bencherit</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rais</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 vaccine booster hesitancy (VBH) and its drivers in Algeria: national cross-sectional survey-based study</article-title><source>Vaccines</source><volume>10</volume><issue>4</issue><year>2022</year><fpage>621</fpage><pub-id pub-id-type="doi">10.3390/vaccines10040621</pub-id><pub-id pub-id-type="pmid">35455371</pub-id><pub-id pub-id-type="pmcid">PMC9031698</pub-id></element-citation></ref><ref id="bib94"><label>141</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Klugar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohanan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pokorna</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 vaccine booster hesitancy (VBH) of healthcare workers in Czechia: national cross-sectional study</article-title><source>Vaccines</source><volume>9</volume><issue>12</issue><year>2021</year><fpage>1437</fpage><pub-id pub-id-type="doi">10.3390/vaccines9121437</pub-id><pub-id pub-id-type="pmid">34960183</pub-id><pub-id pub-id-type="pmcid">PMC8705445</pub-id></element-citation></ref><ref id="bib95"><label>142</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Dziedzic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Issa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanasiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wojtyczka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kubina</surname><given-names>R.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine booster hesitancy (VBH) of healthcare professionals and students in Poland: cross-sectional survey-based study</article-title><source>Front Public Health</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">938067</object-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.938067</pub-id><pub-id pub-id-type="pmcid">PMC9359622</pub-id><pub-id pub-id-type="pmid">35958845</pub-id></element-citation></ref><ref id="bib96"><label>143</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Attia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mausbach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klugar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Howaldt</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name></person-group><article-title>Prevalence and drivers of COVID-19 vaccine booster hesitancy among German University students and employees</article-title><source>Front Public Health</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">846861</object-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.846861</pub-id><pub-id pub-id-type="pmcid">PMC9021373</pub-id><pub-id pub-id-type="pmid">35462827</pub-id></element-citation></ref><ref id="bib97"><label>144</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Hatmal</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Al-Hatamleh</surname><given-names>M.A.I.</given-names></name><name name-style="western"><surname>Olaimat</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Hatmal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alhaj-Qasem</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Olaimat</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects</article-title><source>Vaccines</source><volume>9</volume><issue>6</issue><year>2021</year><pub-id pub-id-type="doi">10.3390/vaccines9060556</pub-id><pub-id pub-id-type="pmcid">PMC8229440</pub-id><pub-id pub-id-type="pmid">34073382</pub-id></element-citation></ref><ref id="bib98"><label>145</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goddard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fireman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zerbo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>K.E.</given-names></name><etal/></person-group><article-title>Surveillance for adverse events after COVID-19 mRNA vaccination</article-title><source>JAMA</source><volume>326</volume><issue>14</issue><year>2021</year><fpage>1390</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.15072</pub-id><pub-id pub-id-type="pmid">34477808</pub-id><pub-id pub-id-type="pmcid">PMC8511971</pub-id></element-citation></ref><ref id="bib99"><label>146</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schunemann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Attia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pericic</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Zuljevic</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Jurisson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>COVID-19 vaccines safety tracking (CoVaST): protocol of a multi-center prospective cohort study for active surveillance of COVID-19 vaccines' side effects</article-title><source>Int J Environ Res Public Health</source><volume>18</volume><issue>15</issue><year>2021</year><fpage>7859</fpage><pub-id pub-id-type="doi">10.3390/ijerph18157859</pub-id><pub-id pub-id-type="pmid">34360156</pub-id><pub-id pub-id-type="pmcid">PMC8345554</pub-id></element-citation></ref><ref id="bib100"><label>147</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Evaluation of the safety profile of COVID-19 vaccines: a rapid review</article-title><source>BMC Med</source><volume>19</volume><issue>1</issue><year>2021</year><fpage>173</fpage><pub-id pub-id-type="doi">10.1186/s12916-021-02059-5</pub-id><pub-id pub-id-type="pmid">34315454</pub-id><pub-id pub-id-type="pmcid">PMC8315897</pub-id></element-citation></ref><ref id="bib101"><label>148</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sagiroglu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ustun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pokorna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klugarova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Attia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey</article-title><source>J&#160;Clin Med</source><volume>10</volume><issue>12</issue><year>2021</year><fpage>2629</fpage><pub-id pub-id-type="doi">10.3390/jcm10122629</pub-id><pub-id pub-id-type="pmid">34203769</pub-id><pub-id pub-id-type="pmcid">PMC8232682</pub-id></element-citation></ref><ref id="bib102"><label>149</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pokorna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Attia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klugarova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klugar</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic</article-title><source>J&#160;Clin Med</source><volume>10</volume><issue>7</issue><year>2021</year><fpage>1428</fpage><pub-id pub-id-type="doi">10.3390/jcm10071428</pub-id><pub-id pub-id-type="pmid">33916020</pub-id><pub-id pub-id-type="pmcid">PMC8037149</pub-id></element-citation></ref><ref id="bib103"><label>150</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hockova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kantorova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Slavik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Spurna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stebel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Side effects of mRNA-based COVID-19 vaccine: nationwide phase IV study among healthcare workers in Slovakia</article-title><source>Pharmaceuticals</source><volume>14</volume><issue>9</issue><year>2021</year><fpage>873</fpage><pub-id pub-id-type="doi">10.3390/ph14090873</pub-id><pub-id pub-id-type="pmid">34577573</pub-id><pub-id pub-id-type="pmcid">PMC8466035</pub-id></element-citation></ref><ref id="bib104"><label>151</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pokorna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klugarova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Antalova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kantorova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Side effects of mRNA-based COVID-19 vaccines among young adults (18-30 Years old): an independent post-marketing study</article-title><source>Pharmaceuticals</source><volume>14</volume><issue>10</issue><year>2021</year><fpage>1049</fpage><pub-id pub-id-type="doi">10.3390/ph14101049</pub-id><pub-id pub-id-type="pmid">34681273</pub-id><pub-id pub-id-type="pmcid">PMC8696621</pub-id></element-citation></ref><ref id="bib105"><label>152</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Yesuf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Riad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sofi-Mahmudi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sudhakar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mekonnen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Endalkachew</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: a cross-sectional study</article-title><source>Front Public Health</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">937794</object-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.937794</pub-id><pub-id pub-id-type="pmcid">PMC9343757</pub-id><pub-id pub-id-type="pmid">35928493</pub-id></element-citation></ref><ref id="bib106"><label>153</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Orebi</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Emara</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Alhindi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Shahin</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hegazy</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Kabbash</surname><given-names>I.A.</given-names></name><etal/></person-group><article-title>Perceptions and experiences of COVID-19 vaccines' side effects among healthcare workers at an Egyptian University Hospital: a cross-sectional study</article-title><source>Trop Med Health</source><volume>50</volume><issue>1</issue><year>2022</year><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/s41182-022-00427-2</pub-id><pub-id pub-id-type="pmid">35637513</pub-id><pub-id pub-id-type="pmcid">PMC9148842</pub-id></element-citation></ref><ref id="bib107"><label>154</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al Ketbi</surname><given-names>L.M.B.</given-names></name><name name-style="western"><surname>Al Kaabi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Al Mansoori</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al Maskari</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Al Shamsi</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Vaccine side effects following COVID-19 vaccination among the residents of the UAE-an observational study</article-title><source>Front Public Health</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">876336</object-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.876336</pub-id><pub-id pub-id-type="pmcid">PMC9120526</pub-id><pub-id pub-id-type="pmid">35602146</pub-id></element-citation></ref><ref id="bib108"><label>155</label><element-citation publication-type="book" id="sref108"><source>Milken Institute's COVID-19 treatment and vaccine tracker</source><year>2020</year><publisher-name>Milken Institute</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid-19tracker.milkeninstitute.org/#vaccines_intro" id="intref0120">https://covid-19tracker.milkeninstitute.org/#vaccines_intro</ext-link></element-citation></ref><ref id="bib109"><label>156</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Karata&#351;</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ceylan</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>H.</given-names></name></person-group><article-title>COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts</article-title><source>Pharm Hosp Clin</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.phclin.2020.06.003</pub-id></element-citation></ref><ref id="bib110"><label>157</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brierley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Moschella</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Declan</surname><given-names>A.B.L.</given-names></name></person-group><article-title>Repurposing therapeutics for potential treatment of SARS-CoV-2: a review</article-title><source>Viruses</source><volume>12</volume><issue>7</issue><year>2020</year><pub-id pub-id-type="doi">10.3390/v12070705</pub-id><pub-id pub-id-type="pmcid">PMC7412090</pub-id><pub-id pub-id-type="pmid">32629804</pub-id></element-citation></ref><ref id="bib111"><label>158</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Rajoli</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Pertinez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arshad</surname><given-names>U.</given-names></name><name name-style="western"><surname>Box</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tatham</surname><given-names>L.</given-names></name><name name-style="western"><surname>Curley</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.05.01.20087130</pub-id><pub-id pub-id-type="pmcid">PMC8056737</pub-id><pub-id pub-id-type="pmid">33085781</pub-id></element-citation></ref><ref id="bib112"><label>159</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kiso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sakai-Tagawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iwatsuki-Horimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Imai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in&#160;vitro in a cell-type-dependent manner</article-title><source>Viruses</source><volume>12</volume><issue>6</issue><year>2020</year><pub-id pub-id-type="doi">10.3390/v12060629</pub-id><pub-id pub-id-type="pmcid">PMC7354595</pub-id><pub-id pub-id-type="pmid">32532094</pub-id></element-citation></ref><ref id="bib113"><label>160</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>A.</given-names></name></person-group><article-title>Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries</article-title><source>Diabetes Metab Syndr</source><volume>14</volume><issue>3</issue><year>2020</year><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.03.011</pub-id><pub-id pub-id-type="pmid">32247211</pub-id><pub-id pub-id-type="pmcid">PMC7102587</pub-id></element-citation></ref><ref id="bib114"><label>161</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title><source>J&#160;Thromb Haemost</source><volume>18</volume><issue>5</issue><year>2020</year><fpage>1094</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1111/jth.14817</pub-id><pub-id pub-id-type="pmid">32220112</pub-id><pub-id pub-id-type="pmcid">PMC9906401</pub-id></element-citation></ref><ref id="bib115"><label>162</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.28.20046144</pub-id><pub-id pub-id-type="pmcid">PMC7719364</pub-id><pub-id pub-id-type="pmid">32881340</pub-id></element-citation></ref><ref id="bib116"><label>163</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A&#160;human neutralizing antibody targets the receptor-binding site of SARS-CoV-2</article-title><source>Nature</source><volume>584</volume><issue>7819</issue><year>2020</year><fpage>120</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2381-y</pub-id><pub-id pub-id-type="pmid">32454512</pub-id></element-citation></ref><ref id="bib117"><label>164</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title><source>Nature</source><volume>584</volume><issue>7821</issue><year>2020</year><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2571-7</pub-id><pub-id pub-id-type="pmid">32698192</pub-id></element-citation></ref><ref id="bib118"><label>165</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Beltramello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Structural and functional analysis of a potent sarbecovirus neutralizing antibody</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.07.023903</pub-id></element-citation></ref><ref id="bib119"><label>166</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>te Velthuis</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>van den Worm</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>van Hemert</surname><given-names>M.J.</given-names></name></person-group><article-title>Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in&#160;vitro and zinc ionophores block the replication of these viruses in cell culture</article-title><source>PLoS Pathog</source><volume>6</volume><issue>11</issue><year>2010</year><object-id pub-id-type="publisher-id">e1001176</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1001176</pub-id><pub-id pub-id-type="pmcid">PMC2973827</pub-id><pub-id pub-id-type="pmid">21079686</pub-id></element-citation></ref><ref id="bib120"><label>167</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chernov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kasuya</surname><given-names>H.</given-names></name></person-group><article-title>Potential role of zinc supplementation in prophylaxis and treatment of COVID-19</article-title><source>Med Hypotheses</source><volume>144</volume><year>2020</year><object-id pub-id-type="publisher-id">109848</object-id><pub-id pub-id-type="doi">10.1016/j.mehy.2020.109848</pub-id><pub-id pub-id-type="pmcid">PMC7247509</pub-id><pub-id pub-id-type="pmid">32512490</pub-id></element-citation></ref><ref id="bib121"><label>168</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Derwand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>M.</given-names></name></person-group><article-title>Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?</article-title><source>Med Hypotheses</source><volume>142</volume><year>2020</year><object-id pub-id-type="publisher-id">109815</object-id><pub-id pub-id-type="doi">10.1016/j.mehy.2020.109815</pub-id><pub-id pub-id-type="pmcid">PMC7202847</pub-id><pub-id pub-id-type="pmid">32408070</pub-id></element-citation></ref><ref id="bib122"><label>169</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.A.</given-names></name></person-group><article-title>What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19?</article-title><source>Clevel Clin J Med</source><year>2020</year><pub-id pub-id-type="doi">10.3949/ccjm.87a.ccc046</pub-id><pub-id pub-id-type="pmid">32513807</pub-id></element-citation></ref><ref id="bib123"><label>170</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hatamleh</surname><given-names>M.A.I.</given-names></name><name name-style="western"><surname>Hatmal</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sattar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>M.D.C.</given-names></name><etal/></person-group><article-title>Antiviral and immunomodulatory effects of phytochemicals from honey against COVID-19: potential mechanisms of action and future directions</article-title><source>Molecules</source><volume>25</volume><year>2020</year><fpage>5017</fpage><pub-id pub-id-type="doi">10.3390/molecules25215017</pub-id><pub-id pub-id-type="pmcid">PMC7672575</pub-id><pub-id pub-id-type="pmid">33138197</pub-id></element-citation></ref><ref id="bib124"><label>171</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Lembo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donalisio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Civra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Argenziano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>R.</given-names></name></person-group><article-title>Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections</article-title><source>Expert Opin Drug Deliv</source><volume>15</volume><issue>1</issue><year>2018</year><fpage>93</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1080/17425247.2017.1360863</pub-id><pub-id pub-id-type="pmid">28749739</pub-id></element-citation></ref><ref id="bib125"><label>172</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.30.20047365</pub-id></element-citation></ref><ref id="bib126"><label>173</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Marano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vaglio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pupella</surname><given-names>S.</given-names></name><name name-style="western"><surname>Facco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Catalano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liumbruno</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Convalescent plasma: new evidence for an old therapeutic tool?</article-title><source>Blood Transfus</source><volume>14</volume><issue>2</issue><year>2016</year><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.2450/2015.0131-15</pub-id><pub-id pub-id-type="pmid">26674811</pub-id><pub-id pub-id-type="pmcid">PMC4781783</pub-id></element-citation></ref><ref id="bib127"><label>174</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirofski</surname><given-names>L.-A.</given-names></name></person-group><article-title>Antibody-mediated regulation of cellular immunity and the inflammatory response</article-title><source>Trends Immunol</source><volume>24</volume><issue>9</issue><year>2003</year><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">12967670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1471-4906(03)00228-x</pub-id></element-citation></ref><ref id="bib128"><label>175</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Bloch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Shoham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sachais</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Shaz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Winters</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Deployment of convalescent plasma for the prevention and treatment of COVID-19</article-title><source>J&#160;Clin Investig</source><volume>130</volume><issue>6</issue><year>2020</year><fpage>2757</fpage><lpage>2765</lpage><pub-id pub-id-type="pmid">32254064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI138745</pub-id><pub-id pub-id-type="pmcid">PMC7259988</pub-id></element-citation></ref><ref id="bib129"><label>176</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Joyner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Pirofski</surname><given-names>L.A.</given-names></name></person-group><article-title>SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities</article-title><source>J&#160;Clin Investig</source><volume>131</volume><issue>7</issue><year>2021</year><pub-id pub-id-type="doi">10.1172/jci148832</pub-id><pub-id pub-id-type="pmcid">PMC8011895</pub-id><pub-id pub-id-type="pmid">33621214</pub-id></element-citation></ref><ref id="bib130"><label>177</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Walensky</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Walke</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>SARS-CoV-2 variants of concern in the United States-challenges and opportunities</article-title><source>JAMA</source><volume>325</volume><issue>11</issue><year>2021</year><fpage>1037</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.2294</pub-id><pub-id pub-id-type="pmid">33595644</pub-id><pub-id pub-id-type="pmcid">PMC9009864</pub-id></element-citation></ref><ref id="bib131"><label>178</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;gin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Callum</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jamula</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heddle</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Tinmouth</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial</article-title><source>Nat Med</source><volume>27</volume><issue>11</issue><year>2021</year><fpage>2012</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01488-2</pub-id><pub-id pub-id-type="pmid">34504336</pub-id><pub-id pub-id-type="pmcid">PMC8604729</pub-id></element-citation></ref><ref id="bib132"><label>179</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirofski</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Joyner</surname><given-names>M.J.</given-names></name></person-group><article-title>The principles of antibody therapy for infectious diseases with relevance for COVID-19</article-title><source>mBio</source><volume>12</volume><issue>2</issue><year>2021</year><pub-id pub-id-type="doi">10.1128/mBio.03372-20</pub-id><pub-id pub-id-type="pmcid">PMC8092292</pub-id><pub-id pub-id-type="pmid">33653885</pub-id></element-citation></ref><ref id="bib133"><label>180</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Lesne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brodin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saint-Girons</surname><given-names>F.</given-names></name></person-group><article-title>Plasma therapy in influenza</article-title><source>Presse Med</source><volume>27</volume><year>1919</year><fpage>181</fpage><lpage>182</lpage></element-citation></ref><ref id="bib134"><label>181</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Mair-Jenkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saavedra-Campos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khaw</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.S.</given-names></name><etal/></person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>J&#160;Infect Dis</source><volume>211</volume><issue>1</issue><year>2015</year><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu396</pub-id><pub-id pub-id-type="pmid">25030060</pub-id><pub-id pub-id-type="pmcid">PMC4264590</pub-id></element-citation></ref><ref id="bib135"><label>182</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Goodarzi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mirzaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hasanvand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sholeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Coronavirus disease 2019 (COVID-19): immunological approaches and emerging pharmacologic treatments</article-title><source>Int Immunopharm</source><volume>88</volume><year>2020</year><object-id pub-id-type="publisher-id">106885</object-id><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106885</pub-id><pub-id pub-id-type="pmcid">PMC7414363</pub-id><pub-id pub-id-type="pmid">32795893</pub-id></element-citation></ref><ref id="bib136"><label>183</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc Natl Acad Sci U S A</source><volume>117</volume><issue>17</issue><year>2020</year><fpage>9490</fpage><lpage>9496</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id><pub-id pub-id-type="pmid">32253318</pub-id><pub-id pub-id-type="pmcid">PMC7196837</pub-id></element-citation></ref><ref id="bib137"><label>184</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.T.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Baine</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wajnberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gumprecht</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Convalescent plasma treatment of severe COVID-19: a propensity score&#8211;matched control study</article-title><source>Nat Med</source><volume>26</volume><issue>11</issue><year>2020</year><fpage>1708</fpage><lpage>1713</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1088-9</pub-id><pub-id pub-id-type="pmid">32934372</pub-id></element-citation></ref><ref id="bib138"><label>185</label><element-citation publication-type="book" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>March</surname><given-names>D.</given-names></name></person-group><part-title>New study validates benefits of convalescent plasma for some patients with COVID-19</part-title><year>2022</year><publisher-name>NYU Langone Health</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://nyulangone.org/news/new-study-validates-benefits-convalescent-plasma-some-patients-covid-19" id="intref0125">https://nyulangone.org/news/new-study-validates-benefits-convalescent-plasma-some-patients-covid-19</ext-link></element-citation></ref><ref id="bib139"><label>186</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Troxel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Petkova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goldfeld</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tarpey</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis</article-title><source>JAMA Netw Open</source><volume>5</volume><issue>1</issue><year>2022</year><comment>e2147331&#8211;e2147331</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.47331</pub-id><pub-id pub-id-type="pmcid">PMC8790669</pub-id><pub-id pub-id-type="pmid">35076699</pub-id></element-citation></ref><ref id="bib140"><label>187</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Simonovich</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Burgos Pratx</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Scibona</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beruto</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Vallone</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A&#160;randomized trial of convalescent plasma in Covid-19 severe pneumonia</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>7</issue><year>2021</year><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">33232588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2031304</pub-id><pub-id pub-id-type="pmcid">PMC7722692</pub-id></element-citation></ref><ref id="bib141"><label>188</label><element-citation publication-type="book" id="sref141"><person-group person-group-type="author"><collab>The Science Advisory Board</collab></person-group><part-title>FDA issues EUA for GSK-Vir COVID-19 mAb treatment</part-title><year>2021</year><publisher-name>The Science Advisory Board</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.scienceboard.net/index.aspx?sec=ser&amp;sub=def&amp;pag=dis&amp;ItemID=2761" id="intref0130">https://www.scienceboard.net/index.aspx?sec=ser&amp;sub=def&amp;pag=dis&amp;ItemID=2761</ext-link></element-citation></ref><ref id="bib142"><label>189</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Dougan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nirula</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Azizad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mocherla</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Bamlanivimab&#160;+&#160;etesevimab for treatment of COVID-19 in high-risk ambulatory patients</article-title><source>Top Antivir Med</source><year>2021</year><comment>33&#8211;33</comment></element-citation></ref><ref id="bib143"><label>190</label><element-citation publication-type="book" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>Hyung</given-names></name><name name-style="western"><surname>Tarpey</surname><given-names>Thaddeus</given-names></name><name name-style="western"><surname>Li</surname><given-names>Yi</given-names></name><name name-style="western"><surname>Petkova</surname><given-names>Eva</given-names></name><name name-style="western"><surname>Antman</surname><given-names>Elliott</given-names></name><name name-style="western"><surname>Troxel</surname><given-names>Andrea</given-names></name></person-group><part-title>Is treatment with convalescent plasma right for your patient</part-title><year>2021</year><publisher-name>COMPILE</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid-convalescentplasma-tbi-calc.org/" id="intref0135">https://covid-convalescentplasma-tbi-calc.org/</ext-link></element-citation></ref><ref id="bib144"><label>191</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Ortigoza</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goldfeld</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Troxel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Daily</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial</article-title><source>JAMA Intern Med</source><volume>182</volume><issue>2</issue><year>2021</year><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2021.6850</pub-id><pub-id pub-id-type="pmcid">PMC8669605</pub-id><pub-id pub-id-type="pmid">34901997</pub-id></element-citation></ref><ref id="bib145"><label>192</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Joyner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Senefeld</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Klassen</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>P.W.</given-names></name><etal/></person-group><article-title>Convalescent plasma antibody levels and the risk of death from Covid-19</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>11</issue><year>2021</year><fpage>1015</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">33523609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2031893</pub-id><pub-id pub-id-type="pmcid">PMC7821984</pub-id></element-citation></ref><ref id="bib146"><label>193</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Luke</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Kilbane</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>S.L.</given-names></name></person-group><article-title>Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</article-title><source>Ann Intern Med</source><volume>145</volume><issue>8</issue><year>2006</year><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">16940336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-145-8-200610170-00139</pub-id></element-citation></ref><ref id="bib147"><label>194</label><element-citation publication-type="book" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Horby</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Estcourt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peto</surname><given-names>L.</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Staplin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Spata</surname><given-names>E.</given-names></name><etal/></person-group><part-title>Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial</part-title><year>2021</year><publisher-name>medRxiv</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00897-7</pub-id><pub-id pub-id-type="pmcid">PMC8121538</pub-id><pub-id pub-id-type="pmid">34000257</pub-id></element-citation></ref><ref id="bib148"><label>195</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Mora-Rillo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arsuaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramirez-Olivencia</surname><given-names>G.</given-names></name><name name-style="western"><surname>de la Calle</surname><given-names>F.</given-names></name><name name-style="western"><surname>Borobia</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sanchez-Seco</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain</article-title><source>Lancet Respir Med</source><volume>3</volume><issue>7</issue><year>2015</year><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(15)00180-0</pub-id><pub-id pub-id-type="pmid">26041403</pub-id></element-citation></ref><ref id="bib149"><label>196</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>M.</given-names></name></person-group><article-title>Convalescent plasma for COVID-19 complicated by ARDS due to TRALI</article-title><source>BMJ Case Rep</source><volume>14</volume><issue>1</issue><year>2021</year><pub-id pub-id-type="doi">10.1136/bcr-2020-239762</pub-id><pub-id pub-id-type="pmcid">PMC10577747</pub-id><pub-id pub-id-type="pmid">33509890</pub-id></element-citation></ref><ref id="bib150"><label>197</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Roback</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Guarner</surname><given-names>J.</given-names></name></person-group><article-title>Convalescent plasma to treat COVID-19: possibilities and challenges</article-title><source>JAMA</source><volume>323</volume><issue>16</issue><year>2020</year><fpage>1561</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.4940</pub-id><pub-id pub-id-type="pmid">32219429</pub-id></element-citation></ref><ref id="bib298"><label>198</label><element-citation publication-type="journal" id="sref298"><person-group person-group-type="author"><name name-style="western"><surname>Teofili</surname><given-names>L.</given-names></name><name name-style="western"><surname>Landolfi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cingolani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Antinori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vecchiet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanguinetti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: a structured summary of a study protocol for a randomised controlled trial</article-title><source>Trials</source><volume>21</volume><issue>1</issue><year>2020</year><fpage>875</fpage><pub-id pub-id-type="doi">10.1186/s13063-020-04821-1</pub-id><pub-id pub-id-type="pmid">33092632</pub-id><pub-id pub-id-type="pmcid">PMC7578576</pub-id></element-citation></ref><ref id="bib299"><label>199</label><element-citation publication-type="journal" id="sref299"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>A.</given-names></name></person-group><article-title>Study to assess the efficacy and safety of convalescent plasma in moderate COVID-19 disease</article-title><source>Clin Trials Regist India</source><year>2020</year><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="bib300"><label>200</label><element-citation publication-type="journal" id="sref300"><person-group person-group-type="author"><name name-style="western"><surname>AlQahtani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdulrahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Almadani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alali</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Al Zamrooni</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hejab</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease</article-title><source>Sci Rep</source><volume>11</volume><issue>1</issue><year>2021</year><pub-id pub-id-type="doi">10.1038/s41598-021-89444-5</pub-id><comment>9927&#8211;9927</comment><pub-id pub-id-type="pmcid">PMC8113529</pub-id><pub-id pub-id-type="pmid">33976287</pub-id></element-citation></ref><ref id="bib301"><label>201</label><element-citation publication-type="journal" id="sref301"><person-group person-group-type="author"><name name-style="western"><surname>Avenda&#241;o-Sol&#225;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramos-Mart&#237;nez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mu&#241;ez-Rubio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruiz-Antor&#225;n</surname><given-names>B.</given-names></name><name name-style="western"><surname>Malo de Molina</surname><given-names>R.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A&#160;multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia</article-title><source>J&#160;Clin Investig</source><volume>131</volume><issue>20</issue><year>2021</year><object-id pub-id-type="publisher-id">e152740</object-id><pub-id pub-id-type="doi">10.1172/JCI152740</pub-id><pub-id pub-id-type="pmcid">PMC8516461</pub-id><pub-id pub-id-type="pmid">34473652</pub-id></element-citation></ref><ref id="bib302"><label>202</label><element-citation publication-type="journal" id="sref302"><person-group person-group-type="author"><name name-style="western"><surname>Bajpai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maheshwari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chhabra</surname><given-names>K.</given-names></name><name name-style="western"><surname>kale</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.10.25.20219337</pub-id></element-citation></ref><ref id="bib303"><label>203</label><element-citation publication-type="journal" id="sref303"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bandopadhyay</surname><given-names>P.</given-names></name><name name-style="western"><surname>D'Rozario</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sarif</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raychaudhuri</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A&#160;phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19</article-title><source>Nat Commun</source><volume>13</volume><issue>1</issue><year>2022</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">35046397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-28064-7</pub-id><pub-id pub-id-type="pmcid">PMC8770561</pub-id></element-citation></ref><ref id="bib304"><label>204</label><element-citation publication-type="journal" id="sref304"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>J.L.B.</given-names></name><name name-style="western"><surname>Gonz&#225;lez G&#225;mez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mendoza Enciso</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Esparza Maldonado</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Palacios</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.03.28.21254507</pub-id></element-citation></ref><ref id="bib305"><label>205</label><element-citation publication-type="journal" id="sref305"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;rper</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zickler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wiesmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zacharowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Corman</surname><given-names>V.M.</given-names></name><etal/></person-group><article-title>Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19</article-title><source>J&#160;Clin Investig</source><issue>20</issue><year>2021</year><fpage>131</fpage><pub-id pub-id-type="doi">10.1172/jci152264</pub-id><pub-id pub-id-type="pmcid">PMC8516466</pub-id><pub-id pub-id-type="pmid">34464358</pub-id></element-citation></ref><ref id="bib306"><label>206</label><element-citation publication-type="journal" id="sref306"><person-group person-group-type="author"><name name-style="western"><surname>O'Donnell</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Justman</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Eckhardt</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>A&#160;randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19</article-title><source>J&#160;Clin Investig</source><volume>131</volume><issue>13</issue><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI150646</pub-id><pub-id pub-id-type="pmcid">PMC8245169</pub-id><pub-id pub-id-type="pmid">33974559</pub-id></element-citation></ref><ref id="bib307"><label>207</label><element-citation publication-type="journal" id="sref307"><person-group person-group-type="author"><name name-style="western"><surname>Rasheed</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fatak</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Hashim</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Maulood</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Kabah</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Almusawi</surname><given-names>Y.A.</given-names></name><etal/></person-group><article-title>The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in Baghdad, Iraq</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.24.20121905</pub-id><pub-id pub-id-type="pmid">32920571</pub-id></element-citation></ref><ref id="bib308"><label>208</label><element-citation publication-type="journal" id="sref308"><person-group person-group-type="author"><name name-style="western"><surname>Simonovich</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Burgos Pratx</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Scibona</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beruto</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Vallone</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A&#160;randomized trial of convalescent plasma in covid-19 severe pneumonia</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>7</issue><year>2020</year><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2031304</pub-id><pub-id pub-id-type="pmid">33232588</pub-id><pub-id pub-id-type="pmcid">PMC7722692</pub-id></element-citation></ref><ref id="bib309"><label>209</label><element-citation publication-type="journal" id="sref309"><person-group person-group-type="author"><name name-style="western"><surname>Axfors</surname><given-names>C.</given-names></name><name name-style="western"><surname>Janiaud</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>van't Hooft</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Haber</surname><given-names>N.A.</given-names></name><etal/></person-group><article-title>Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials</article-title><source>BMC Infect Dis</source><volume>21</volume><issue>1</issue><year>2021</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">34800996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12879-021-06829-7</pub-id><pub-id pub-id-type="pmcid">PMC8605464</pub-id></element-citation></ref><ref id="bib310"><label>210</label><element-citation publication-type="book" id="sref310"><person-group person-group-type="author"><name name-style="western"><surname>Averyanov</surname><given-names>Alexander V.</given-names></name><name name-style="western"><surname>Baklaushev</surname><given-names>Vladimir P.</given-names></name></person-group><part-title>Hyperimmune convalescent plasma in moderate and severe COVID-19 disease</part-title><year>2020</year><publisher-name>ClinicalTrials</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/record/NCT04392414?term=NCT04392414&amp;draw=2&amp;rank=1" id="intref0335">https://www.clinicaltrials.gov/ct2/show/record/NCT04392414?term=NCT04392414&amp;draw=2&amp;rank=1</ext-link></element-citation></ref><ref id="bib311"><label>211</label><element-citation publication-type="book" id="sref311"><person-group person-group-type="author"><name name-style="western"><surname>Cabrera</surname><given-names>J.M.A.</given-names></name></person-group><part-title>Convalescent plasma for patients with COVID-19: a randomized, single blinded, parallel, controlled clinical study (CP-COVID-19)</part-title><year>2020</year><publisher-name>ClinicalTrials</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/record/NCT04332835?term=NCT04332835&amp;draw=2&amp;rank=1" id="intref0340">https://www.clinicaltrials.gov/ct2/show/record/NCT04332835?term=NCT04332835&amp;draw=2&amp;rank=1</ext-link></element-citation></ref><ref id="bib312"><label>212</label><element-citation publication-type="book" id="sref312"><person-group person-group-type="author"><collab>Andalusian Network for Design and Translation of Advanced Therapies</collab></person-group><part-title>Clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection</part-title><year>2020</year><publisher-name>ClinicalTrials</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/study/NCT04366245?term=NCT04366245&amp;draw=2&amp;rank=1" id="intref0345">https://www.clinicaltrials.gov/ct2/show/study/NCT04366245?term=NCT04366245&amp;draw=2&amp;rank=1</ext-link></element-citation></ref><ref id="bib313"><label>213</label><element-citation publication-type="journal" id="sref313"><person-group person-group-type="author"><name name-style="western"><surname>Self</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>El Atrouni</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bistran-Hall</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults</article-title><source>Res Sq</source><year>2021</year><pub-id pub-id-type="doi">10.21203/rs.3.rs-227796/v1</pub-id><pub-id pub-id-type="pmcid">PMC7980732</pub-id><pub-id pub-id-type="pmid">33743799</pub-id></element-citation></ref><ref id="bib314"><label>214</label><element-citation publication-type="journal" id="sref314"><person-group person-group-type="author"><name name-style="western"><surname>Shoham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gebo</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.12.13.21267611</pub-id><pub-id pub-id-type="pmcid">PMC9129191</pub-id><pub-id pub-id-type="pmid">35579509</pub-id></element-citation></ref><ref id="bib315"><label>215</label><element-citation publication-type="journal" id="sref315"><person-group person-group-type="author"><name name-style="western"><surname>Ortigoza</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goldfeld</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Troxel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Daily</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial</article-title><source>JAMA Intern Med</source><volume>182</volume><issue>2</issue><year>2022</year><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2021.6850</pub-id><pub-id pub-id-type="pmid">34901997</pub-id><pub-id pub-id-type="pmcid">PMC8669605</pub-id></element-citation></ref><ref id="bib316"><label>216</label><element-citation publication-type="journal" id="sref316"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Gebo</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Shoham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shenoy</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Early outpatient treatment for covid-19 with convalescent plasma</article-title><source>N&#160;Engl J Med</source><year>2022</year><pub-id pub-id-type="doi">10.1056/NEJMoa2119657</pub-id><pub-id pub-id-type="pmcid">PMC9006786</pub-id><pub-id pub-id-type="pmid">35353960</pub-id></element-citation></ref><ref id="bib317"><label>217</label><element-citation publication-type="journal" id="sref317"><person-group person-group-type="author"><name name-style="western"><surname>Pouladzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Safdarian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eshghi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abolghasemi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bavani</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sheibani</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A&#160;randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm</article-title><source>Intern Emerg Med</source><volume>16</volume><issue>8</issue><year>2021</year><fpage>2181</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1007/s11739-021-02734-8</pub-id><pub-id pub-id-type="pmid">33837906</pub-id><pub-id pub-id-type="pmcid">PMC8035885</pub-id></element-citation></ref><ref id="bib318"><label>218</label><element-citation publication-type="journal" id="sref318"><person-group person-group-type="author"><collab>RECOVERY Collaborative Group</collab></person-group><article-title>Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial</article-title><source>Lancet</source><volume>397</volume><issue>10289</issue><year>2021</year><fpage>2049</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(21)00897-7</pub-id><pub-id pub-id-type="pmid">34000257</pub-id><pub-id pub-id-type="pmcid">PMC8121538</pub-id></element-citation></ref><ref id="bib319"><label>219</label><element-citation publication-type="journal" id="sref319"><person-group person-group-type="author"><collab>Writing Committee for the REMAP-CAP Investigators</collab><name name-style="western"><surname>Estcourt</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Turgeon</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>McQuilten</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>McVerry</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Al-Beidh</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial</article-title><source>JAMA</source><volume>326</volume><issue>17</issue><year>2021</year><fpage>1690</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.18178</pub-id><pub-id pub-id-type="pmid">34606578</pub-id><pub-id pub-id-type="pmcid">PMC8491132</pub-id></element-citation></ref><ref id="bib320"><label>220</label><element-citation publication-type="journal" id="sref320"><person-group person-group-type="author"><name name-style="western"><surname>Investigators</surname><given-names>T.R.-C.</given-names></name><name name-style="western"><surname>Estcourt</surname><given-names>L.J.</given-names></name></person-group><article-title>Convalescent plasma in critically ill patients with covid-19</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.06.11.21258760</pub-id></element-citation></ref><ref id="bib321"><label>221</label><element-citation publication-type="book" id="sref321"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muljono</surname><given-names>I.</given-names></name><name name-style="western"><surname>Idaian</surname><given-names>Sri</given-names></name><name name-style="western"><surname>Fajarwati</surname><given-names>Tetra</given-names></name></person-group><part-title>Convalescent plasma as adjunct therapy for COVID-19 (PlaSenTer)</part-title><year>2021</year><publisher-name>ClinicalTrials</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/record/NCT04873414?term=NCT04873414&amp;draw=2&amp;rank=1" id="intref0350">https://clinicaltrials.gov/ct2/show/record/NCT04873414?term=NCT04873414&amp;draw=2&amp;rank=1</ext-link></element-citation></ref><ref id="bib322"><label>222</label><element-citation publication-type="book" id="sref322"><person-group person-group-type="author"><name name-style="western"><surname>Bennett-Guerrero</surname><given-names>E.</given-names></name></person-group><part-title>Convalescent plasma vs. standard plasma for COVID-19</part-title><year>2021</year><publisher-name>ClinicalTrials</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04344535?term=NCT04344535&amp;draw=2&amp;rank=1" id="intref0355">https://www.clinicaltrials.gov/ct2/show/NCT04344535?term=NCT04344535&amp;draw=2&amp;rank=1</ext-link></element-citation></ref><ref id="bib323"><label>223</label><element-citation publication-type="journal" id="sref323"><person-group person-group-type="author"><name name-style="western"><surname>Gharbharan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jordans</surname><given-names>C.C.E.</given-names></name><name name-style="western"><surname>Geurtsvankessel</surname><given-names>C.</given-names></name><name name-style="western"><surname>den Hollander</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Karim</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mollema</surname><given-names>F.P.N.</given-names></name><etal/></person-group><article-title>Convalescent Plasma for COVID-19. A randomized clinical trial</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.01.20139857</pub-id></element-citation></ref><ref id="bib324"><label>224</label><element-citation publication-type="journal" id="sref324"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial</article-title><source>JAMA</source><volume>324</volume><issue>5</issue><year>2020</year><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.10044</pub-id><pub-id pub-id-type="pmid">32492084</pub-id><pub-id pub-id-type="pmcid">PMC7270883</pub-id></element-citation></ref><ref id="bib325"><label>225</label><element-citation publication-type="journal" id="sref325"><person-group person-group-type="author"><name name-style="western"><surname>Libster</surname><given-names>R.</given-names></name><name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wappner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coviello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braem</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Early high-titer plasma therapy to prevent severe covid-19 in older adults</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>7</issue><year>2021</year><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2033700</pub-id><pub-id pub-id-type="pmid">33406353</pub-id><pub-id pub-id-type="pmcid">PMC7793608</pub-id></element-citation></ref><ref id="bib151"><label>226</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Giurgea</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Morens</surname><given-names>D.M.</given-names></name></person-group><article-title>Great expectations of COVID-19 herd immunity</article-title><source>mBio</source><volume>13</volume><issue>1</issue><year>2022</year><comment>e03495-03421</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mbio.03495-21</pub-id><pub-id pub-id-type="pmcid">PMC8787463</pub-id><pub-id pub-id-type="pmid">35073740</pub-id></element-citation></ref><ref id="bib152"><label>227</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Hinman</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Orenstein</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Papania</surname><given-names>M.J.</given-names></name></person-group><article-title>Evolution of measles elimination strategies in the United States</article-title><source>J&#160;Infect Dis</source><volume>189</volume><issue>Suppl.&#160;1</issue><year>2004</year><fpage>S17</fpage><lpage>S22</lpage><pub-id pub-id-type="doi">10.1086/377694</pub-id><pub-id pub-id-type="pmid">15106084</pub-id></element-citation></ref><ref id="bib153"><label>228</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Hedrich</surname><given-names>A.W.</given-names></name></person-group><article-title>Monthly estimates of the child population &#8220;susceptible&#8217; to measles, 1900&#8211;1931, Baltimore, MD</article-title><source>Am J Epidemiol</source><volume>17</volume><issue>3</issue><year>1933</year><fpage>613</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a117929</pub-id></element-citation></ref><ref id="bib154"><label>229</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>P.</given-names></name><name name-style="western"><surname>Eames</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>D.L.</given-names></name></person-group><article-title>&#8220;Herd immunity&#8221;: a rough guide</article-title><source>Clin Infect Dis</source><volume>52</volume><issue>7</issue><year>2011</year><fpage>911</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1093/cid/cir007</pub-id><pub-id pub-id-type="pmid">21427399</pub-id></element-citation></ref><ref id="bib155"><label>230</label><element-citation publication-type="book" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Heymann</surname><given-names>D.L.</given-names></name></person-group><part-title>Control of communicable diseases manual</part-title><year>2008</year><publisher-name>American Public Health Association</publisher-name></element-citation></ref><ref id="bib156"><label>231</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Prajapati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Narasimha Kumar</surname><given-names>G.V.</given-names></name></person-group><article-title>Assumption of herd immunity against COVID-19: a plausibility and hope or a terrible thought in modern-day to save the life</article-title><source>J&#160;Infect Dis</source><volume>6</volume><year>2020</year><fpage>147</fpage><pub-id pub-id-type="doi">10.23937/2474-3658/1510147</pub-id></element-citation></ref><ref id="bib157"><label>232</label><element-citation publication-type="book" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Foppa</surname><given-names>I.M.</given-names></name><collab>Diekmann O, Heesterbeek J, and Metz JA (1991) and Van den Driessche P and Watmough J (2002)</collab></person-group><part-title>The spread of infectious diseases in heterogeneous populations</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Foppa</surname><given-names>I.M.</given-names></name></person-group><source>A&#160;historical introduction to mathematical modeling of infectious diseases</source><year>2017</year><publisher-name>Academic Press</publisher-name><publisher-loc>Boston</publisher-loc><fpage>157</fpage><lpage>194</lpage></element-citation></ref><ref id="bib158"><label>233</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Achaiah</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Subbarajasetty</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Shetty</surname><given-names>R.M.</given-names></name></person-group><article-title>R(0) and R(e) of COVID-19: can we predict when the pandemic outbreak will be contained?</article-title><source>Indian J Crit Care Med</source><volume>24</volume><issue>11</issue><year>2020</year><fpage>1125</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.5005/jp-journals-10071-23649</pub-id><pub-id pub-id-type="pmid">33384521</pub-id><pub-id pub-id-type="pmcid">PMC7751056</pub-id></element-citation></ref><ref id="bib159"><label>234</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Delamater</surname><given-names>P.</given-names></name><name name-style="western"><surname>Street</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>K.</given-names></name></person-group><article-title>Complexity of the basic reproduction number (R<sub>0</sub>)</article-title><source>Emerg Infect Dis J</source><volume>25</volume><issue>1</issue><year>2019</year><fpage>1</fpage><pub-id pub-id-type="doi">10.3201/eid2501.171901</pub-id><pub-id pub-id-type="pmcid">PMC6302597</pub-id><pub-id pub-id-type="pmid">30560777</pub-id></element-citation></ref><ref id="bib160"><label>235</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Pellis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>F.</given-names></name><name name-style="western"><surname>Trapman</surname><given-names>P.</given-names></name></person-group><article-title>Reproduction numbers for epidemic models with households and other social structures. I. Definition and calculation of R0</article-title><source>Math Biosci</source><volume>235</volume><issue>1</issue><year>2012</year><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.mbs.2011.10.009</pub-id><pub-id pub-id-type="pmid">22085761</pub-id><pub-id pub-id-type="pmcid">PMC3693038</pub-id></element-citation></ref><ref id="bib161"><label>236</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Heffernan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>L.M.</given-names></name></person-group><article-title>Perspectives on the basic reproductive ratio</article-title><source>J&#160;R Soc Interface</source><volume>2</volume><issue>4</issue><year>2005</year><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1098/rsif.2005.0042</pub-id><pub-id pub-id-type="pmid">16849186</pub-id><pub-id pub-id-type="pmcid">PMC1578275</pub-id></element-citation></ref><ref id="bib162"><label>237</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>M.G.</given-names></name></person-group><article-title>The pluses and minuses of R0</article-title><source>J&#160;R Soc Interface</source><volume>4</volume><issue>16</issue><year>2007</year><fpage>949</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1098/rsif.2007.1031</pub-id><pub-id pub-id-type="pmid">17490942</pub-id><pub-id pub-id-type="pmcid">PMC2075534</pub-id></element-citation></ref><ref id="bib163"><label>238</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Chowell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nishiura</surname><given-names>H.</given-names></name></person-group><article-title>Transmission dynamics and control of Ebola virus disease (EVD): a review</article-title><source>BMC Med</source><volume>12</volume><year>2014</year><fpage>196</fpage><pub-id pub-id-type="doi">10.1186/s12916-014-0196-0</pub-id><pub-id pub-id-type="pmid">25300956</pub-id><pub-id pub-id-type="pmcid">PMC4207625</pub-id></element-citation></ref><ref id="bib164"><label>239</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>P.E.</given-names></name></person-group><article-title>Herd immunity: history, theory, practice</article-title><source>Epidemiol Rev</source><volume>15</volume><issue>2</issue><year>1993</year><fpage>265</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.epirev.a036121</pub-id><pub-id pub-id-type="pmid">8174658</pub-id></element-citation></ref><ref id="bib165"><label>240</label><element-citation publication-type="book" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Van Seventer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hochberg</surname><given-names>N.S.</given-names></name></person-group><part-title>Principles of infectious diseases: transmission, diagnosis, prevention, and control</part-title><year>2017</year><publisher-name>International encyclopedia of public health</publisher-name><fpage>22</fpage></element-citation></ref><ref id="bib166"><label>241</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Sy</surname><given-names>K.T.L.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>B.E.</given-names></name></person-group><article-title>Population density and basic reproductive number of COVID-19 across United States counties</article-title><source>PLoS One</source><volume>16</volume><issue>4</issue><year>2021</year><object-id pub-id-type="publisher-id">e0249271</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0249271</pub-id><pub-id pub-id-type="pmcid">PMC8059825</pub-id><pub-id pub-id-type="pmid">33882054</pub-id></element-citation></ref><ref id="bib167"><label>242</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Locatelli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tr&#228;chsel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rousson</surname><given-names>V.</given-names></name></person-group><article-title>Estimating the basic reproduction number for COVID-19 in Western Europe</article-title><source>PLoS One</source><volume>16</volume><issue>3</issue><year>2021</year><object-id pub-id-type="publisher-id">e0248731</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0248731</pub-id><pub-id pub-id-type="pmcid">PMC7968714</pub-id><pub-id pub-id-type="pmid">33730041</pub-id></element-citation></ref><ref id="bib168"><label>243</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Musa</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak</article-title><source>Int J Infect Dis</source><volume>92</volume><year>2020</year><fpage>214</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">32007643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.01.050</pub-id><pub-id pub-id-type="pmcid">PMC7110798</pub-id></element-citation></ref><ref id="bib169"><label>244</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N&#160;Engl J Med</source><volume>382</volume><issue>13</issue><year>2020</year><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmid">31995857</pub-id><pub-id pub-id-type="pmcid">PMC7121484</pub-id></element-citation></ref><ref id="bib170"><label>245</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E.</given-names></name></person-group><article-title>Covid-19: what is the R number?</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m1891</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1891</pub-id><pub-id pub-id-type="pmid">32398287</pub-id></element-citation></ref><ref id="bib171"><label>246</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Lippi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>B.M.</given-names></name></person-group><article-title>How will emerging SARS-CoV-2 variants impact herd immunity?</article-title><source>Ann Transl Med</source><volume>9</volume><issue>7</issue><year>2021</year><fpage>585</fpage><pub-id pub-id-type="doi">10.21037/atm-21-893</pub-id><pub-id pub-id-type="pmid">33987283</pub-id><pub-id pub-id-type="pmcid">PMC8105864</pub-id></element-citation></ref><ref id="bib172"><label>247</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rockl&#246;v</surname><given-names>J.</given-names></name></person-group><article-title>The reproductive number of the delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus</article-title><source>J Travel Med</source><volume>28</volume><issue>7</issue><year>2021</year><fpage>taab124</fpage><pub-id pub-id-type="doi">10.1093/jtm/taab124</pub-id><pub-id pub-id-type="pmid">34369565</pub-id><pub-id pub-id-type="pmcid">PMC8436367</pub-id></element-citation></ref><ref id="bib173"><label>248</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Del Rio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malani</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Omer</surname><given-names>S.B.</given-names></name></person-group><article-title>Confronting the delta variant of SARS-CoV-2, summer 2021</article-title><source>JAMA</source><volume>326</volume><issue>11</issue><year>2021</year><fpage>1001</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.14811</pub-id><pub-id pub-id-type="pmid">34406361</pub-id></element-citation></ref><ref id="bib174"><label>249</label><element-citation publication-type="journal" id="sref1174"><person-group person-group-type="author"><name name-style="western"><surname>Nishiura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anzai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piantham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Morales</surname><given-names>A.J.</given-names></name></person-group><article-title>Relative reproduction number of SARS-CoV-2 Omicron (B. 1.1. 529) compared with Delta variant in South Africa</article-title><source>J Clin Med</source><volume>11</volume><issue>1</issue><year>2021</year><fpage>30</fpage><pub-id pub-id-type="doi">10.3390/jcm11010030</pub-id><pub-id pub-id-type="pmid">35011781</pub-id><pub-id pub-id-type="pmcid">PMC8745053</pub-id></element-citation></ref><ref id="bib175"><label>250</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Petrie</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Bazzi</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Follmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hatcher</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Coronavirus occurrence in the household influenza vaccine evaluation (HIVE) cohort of Michigan households: reinfection frequency and serologic responses to seasonal and severe acute respiratory syndrome coronaviruses</article-title><source>J Infect Dis</source><volume>224</volume><issue>1</issue><year>2021</year><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab161</pub-id><pub-id pub-id-type="pmid">33755731</pub-id><pub-id pub-id-type="pmcid">PMC8083771</pub-id></element-citation></ref><ref id="bib176"><label>251</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Memoli</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>K.-A.</given-names></name><name name-style="western"><surname>Czajkowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Athota</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Influenza A reinfection in sequential human challenge: implications for protective immunity and &#8220;universal&#8221; vaccine development</article-title><source>Clin Infect Dis</source><volume>70</volume><issue>5</issue><year>2020</year><fpage>748</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz281</pub-id><pub-id pub-id-type="pmid">30953061</pub-id><pub-id pub-id-type="pmcid">PMC7319262</pub-id></element-citation></ref><ref id="bib177"><label>252</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Hayman</surname><given-names>D.T.S.</given-names></name></person-group><article-title>Measles vaccination in an increasingly immunized and developed world</article-title><source>Hum Vaccin Immunother</source><volume>15</volume><issue>1</issue><year>2019</year><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1517074</pub-id><pub-id pub-id-type="pmid">30156949</pub-id><pub-id pub-id-type="pmcid">PMC6363159</pub-id></element-citation></ref><ref id="bib178"><label>253</label><element-citation publication-type="book" id="sref178"><source>Global measles and rubella strategic plan: 2012-2020 Geneva, Switzerland</source><year>2012</year><publisher-name>World Health Organization</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://apps.who.int/iris/rest/bitstreams/53400/retrieve" id="intref0140">https://apps.who.int/iris/rest/bitstreams/53400/retrieve</ext-link></element-citation></ref><ref id="bib179"><label>254</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>A.B.</given-names></name></person-group><article-title>Efforts at COVID-19 vaccine development: challenges and successes</article-title><source>Vaccines</source><volume>8</volume><issue>4</issue><year>2020</year><fpage>739</fpage><pub-id pub-id-type="pmid">33291245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8040739</pub-id><pub-id pub-id-type="pmcid">PMC7762169</pub-id></element-citation></ref><ref id="bib180"><label>255</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Neagu</surname><given-names>M.</given-names></name></person-group><article-title>The bumpy road to achieve herd immunity in COVID-19</article-title><source>J&#160;Immunoassay Immunochem</source><volume>41</volume><issue>6</issue><year>2020</year><fpage>928</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1080/15321819.2020.1833919</pub-id><pub-id pub-id-type="pmid">33086932</pub-id></element-citation></ref><ref id="bib181"><label>256</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Khoury</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Cromer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reynaldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schlub</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Juno</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection</article-title><source>Nat Med</source><volume>27</volume><issue>7</issue><year>2021</year><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">34002089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01377-8</pub-id></element-citation></ref><ref id="bib182"><label>257</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fontes-Garfias</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Neutralizing activity of BNT162b2-elicited serum</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>15</issue><year>2021</year><fpage>1466</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">33684280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2102017</pub-id><pub-id pub-id-type="pmcid">PMC7944950</pub-id></element-citation></ref><ref id="bib183"><label>258</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Planas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veyer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baidaliuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Staropoli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guivel-Benhassine</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rajah</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization</article-title><source>Nature</source><volume>596</volume><issue>7871</issue><year>2021</year><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">34237773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03777-9</pub-id></element-citation></ref><ref id="bib184"><label>259</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>C&#225;rdenas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>23</issue><year>2021</year><fpage>2187</fpage><lpage>2201</lpage><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id></element-citation></ref><ref id="bib185"><label>260</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S.A.C.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><volume>397</volume><issue>10269</issue><year>2021</year><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="bib186"><label>261</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weisblum</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bednarski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Plasma neutralization of the SARS-CoV-2 Omicron variant</article-title><source>N&#160;Engl J Med</source><volume>386</volume><issue>6</issue><year>2022</year><fpage>599</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">35030645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2119641</pub-id><pub-id pub-id-type="pmcid">PMC8757565</pub-id></element-citation></ref><ref id="bib187"><label>262</label><element-citation publication-type="book" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Steenhuysen</surname><given-names>J.</given-names></name></person-group><part-title>Analysis: how Omicron highlights fading hope of herd immunity from COVID</part-title><year>2022</year><publisher-name>REUTERS</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.reuters.com/business/healthcare-pharmaceuticals/how-omicron-highlights-fading-hope-herd-immunity-covid-2022-01-20/" id="intref0145">https://www.reuters.com/business/healthcare-pharmaceuticals/how-omicron-highlights-fading-hope-herd-immunity-covid-2022-01-20/</ext-link></element-citation></ref><ref id="bib188"><label>263</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Pulliam</surname><given-names>J.R.C.</given-names></name><name name-style="western"><surname>van Schalkwyk</surname><given-names>C.</given-names></name><name name-style="western"><surname>Govender</surname><given-names>N.</given-names></name><name name-style="western"><surname>von Gottberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Groome</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.11.11.21266068</pub-id><pub-id pub-id-type="pmcid">PMC8995029</pub-id><pub-id pub-id-type="pmid">35289632</pub-id></element-citation></ref><ref id="bib189"><label>264</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Collie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Champion</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moultrie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G.</given-names></name></person-group><article-title>Effectiveness of BNT162b2 vaccine against omicron variant in South Africa</article-title><source>N&#160;Engl J Med</source><volume>386</volume><issue>5</issue><year>2022</year><fpage>494</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2119270</pub-id><pub-id pub-id-type="pmid">34965358</pub-id><pub-id pub-id-type="pmcid">PMC8757569</pub-id></element-citation></ref><ref id="bib190"><label>265</label><element-citation publication-type="book" id="sref190"><person-group person-group-type="author"><collab>UK Health Security Agency</collab></person-group><part-title>COVID-19 vaccine surveillance report</part-title><year>2022</year><publisher-name>United Kingdom</publisher-name><comment>Report No.: GOV-11969 Contract No.: GOV-11969</comment></element-citation></ref><ref id="bib191"><label>266</label><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Angulo</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Anis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study</article-title><source>Lancet Infect Dis</source><volume>22</volume><issue>3</issue><year>2022</year><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(21)00566-1</pub-id><pub-id pub-id-type="pmid">34562375</pub-id><pub-id pub-id-type="pmcid">PMC8457761</pub-id></element-citation></ref><ref id="bib192"><label>267</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Cabezas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coma</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mora-Fernandez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Martinez-Marcos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fina</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study</article-title><source>Bmj</source><volume>374</volume><year>2021</year><fpage>n1868</fpage><pub-id pub-id-type="doi">10.1136/bmj.n1868</pub-id><pub-id pub-id-type="pmid">34407952</pub-id><pub-id pub-id-type="pmcid">PMC8371258</pub-id></element-citation></ref><ref id="bib193"><label>268</label><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fluss</surname><given-names>R.</given-names></name><name name-style="western"><surname>Indenbaum</surname><given-names>V.</given-names></name><name name-style="western"><surname>Amit</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months</article-title><source>N&#160;Engl J Med</source><volume>385</volume><issue>24</issue><year>2021</year><fpage>e84</fpage><pub-id pub-id-type="doi">10.1056/NEJMoa2114583</pub-id><pub-id pub-id-type="pmid">34614326</pub-id><pub-id pub-id-type="pmcid">PMC8522797</pub-id></element-citation></ref><ref id="bib194"><label>269</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Shekhar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kottewar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>A.B.</given-names></name></person-group><article-title>COVID-19 vaccine booster: to boost or not to boost</article-title><source>Infect Dis Rep</source><volume>13</volume><issue>4</issue><year>2021</year><fpage>924</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.3390/idr13040084</pub-id><pub-id pub-id-type="pmid">34842753</pub-id><pub-id pub-id-type="pmcid">PMC8628913</pub-id></element-citation></ref><ref id="bib195"><label>270</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alahmad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al-Shammari</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Alterki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cherian</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Previous COVID-19 infection and antibody levels after vaccination</article-title><source>Front Public Health</source><volume>9</volume><year>2021</year><pub-id pub-id-type="doi">10.3389/fpubh.2021.778243</pub-id><pub-id pub-id-type="pmcid">PMC8671167</pub-id><pub-id pub-id-type="pmid">34926392</pub-id></element-citation></ref><ref id="bib196"><label>271</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kirsebom</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Toffa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England</article-title><source>Nat Med</source><volume>28</volume><issue>4</issue><year>2022</year><fpage>831</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01699-1</pub-id><pub-id pub-id-type="pmid">35045566</pub-id><pub-id pub-id-type="pmcid">PMC9018410</pub-id></element-citation></ref><ref id="bib197"><label>272</label><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19: booster vaccine gives &#8220;significant increased protection&#8221; in over 50s</article-title><source>BMJ</source><volume>375</volume><year>2021</year><object-id pub-id-type="publisher-id">n2814</object-id><pub-id pub-id-type="doi">10.1136/bmj.n2814</pub-id><pub-id pub-id-type="pmid">34789456</pub-id></element-citation></ref><ref id="bib198"><label>273</label><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Chemaitelly</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>AlMukdad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Benslimane</surname><given-names>F.M.</given-names></name><etal/></person-group><article-title>Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar</article-title><source>N&#160;Engl J Med</source><volume>385</volume><issue>24</issue><year>2021</year><fpage>e83</fpage><pub-id pub-id-type="pmid">34614327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2114114</pub-id><pub-id pub-id-type="pmcid">PMC8522799</pub-id></element-citation></ref><ref id="bib199"><label>274</label><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Chemaitelly</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Benslimane</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Al Khatib</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar</article-title><source>Nat Med</source><volume>27</volume><issue>9</issue><year>2021</year><fpage>1614</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">34244681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01446-y</pub-id></element-citation></ref><ref id="bib200"><label>275</label><element-citation publication-type="journal" id="sref200"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Chemaitelly</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Benslimane</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Al Khatib</surname><given-names>H.A.</given-names></name><etal/></person-group><article-title>BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar</article-title><source>Nat Med</source><volume>27</volume><issue>12</issue><year>2021</year><fpage>2136</fpage><lpage>2143</lpage><pub-id pub-id-type="pmid">34728831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01583-4</pub-id></element-citation></ref><ref id="bib201"><label>276</label><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Cohn</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Krigbaum</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>A.W.</given-names></name></person-group><article-title>SARS-CoV-2 vaccine protection and deaths among US veterans during 2021</article-title><source>Science</source><volume>375</volume><issue>6578</issue><year>2022</year><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">34735261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abm0620</pub-id><pub-id pub-id-type="pmcid">PMC9836205</pub-id></element-citation></ref><ref id="bib202"><label>277</label><element-citation publication-type="journal" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Barda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dagan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kohane</surname><given-names>I.S.</given-names></name><etal/></person-group><article-title>Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study</article-title><source>Lancet</source><volume>398</volume><issue>10316</issue><year>2021</year><fpage>2093</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">34756184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02249-2</pub-id><pub-id pub-id-type="pmcid">PMC8555967</pub-id></element-citation></ref><ref id="bib203"><label>278</label><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Bar-On</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mandel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bodenheimer</surname><given-names>O.</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kalkstein</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Protection of BNT162b2 vaccine booster against Covid-19 in Israel</article-title><source>N&#160;Engl J Med</source><volume>385</volume><issue>15</issue><year>2021</year><fpage>1393</fpage><lpage>1400</lpage><pub-id pub-id-type="pmid">34525275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2114255</pub-id><pub-id pub-id-type="pmcid">PMC8461568</pub-id></element-citation></ref><ref id="bib204"><label>279</label><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Munro</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Janani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cornelius</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Babbage</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial</article-title><source>Lancet</source><volume>398</volume><issue>10318</issue><year>2021</year><fpage>2258</fpage><lpage>2276</lpage><pub-id pub-id-type="pmid">34863358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02717-3</pub-id><pub-id pub-id-type="pmcid">PMC8639161</pub-id></element-citation></ref><ref id="bib205"><label>280</label><element-citation publication-type="journal" id="sref205"><person-group person-group-type="author"><name name-style="western"><surname>Menni</surname><given-names>C.</given-names></name><name name-style="western"><surname>May</surname><given-names>A.</given-names></name><name name-style="western"><surname>Polidori</surname><given-names>L.</given-names></name><name name-style="western"><surname>Louca</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Capdevila</surname><given-names>J.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study</article-title><source>Lancet Infect Dis</source><volume>22</volume><issue>7</issue><year>2022</year><fpage>1002</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00146-3</pub-id><pub-id pub-id-type="pmid">35405090</pub-id><pub-id pub-id-type="pmcid">PMC8993156</pub-id></element-citation></ref><ref id="bib206"><label>281</label><element-citation publication-type="journal" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Grewal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kitchen</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buchan</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study</article-title><source>BMJ</source><volume>378</volume><year>2022</year><object-id pub-id-type="publisher-id">e071502</object-id><pub-id pub-id-type="doi">10.1136/bmj-2022-071502</pub-id><pub-id pub-id-type="pmcid">PMC9257064</pub-id><pub-id pub-id-type="pmid">35793826</pub-id></element-citation></ref><ref id="bib207"><label>282</label><element-citation publication-type="journal" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Madewell</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Longini</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Halloran</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>N.E.</given-names></name></person-group><article-title>Household transmission of SARS-CoV-2: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><volume>3</volume><issue>12</issue><year>2020</year><comment>e2031756&#8211;e2031756</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.31756</pub-id><pub-id pub-id-type="pmcid">PMC7737089</pub-id><pub-id pub-id-type="pmid">33315116</pub-id></element-citation></ref><ref id="bib208"><label>283</label><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Wilmes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Glod</surname><given-names>F.</given-names></name><name name-style="western"><surname>Veiber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mombaerts</surname><given-names>L.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 transmission risk from asymptomatic carriers: results from a mass screening programme in Luxembourg</article-title><source>Lancet Reg Health Eur</source><volume>4</volume><year>2021</year><object-id pub-id-type="publisher-id">100056</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanepe.2021.100056</pub-id><pub-id pub-id-type="pmcid">PMC7912359</pub-id><pub-id pub-id-type="pmid">33997830</pub-id></element-citation></ref><ref id="bib209"><label>284</label><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Angel</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Spitzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Henig</surname><given-names>O.</given-names></name><name name-style="western"><surname>Saiag</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sprecher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Padova</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers</article-title><source>JAMA</source><volume>325</volume><issue>24</issue><year>2021</year><fpage>2457</fpage><lpage>2465</lpage><pub-id pub-id-type="pmid">33956048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.7152</pub-id><pub-id pub-id-type="pmcid">PMC8220476</pub-id></element-citation></ref><ref id="bib210"><label>285</label><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>El Sahly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Doblecki-Lewis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase</article-title><source>N&#160;Engl J Med</source><volume>385</volume><issue>19</issue><year>2021</year><fpage>1774</fpage><lpage>1785</lpage><pub-id pub-id-type="pmid">34551225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2113017</pub-id><pub-id pub-id-type="pmcid">PMC8482810</pub-id></element-citation></ref><ref id="bib211"><label>286</label><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Giurgea</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Han</surname><given-names>A.</given-names></name><name name-style="western"><surname>Memoli</surname><given-names>M.J.</given-names></name></person-group><article-title>Universal coronavirus vaccines: the time to start is now</article-title><source>Npj Vaccines</source><volume>5</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">32528732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-0198-1</pub-id><pub-id pub-id-type="pmcid">PMC7256035</pub-id></element-citation></ref><ref id="bib212"><label>287</label><element-citation publication-type="book" id="sref212"><person-group person-group-type="author"><collab>MU Health Care</collab></person-group><part-title>COVID-19 vaccine key to reaching &#8216;herd immunity&#8217;</part-title><year>2022</year><publisher-name>Health Care</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.muhealth.org/our-stories/covid-19-vaccine-key-reaching-herd-immunity" id="intref0150">https://www.muhealth.org/our-stories/covid-19-vaccine-key-reaching-herd-immunity</ext-link></element-citation></ref><ref id="bib213"><label>288</label><element-citation publication-type="journal" id="sref213"><person-group person-group-type="author"><name name-style="western"><surname>Batisse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Benech</surname><given-names>N.</given-names></name><name name-style="western"><surname>Botelho-Nevers</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bouiller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Collarino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound?</article-title><source>J&#160;Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.06.073</pub-id><pub-id pub-id-type="pmcid">PMC7326402</pub-id><pub-id pub-id-type="pmid">32619697</pub-id></element-citation></ref><ref id="bib214"><label>289</label><element-citation publication-type="journal" id="sref214"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report</article-title><source>Int J Infect Dis</source><volume>93</volume><year>2020</year><fpage>297</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.003</pub-id><pub-id pub-id-type="pmid">32147538</pub-id><pub-id pub-id-type="pmcid">PMC7129213</pub-id></element-citation></ref><ref id="bib215"><label>290</label><element-citation publication-type="journal" id="sref215"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name></person-group><article-title>Letter to the Editor: three cases of redetectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies</article-title><source>J&#160;Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25968</pub-id><pub-id pub-id-type="pmcid">PMC7267393</pub-id><pub-id pub-id-type="pmid">32369214</pub-id></element-citation></ref><ref id="bib216"><label>291</label><element-citation publication-type="book" id="sref216"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name></person-group><part-title>South Korea reports more recovered coronavirus patients testing positive again</part-title><year>2020</year><publisher-name>Reuters</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.reuters.com/article/us-health-coronavirus-southkorea/south-korea-reports-more-recovered-coronavirus-patients-testing-positive-again-idUSKCN21V0JQ" id="intref0155">https://www.reuters.com/article/us-health-coronavirus-southkorea/south-korea-reports-more-recovered-coronavirus-patients-testing-positive-again-idUSKCN21V0JQ</ext-link></element-citation></ref><ref id="bib217"><label>292</label><element-citation publication-type="book" id="sref217"><person-group person-group-type="author"><name name-style="western"><surname>Kayat</surname><given-names>S.</given-names></name></person-group><part-title>Doctor's note: can the coronavirus reactivate?</part-title><year>2020</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aljazeera.com/indepth/features/doctor-note-coronavirus-reactivate-200412062905537.html" id="intref0160">https://www.aljazeera.com/indepth/features/doctor-note-coronavirus-reactivate-200412062905537.html</ext-link></element-citation></ref><ref id="bib218"><label>293</label><element-citation publication-type="journal" id="sref218"><person-group person-group-type="author"><name name-style="western"><surname>Ravioli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ochsner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>G.</given-names></name></person-group><article-title>Reactivation of COVID-19 pneumonia: a report of two cases</article-title><source>J&#160;Infect</source><volume>81</volume><issue>2</issue><year>2020</year><fpage>e72</fpage><lpage>e73</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.05.008</pub-id><pub-id pub-id-type="pmcid">PMC7204684</pub-id><pub-id pub-id-type="pmid">32389787</pub-id></element-citation></ref><ref id="bib219"><label>294</label><element-citation publication-type="journal" id="sref219"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation</article-title><source>J&#160;Infect</source><volume>80</volume><issue>5</issue><year>2020</year><fpage>e14</fpage><lpage>e17</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.001</pub-id><pub-id pub-id-type="pmcid">PMC7102560</pub-id><pub-id pub-id-type="pmid">32171867</pub-id></element-citation></ref><ref id="bib220"><label>295</label><element-citation publication-type="journal" id="sref220"><person-group person-group-type="author"><name name-style="western"><surname>Loconsole</surname><given-names>D.</given-names></name><name name-style="western"><surname>Passerini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Palmieri</surname><given-names>V.O.</given-names></name><name name-style="western"><surname>Centrone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sallustio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Recurrence of COVID-19 after recovery: a case report from Italy</article-title><source>Infection</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s15010-020-01444-1</pub-id><pub-id pub-id-type="pmcid">PMC7228864</pub-id><pub-id pub-id-type="pmid">32415334</pub-id></element-citation></ref><ref id="bib221"><label>296</label><element-citation publication-type="journal" id="sref221"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Lack of reinfection in rhesus macaques infected with SARS-CoV-2</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.13.990226</pub-id></element-citation></ref><ref id="bib222"><label>297</label><element-citation publication-type="journal" id="sref222"><person-group person-group-type="author"><name name-style="western"><surname>Seow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Merrick</surname><given-names>B.</given-names></name><name name-style="western"><surname>Acors</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steel</surname><given-names>K.J.A.</given-names></name><name name-style="western"><surname>Hemmings</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.09.20148429</pub-id></element-citation></ref><ref id="bib223"><label>298</label><element-citation publication-type="journal" id="sref223"><person-group person-group-type="author"><name name-style="western"><surname>Lumley</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stoesser</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hatch</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>Antibody status and incidence of SARS-CoV-2 infection in health care workers</article-title><source>N&#160;Engl J Med</source><volume>384</volume><issue>6</issue><year>2020</year><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034545</pub-id><pub-id pub-id-type="pmid">33369366</pub-id><pub-id pub-id-type="pmcid">PMC7781098</pub-id></element-citation></ref><ref id="bib224"><label>299</label><element-citation publication-type="journal" id="sref224"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>G.</given-names></name></person-group><article-title>The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2</article-title><source>Int J Infect Dis</source><volume>106</volume><year>2021</year><fpage>61</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">33713819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2021.01.061</pub-id><pub-id pub-id-type="pmcid">PMC7944804</pub-id></element-citation></ref><ref id="bib225"><label>300</label><element-citation publication-type="journal" id="sref225"><person-group person-group-type="author"><name name-style="western"><surname>Struck</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schreiner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Staschik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wochinz-Richter</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soutschek</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Vaccination versus infection with SARS-CoV-2: establishment of a high avidity IgG response versus incomplete avidity maturation</article-title><source>J&#160;Med Virol</source><volume>93</volume><issue>12</issue><year>2021</year><fpage>6765</fpage><lpage>6777</lpage><pub-id pub-id-type="pmid">34387884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.27270</pub-id><pub-id pub-id-type="pmcid">PMC8427118</pub-id></element-citation></ref><ref id="bib226"><label>301</label><element-citation publication-type="journal" id="sref226"><person-group person-group-type="author"><name name-style="western"><surname>Rivelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>V.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>C.</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>K.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.</given-names></name></person-group><article-title>Incidence of COVID-19 reinfection among Midwestern healthcare employees</article-title><source>PLoS One</source><volume>17</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">e0262164</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0262164</pub-id><pub-id pub-id-type="pmcid">PMC8726474</pub-id><pub-id pub-id-type="pmid">34982800</pub-id></element-citation></ref><ref id="bib227"><label>302</label><element-citation publication-type="journal" id="sref227"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pennington</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Coffin</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 infection in public school district employees following a district-wide vaccination program&#8212;Philadelphia County, Pennsylvania, March 21&#8211;April 23, 2021</article-title><source>Morb Mortal Wkly Rep</source><volume>70</volume><issue>30</issue><year>2021</year><fpage>1040</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7030e1</pub-id><pub-id pub-id-type="pmcid">PMC8323551</pub-id><pub-id pub-id-type="pmid">34324479</pub-id></element-citation></ref><ref id="bib228"><label>303</label><element-citation publication-type="journal" id="sref228"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Raddad</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Chemaitelly</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ayoub</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Benslimane</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Al Khatib</surname><given-names>H.A.</given-names></name><etal/></person-group><article-title>Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.07.25.21261093</pub-id></element-citation></ref><ref id="bib229"><label>304</label><element-citation publication-type="journal" id="sref229"><person-group person-group-type="author"><name name-style="western"><surname>Bergwerk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Amit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Covid-19 breakthrough infections in vaccinated health care workers</article-title><source>N&#160;Engl J Med</source><volume>385</volume><issue>16</issue><year>2021</year><fpage>1474</fpage><lpage>1484</lpage><pub-id pub-id-type="pmid">34320281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2109072</pub-id><pub-id pub-id-type="pmcid">PMC8362591</pub-id></element-citation></ref><ref id="bib230"><label>305</label><element-citation publication-type="journal" id="sref230"><person-group person-group-type="author"><collab>CDC COVID-19 Vaccine Breakthrough Case Investigations Team</collab></person-group><article-title>COVID-19 vaccine breakthrough infections reported to CDC&#8212;United States, January 1&#8211;April 30, 2021</article-title><source>Morb Mortal Wkly Rep</source><volume>70</volume><issue>21</issue><year>2021</year><fpage>792</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7021e3</pub-id><pub-id pub-id-type="pmcid">PMC8158893</pub-id><pub-id pub-id-type="pmid">34043615</pub-id></element-citation></ref><ref id="bib231"><label>306</label><element-citation publication-type="journal" id="sref231"><person-group person-group-type="author"><name name-style="western"><surname>Cavanaugh</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Spicer</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Thoroughman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Glick</surname><given-names>C.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>K.</given-names></name></person-group><article-title>Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination&#8212;Kentucky, May&#8211;June 2021</article-title><source>Morb Mortal Wkly Rep</source><volume>70</volume><issue>32</issue><year>2021</year><fpage>1081</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7032e1</pub-id><pub-id pub-id-type="pmcid">PMC8360277</pub-id><pub-id pub-id-type="pmid">34383732</pub-id></element-citation></ref><ref id="bib232"><label>307</label><element-citation publication-type="journal" id="sref232"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Pade</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Otter</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Menacho</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose</article-title><source>Science</source><volume>372</volume><issue>6549</issue><year>2021</year><fpage>1418</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">33931567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abh1282</pub-id><pub-id pub-id-type="pmcid">PMC8168614</pub-id></element-citation></ref><ref id="bib233"><label>308</label><element-citation publication-type="journal" id="sref233"><person-group person-group-type="author"><name name-style="western"><surname>Stamatatos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Czartoski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Homad</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>H.</given-names></name><etal/></person-group><article-title>mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection</article-title><source>Science</source><volume>372</volume><issue>6549</issue><year>2021</year><fpage>1413</fpage><lpage>1418</lpage><pub-id pub-id-type="pmid">33766944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg9175</pub-id><pub-id pub-id-type="pmcid">PMC8139425</pub-id></element-citation></ref><ref id="bib234"><label>309</label><element-citation publication-type="journal" id="sref234"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Piani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andreini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meini</surname><given-names>S.</given-names></name></person-group><article-title>Reinfection of SARS-CoV-2&#8211;analysis of 23 cases from the literature</article-title><source>Infect Dis</source><volume>53</volume><issue>7</issue><year>2021</year><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/23744235.2021.1905174</pub-id><pub-id pub-id-type="pmcid">PMC8054490</pub-id><pub-id pub-id-type="pmid">33849385</pub-id></element-citation></ref><ref id="bib235"><label>310</label><element-citation publication-type="journal" id="sref235"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection</article-title><source>Front Med</source><volume>14</volume><issue>6</issue><year>2020</year><fpage>746</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">33017040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11684-020-0822-5</pub-id><pub-id pub-id-type="pmcid">PMC7533664</pub-id></element-citation></ref><ref id="bib236"><label>311</label><element-citation publication-type="journal" id="sref236"><person-group person-group-type="author"><name name-style="western"><surname>Larson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brodniak</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Voegtly</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Cer</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Glang</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Malagon</surname><given-names>F.J.</given-names></name><etal/></person-group><article-title>A case of early reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title><source>Clin Infect Dis</source><volume>73</volume><issue>9</issue><year>2020</year><fpage>e2827</fpage><lpage>e2828</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1436</pub-id><pub-id pub-id-type="pmcid">PMC7543357</pub-id><pub-id pub-id-type="pmid">32949240</pub-id></element-citation></ref><ref id="bib237"><label>312</label><element-citation publication-type="journal" id="sref237"><person-group person-group-type="author"><name name-style="western"><surname>Bernal</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thelwall</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effectiveness of COVID-19 vaccines against the B.1.617.2 variant</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.05.22.21257658</pub-id></element-citation></ref><ref id="bib238"><label>313</label><element-citation publication-type="journal" id="sref238"><person-group person-group-type="author"><name name-style="western"><surname>Emary</surname><given-names>K.</given-names></name><name name-style="western"><surname>Golubchik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ariani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S.</given-names></name><etal/><collab>C.-GU consortium, A. Project, C.-VTG Oxford</collab></person-group><article-title>Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>1351</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">33798499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00628-0</pub-id><pub-id pub-id-type="pmcid">PMC8009612</pub-id></element-citation></ref><ref id="bib240"><label>314</label><element-citation publication-type="journal" id="sref240"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Vostok</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gharpure</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sami</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings&#8212;Barnstable County, Massachusetts, July 2021</article-title><source>Morb Mortal Wkly Rep</source><volume>70</volume><issue>31</issue><year>2021</year><fpage>1059</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7031e2</pub-id><pub-id pub-id-type="pmcid">PMC8367314</pub-id><pub-id pub-id-type="pmid">34351882</pub-id></element-citation></ref><ref id="bib241"><label>315</label><element-citation publication-type="journal" id="sref241"><person-group person-group-type="author"><name name-style="western"><surname>MacIntyre</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Chughtai</surname><given-names>A.A.</given-names></name></person-group><article-title>Recurrence and reinfection &#8211; a new paradigm for the management of Ebola virus disease</article-title><source>Int J Infect Dis</source><volume>43</volume><year>2016</year><fpage>58</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2015.12.011</pub-id><pub-id pub-id-type="pmid">26711624</pub-id></element-citation></ref><ref id="bib242"><label>316</label><element-citation publication-type="journal" id="sref242"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group><article-title>COVID-19 reinfection: myth or truth?</article-title><source>SN Compr Clin Med</source><year>2020</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s42399-020-00335-8</pub-id><pub-id pub-id-type="pmcid">PMC7255905</pub-id><pub-id pub-id-type="pmid">32838134</pub-id></element-citation></ref><ref id="bib243"><label>317</label><element-citation publication-type="book" id="sref243"><source>Transmission of SARS-CoV-2: implications for infection prevention precautions</source><year>2020</year><publisher-name>World Health Organization</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions" id="intref0165">https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions</ext-link></element-citation></ref><ref id="bib244"><label>318</label><element-citation publication-type="journal" id="sref244"><person-group person-group-type="author"><name name-style="western"><surname>To</surname><given-names>K.K.-W.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>I.F.-N.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>A.W.-H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.-M.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing</article-title><source>Clin Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa1275</pub-id><pub-id pub-id-type="pmcid">PMC7499500</pub-id><pub-id pub-id-type="pmid">32840608</pub-id></element-citation></ref></ref-list><fn-group><fn id="d35e3814"><p id="ntpara0010">Peer review under responsibility of Taibah University.</p></fn></fn-group></back></article></pmc-articleset>